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ABSTRACT
The study of human mutagenesis requires methods of measuring somatic mutations in
normal human tissues and inherited mutations in human populations. Such methods
should permit measurement of rare mutations in the presence of abundant wild-type
copies and should be general to the human genome.
A sensitivity of 2 x 10-6 for point mutations was recently achieved in human cells
using a novel method of target isolation, constant denaturant capillary electrophoresis
(CDCE), and high-fidelity polymerase chain reaction (hifi-PCR) (Li-Sucholeiki and
Thilly, 2000). This method is applicable to 100-base pair (bp) DNA domains juxtaposed
with a naturally occurring domain of a higher melting temperature, or a natural clamp.
Such sequence domains represent about 9% of the human genome.
To permit analysis of rare point mutations in the human genome more generally, this
thesis developed a procedure in which a clamp can be ligated to any 100-bp sequence of
interest. This procedure was combined with the previous method to create a new method
of point mutational analysis that is not dependent on a naturally occurring clamp. To
demonstrate the new method, a sequence with a natural clamp, a part of the human
hypoxanthine-guanine phosphoribosyl transferase (HPRT) gene (cDNA-bp 223-318), was
analyzed using both the natural and ligated clamps.
A sensitivity of 2 x 10-5 in human cells was demonstrated using the ligated clamp as
opposed to 5 x 10-6 using the natural clamp. The sensitivity of the new method using the
ligated clamp was demonstrated to be limited by the fidelity of Pfu DNA polymerase
used for PCR. The sequence of the ligated clamp accounted for the differences in
sensitivity as a result of causing a decreased efficiency of mutant enrichment by CDCE.
The new method can be applied to measure somatic mutations in normal human
tissues, such as lung tissues, in which point mutations at fractions above 10-5 have been
observed. This method can also detect predominant inherited mutations even for genes
carrying recessive deleterious alleles in pooled samples derived from a large number of
individuals.
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1 INTRODUCTION
Many mutations have been found in both inherited and somatic cases of human
disease (Bos, 1989; Kogelnik et aI., 1998; Beroud et aI., 2000; Krawczak et aI., 2000).
However, causes of human mutation are yet to be determined. Possible sources of human
mutation are exogenous agents, endogenous metabolites, and DNA replication errors
(Lindahl, 1993; Greenblatt et aI., 1994; Coller and Thilly, 1998; Hussain and Harris,
1998; Krawczak et aI., 1998; Loeb and Loeb, 2000).
It has been hypothesized that if environmental agents are the primary cause of human
mutation, agent-specific distributions of mutations in a given DNA sequence are expected
in individuals exposed to these agents (Cariello and Thilly, 1986; Thilly, 1993; Coller
and Thilly, 1994). However, testing such a hypothesis is hindered by the lack of
genotype-based methods of measuring somatic mutations in normal tissues. Such
methods should permit measurement of rare mutations in the presence of their abundant
wild-type and should be general to the human genome. Methods that can fulfill these
requirements should also allow analysis of inherited mutations in pooled samples derived
from a large number of individuals.
The ability to analyze mutations based on their genotype, rather than phenotype, offers
a larger pool of target genes and tissues. Most phenotype-based methods are only
applicable to cultured cells and to certain tissue types, the cells of which can be grown in
vitro (e.g., blood). In addition, phenotype-based methods are limited to selectable genes.
Thus, genotype-based methods are the methods of choice. However, genotype-based
point mutation detection methods for rare mutational analysis offer a small target size of
1- to 6-base pairs (bp) (Aguilar et aI., 1994; Hussain et aI., 1994; Nakazawa et aI., 1994;
Ouhtit et aI., 1997; Wilson et aI., 2000).
For genotype-based mutational analysis of a larger target size of about 100-bp, our
laboratory has developed a method called constant denaturant capillary electrophoresis
(CDCE) (Khrapko et aI., 1994a). CDCE differentiates mutant from wild-type sequences
based on differences in their melting temperatures. When combined with additional
techniques, CDCE allows detection of point mutations in a variety of human samples
(Khrapko et aI., 1997a; Li-Sucholeiki and Thilly, 2000; Kim et aI., 2001). A recent
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technological development in which CDCE is combined with target isolation and high-
fidelity polymerase chain reaction (hifi-PCR) allows analysis of mutations at fractions as
low as 10-6 (Li-Sucholeiki and Thilly, 2000). This development can be applied to only
those DNA sequences with a natural clamp, representing about 9% of the human genome.
For genotype-based mutational analysis of a larger target-pool size, this thesis presents
a further technological development, a combined method of clamp ligation and target
isolation/CDCE/hifi-PCR. This development opens up an additional 89% of the human
genome suitable for analysis of rare point mutations. This combined method may allow
understanding of human point mutagenesis by performing mutational analysis in a variety
of human samples, including normal tissues.
18
2 LITERATURE REVIEW
2.1 Mutational spectra
Understanding of human mutagenesis requires mutational analysis in humans. Section
2.1.1 defines mutational spectra and discusses how mutational spectra can be used to
understand human mutagenesis. Sections 2.1.2 and 2.1.3 review studies on point
mutational spectra observed in a variety of human samples.
2.1.1 Definition and purpose of analysis
Benzer and Freese (1958), followed by Benzer (1961), primarily demonstrated
mutational spectra, distributions of mutations with regard to position, kind, and frequency
in a given DNA sequence. In these studies, each test mutagen was shown to induce a
nonrandom distribution of mutations in the rII region of the phage T4 genome. These
studies also showed that the induced mutations appear more frequently than expected by
chance, called hotspot mutations. Since these studies, analysis of mutational spectra has
been extended to bacteria, yeast, as well as human cells and tissues (Coulondre and
Miller, 1977; Armstrong and Kunz, 1990; Cariello et aI., 1990; Khrapko et aI., 1997a).
Mutational spectra have been suggested as a tool to understand cause-and-effect
relationships (Cariello and Thilly, 1986; Thilly, 1993; Coller and Thilly, 1994). These
studies proposed that if environmental agents are the primary cause of human mutation,
agent-specific mutational spectra are expected in individuals exposed to these agents.
Exogenous agents, endogenous metabolites, and DNA replication errors have been
hypothesized as possible sources of human mutation (Lindahl, 1993; Greenblatt et aI.,
1994; Coller and Thilly, 1998; Hussain and Harris, 1998; Krawczak et aI., 1998; Loeb
and Loeb, 2000). However, causes of human mutation are yet to be determined. Causes
of human mutation may be revealed by a sensitive and general means of measuring
mutational spectra in a variety of human samples.
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2.1.2 Point mutational spectra in human HPRT gene in vitro
For mutational analysis of a larger pool of target genes and tissues, genotype-based
methods are preferred over phenotype-based methods. Most phenotype-based methods
are only applicable to cultured cells and to certain tissue types, the cells of which can be
grown irl vitro (e.g., blood). In addition, phenotype-based methods are limited to
selectable genes. Despite these limitations, earlier mutational studies have been primarily
based on reference to phenotypic selection. This section reviews studies on point
mutational spectra observed in cultured human cells using the hypoxanthine-guanine
phosphoribosyl transferase (HPRT) gene as a selectable marker.
The human HPRT gene is comprised of 57,OOO-bp and consists of nine exons
(Edwards et aI., 1990). This gene is on the X-chromosome, present as one copy per cell
in males (Stout and Caskey, 1985). Many HPRTmutations have been found to be
associated with inherited cases of human disease, such as Lesch-Nyhan syndrome (Stout
and Caskey, 1985; Mohrenweiser and Jones, 1990; Cariello and Skopek, 1993a;
Krawczak et aI., 2000). This gene is related not only to disease but can be used as a
selectable marker. The HPRT enzyme is involved in the purine salvage pathway,
maintaining purine nucleotide pools in cells (Krenitsky et aI., 1969; Stout and Caskey,
1985). Thus, HPRT mutants that alter physiological function of the gene product can be
selected in vitro by their ability to grow in the presence of purine analogs, such as 6-
thioguanine (6TG). 6TG is toxic when incorporated into a cell's DNA (Stout and
Caskey, 1985).
An en masse selection-based method has been developed for analysis of point
mutational spectra in selectable genes, such as HPRT, in vitro (Keohavong and Thilly,
1992a). Human cells are exposed to each test mutagen of a fixed condition, and mutant
cells resistant to a selecting agent (6TG) are en masse selected. After polymerase chain
reaction (PCR) amplification of a chosen target, selected and amplified mutants are
analyzed by denaturing gradient gel electrophoresis (DGGE). DGGE is a DNA
separation technique, which differentiates mutant from wild-type sequences based on
differences in their melting temperatures (Fischer and Lerman, 1983).
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This combined method of en masse selection, PCR, and DGGE allows detection of
mutations, each representing as low as 1% of selected cells (2::10-2), with statistical
significance (±20% precision) (Keohavong and Thilly, 1992a). The advantage of this en
masse selection-based method over a clone-by-clone approach is its ability to analyze all
detectable point mutations in a chosen target simultaneously. Generating the same
outcome by a clone-by-clone approach requires DNA sequencing of numerous mutant
clones that are individually selected, thereby making the analysis rather laborious.
The combined method of en masse selection, PCR, and DGGE has been applied to
analysis of point mutational spectra in a human lymphoblastoid line, TK6. Figure 1
illustrates the distributions of hotspot point mutations with regard to position, kind, and
frequency in a part of the human HPRT gene. These distributions show that the point
mutational spectra in a cultured human cell system are characterized by test mutagens to
which the system is exposed. The test mutagens are ICR-191, N-methyl-N'-nitro-N-
nitrosoguanidine (MNNG), ultraviolet light (UV), and benzo[a]pyrene 7,8-diol-9,10-
epoxides (BPDE). Such mutagen-specific mutational spectra are shown to be different
from the spontaneous spectrum (see Figure 1).
More importantly, different mutagen-exposure conditions produce different point
mutational spectra. As Figure 2 shows, the AHH-l human lymphoblastoid line exposed
to benzo[a]pyrene (BP) under conditions differing in concentration and duration
produced dissimilar point mutational spectra.
These results based on phenotypic selection indicate that mutational spectra observed
in cultured human cells treated with a mutagen at high dose(s) for a short term cannot be
used to predict human in vivo mutagenesis. Thus, understanding of human in vivo
mutagenesis requires mutational analysis in human tissues. However, mutation detection
methods based on phenotypic selection are limited to selectable genes, such as HPRT,
and certain tissue types, such as blood. For these reasons, genotype-based methods are
necessary for analysis of mutational spectra in a larger pool of target genes and tissues.
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Figure 1. Mutagen-specific point mutational spectra in human cells (TK6)
Human cells, TK6, were exposed to each test mutagen of a fixed condition or left
untreated. Mutant cells resistant to 6TG were then en masse selected. After peR
amplification of a chosen target, selected and amplified mutants were analyzed by
DGGE. DGGE allows analysis of point mutations with regard to position, kind, and
frequency in a chosen DNA sequence, thereby generating point mutational spectra.
Sources: ICR-191 and MNNG (Cariello et aI., 1990); BPDE (Keohavong and Thilly, 1992b); UV
(Keohavong et aI., 1991); Spontaneous (Oller and Thilly, 1992).
22

Figure 2. BP exposure condition-specific point mutational spectra in human cells
(ARR-I)
Human cells, AHHl, were treated with BP of different concentrations for different
periods of time. Mutant cells resistant to 6TG were then en masse selected. After peR
amplification of a chosen target, selected and amplified mutants were analyzed by
DGGE. DGGE allows analysis of point mutations with regard to position, kind, and
frequency in a chosen DNA sequence, thereby generating point mutational spectra.
Source: Chen and Thilly, 1996.
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2.1.3 Point mutational spectra in human mitochondrial DNA in vitro and in vivo
Using a genotype-based mutation detection method, point mutational spectra in a part
of hllman mitochondrial DNA have been analyzed in a variety of human samples,
including normal tissues (Khrapko et aI., 1997a; Coller et aI., 1998; Marcelino et aI.,
1998). This section reviews studies related to such analysis and summarizes the analysis
results, allowing understanding of human mitochondrial mutagenesis.
The human mitochondrial genome, distinct from ~he nuclear genome, is a circular,
double-stranded DNA of 16, 569-bp, inherited from the mother (Giles et aI., 1980;
Anderson et aI., 1981; Attardi and Schatz, 1988). It encodes for 13 protein subunits that
are involved in synthesizing the respiratory chain complex (Anderson et aI., 1981; Attardi
and Schatz, 1988). It also encodes for 2 ribosomal RNAs (rRNAs) and 22 transfer RNAs
(tRNAs) essential for mitochondrial protein synthesis (Anderson et aI., 1981; Attardi and
Schatz, 1988). Many mitochondrial mutations have been found to be associated with
human aging and disease (Kogelnik et aI., 1998; Chinnery and Turnbull, 1999; Wallace,
1999; Cottrell et aI., 2000).
When analyzing mutations in human samples, two factors make mitochondrial DNA a
more attractive target than nuclear DNA. The first is its ffiulticopy nature: it is present as
a few hundred to a thousand copies per cell (Robin and Wong, 1988; Marcelino et aI.,
1998; Khrapko et aI., 1999). This multicopy nature allows detection of mitochondrial
mutations using a smaller sample size than that necessary for single copy nuclear
mutations. Assuming a thousand mitochondrial DNA copies per cell, a thousand times
smaller sample size is expected to be necessary for detection of mitochondrial mutations
compared to that required for nuclear mutations of the same fraction. The second factor
is the higher mutation rate observed for mitochondrial DNA compared to that for nuclear
DNA (Khrapko et aI., 1997a). This factor is expected to generate higher mitochondrial
mutant fractions in organ tissues. This expectation suggests that a means of analyzing
mitochondrial mutations does not have to be as sensitive as is necessary for nuclear
mutations.
A genotype-based method has been developed for analysis of point mutations in 100-
bp multicopy sequences (e.g., ~1000 copies per cell) (Khrapko et al., 1997b). The
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sensitivity of this method is 10-6, detecting at least 102 copies of each mutant in the
presence of 108 copies of the wild-type. This method is based on constant denaturant gel
electrophoresis (eDGE), hifi-PCR, and CDCE. CDGE (Hovig et aI., 1991) and CDCE
(Khrapko et aI., 1994a), both derived from DGGE, separate mutant from wild-type
sequences based on differences in their melting temperatures.
For mutational analysis by this genotype-based method, human genomic DNA is
restriction digested to liberate a chosen target. Mutations in a chosen target from the
wild-type are then separated by eDGE, followed by elution of these separated mutations.
These separation and elution procedures allow genotype-based enrichment of mutant
sequences relative to the wild-type. Mutant-enriched samples are PCR amplified and are
separated by CDCE for further mutant enrichment. PCR is then performed prior to
mutational analysis by CDCE.
This combined method of CDGE, peR, and CDCE has been applied to measure
mitochondrial point mutational spectra in a variety of human samples (Khrapko et al.,
1997a; Coller et aI., 1998; Marcelino et aI., 1998). In the study of Khrapko et a1. (1997a),
normal human tissues, their derived tumors, and human cells grown under pristine
conditions were analyzed. In all of these samples, the same set of 17 point mutations
with regard to position and kind was observed in a 100-bp mitochondrial sequence. Most
of these mutations are G to A and A to G transitions, with the average mutant fractions
ranging from 10-6 to 4 X 10-4. When the same mitochondrial sequence was analyzed in
human bronchial epithelial cells of smoking and nonsmoking twins, the same set of 17
point mutations as in Khrapko et a1. (1997a) was observed (Coller et aI., 1998). In
addition, Coller et a1. (1998) observed no increase in the overall mutant fractions in the
smokers' samples compared to those in the nonsmokers'. These studies suggest the
spontaneous origin of the observed human mitochondrial point mutations.
DNA replication errors and endogenous damage have been hypothesized as probable
spontaneous sources of the set of mitochondrial point mutations observed in Khrapko et
a1. (1997a), as well as in Coller et a1. (1998) (Khrapko et aI., 1997a; Marcelino and
Thilly, 1999). To date, one of the hypotheses has been tested using human DNA
polymerase y and using the same mitochondrial sequence studied in Khrapko et al.
(1997a) and Coller et a1. (1998) (Zhang, unpublished results). In this study, about 60% of
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polymerase y-generated hotspot point mutations was determined to be the same as those
observed in Khrapko et a1. (1997a) and Coller et a1. (1998). DNA polymerase y is the
only known polymerase responsible for replicating human mitochondrial DNA (Shadel
and Clayton, 1997).
These mutational studies suggest the spontaneous origin of human mitochondrial
mutation. While the same type of studies remains to be completed for nuclear sequences,
such studies are hindered by the lack of a general and sensitive means of measuring
mutations in normal tissues. A desired means should permit measurement of rare nuclear
mutations in the presence of their abundant wild-type and should be general to the human
genome.
2.2 Nuclear genes associated with human cancer
Mutational analysis of nuclear genes in human tissues is necessary to understand
human nuclear mutagenesis. Proto-oncogenes and tumor suppressor genes are the
primary nuclear genes of interest since many mutations in these genes have been found to
be associated with human cancer (Bos, 1989; Beroud et aI., 2000; Krawczak et aI., 2000).
Cancer is the one of the leading causes of death in the United States (Vital statistics of the
United States). This section reviews studies on these primary nuclear genes of interest.
Oncogenes are mutant forms of their normal genes, proto-oncogenes (Diamandis,
1997). The normal gene products are mainly involved in signaling pathways, positively
regulating cell division (Wynford-Thomas, 1991; Yarbo, 1992; Baserga et aI., 1993).
Mutations in proto-oncogenes can deregulate cell growth by expressing an increased
level of the gene products, leading to malignant transformation (Wynford-Thomas, 1991;
Diarnandis, 1997). Such mutations are called gain-of-function, or activating, mutations
(Haber and Fearon, 1998). Oncogenes are thought to be 'dominant' genes since one
mutated allele is capable of transforming cells (Diamandis, 1997).
Unlike oncogenes, tumor suppressor genes are thought to be 'recessive' genes since
mutations in both alleles are necessary for malignant transformation (Brown, 1997;
Diamandis, 1997). Most tumor suppressor genes are negative regulators of cell growth
and development. Mutations in these genes can free cells from negative growth signals
28
and lead to malignant transformation (Weinberg, 1991; Wynford-Thomas, 1991; Yarbro,
1992; Brown, 1997). Such mutations are called loss-af-function, or inactivating,
mutations (Brown, 1997; Haber and Fearon, 1998).
Tables 1 and 2 summarize the characteristics of selected human proto-oncogenes and
tumor suppressor genes, respectively. The major mutation type(s) found in cancer is
specific to each gene. In addition, each gene is associated with one, or multiple cancer
types or multiple genes are associated with one cancer type. Thus, gene, mutation type,
and tissue type of interest should be considered together when planning mutational
analysis in human tissues.
2.3 Nuclear mutations associated with human disease
Many mutations in nuclear genes have been found to be associated with a variety of
human diseases (Beroud et aI., 2000; Krawczak et aI., 2000). Studies on mutations
associated with human disease can be used as a guide when planning mutational analysis
of a variety of human samples, including normal tissues. This section reviews studies on
nuclear mutations found in either inherited or somatic cases of human disease.
2.3.1 Irlherited mutations
A comprehensive core collection of published germline mutations associated with
human disease has been compiled as a database, the Human Gene Mutation Database
(HGMD) (Cooper et aI., 1998; Krawczak et aI., 2000). Somatic gene mutations and
mitochondrial genome mutations are not included in this database. To date, the database
comprises over 20, 000 different mutations, each found in coding, regulatory, or splicing-
relevant regions of about 1,000 different nuclear genes.
When the HGMD entries were sorted by mutation type, a hierarchy was found, as
Table 3 summarizes (Cooper et aI., 1998; Krawczak et aI., 2000). Point mutations are the
major mutation type observed. Point mutations include single base-pair substitutions
(70.10/0), as well as small (~20-bp) insertions and deletions (22.50/0). A hierarchy was
also found when the single base-pair substitutions found in gene-coding regions were
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Table 1. Characteristics of selected human proto-oncogenes
Gene Function
K-ras p21 guanine trinucleotide
phosphatase
N-ras p21 guanine trinucleotide
phosphatase
H-ras p21 guanine trinucleotide
phosphatase
EGFR Growth-factor receptor
(ERB-B)
NEU Growth-factor receptor
(ERB-B2)
C-lnyc Transcription factor
N-lnyc Transcription factor
L-lnyc Transcription factor
BCL-2 Antiapotosis protein
eyeD} Cyclin-D, cell-cycle control
BCR-ABL
RET
CDK4
SMO
{3-CAT
HST
PML-RAR
W2A-PBXl
MDM-2
GLI
TTG
Chimaeric non-receptor
tyrosine kinase
Glial-derived neutropic
facotr-receptor tyrosine
kinase
Cyclin-dependent kinase
Transmembrane signaling
molecule in sonic hedgehog
pathway
Transcriptional co-
activator, links E-cadherin
to cytoskeleton
Growth factor
Chimaeric transcription
factor
Chimaeric transcription
factor
P53-binding protein
Transcription factor
Transcription factor
Major mutation
type(s)
Point mutation
Point mutation
Point mutation
Amplification
Amplification
Chromosome
translocation,
amplification
Amplification
Amplification
Chromosome
translocation
Amplification,
chromosome
translocation
Chromosome
translocation
Chromosome
translocation,
point mutation
Amplification,
point mutation
Point mutation
Point mutation,
in-frame
deletion
Amplification
Chromosome
translocation
Chromosome
transIocation
Amplification
Amplification
Chromosome
translocation
Cancer type(s)
Pancreatic, colorectal, lung,
endometrial, other carcinomas
Myeloid leukemia
Bladder
Gliomas, squamous and other
carCInomas
Breast, ovarian, gastric, other
carCInomas
Burkitts' lymphoma, small-
cell carcinoma of the lung,
other carcinomas
Neuroblastolna, small-cell
carcinoma of the lung
small-cell carcinoma of the
lung
B-celllymphoma
Breast and other carcinomas,
B-celllymphoma, parathyroid
adenomas
Chronic myelogenous
leukemia, acute lymphocytic
leukemia
Thyroid
Sarcoma
Basal-cell skin
Melanoma, colorectal
Gastric
Acute promyelocytic leukemia
Pre-B acute lymphocytic
leukemia
Sarcoma
Sarcoma, glioma
T-cell acute lymphocytic
leukemia
Adapted from Haber and Fearon, 1998; Verma and Triantafillou, 1998.
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Table 2. Characteristics of selected human tumor suppressor genes
Gene
RBi
p53
APe
WTi
NFl
NF2
pi6
VHL
BRCAl
BRCA2
Function
Transcriptional regulator
Transcription factor
Regulator of ~-catenin
function
Transcription factor
Regulator of G protein-
mediated signal
transduction
Juxta-membrane link to
cytoskeleton
Cyelin-dependent kinase
inhibitor
Modulator of RNA
polymerase II
DNA repair
DNA repair
Major mutation
type(s)
Deletion
Point mutation
Truncating
mutation
Point mutation
Truncating
mutation
Truncating
mutation
Truncating
mutation
Truncating and
point mutations
Truncating
mutation
Truncating
mutation
Cancer type(s)
Retinoblastoma,
osteosarcoma, small-cell
lung carcinoma of the
lung, breast, and bladder
50% of all cancers
Colorectal
Wilms' tumor, renal
Melanoma,
neuroblastoma
Schwannomas,
menIngIomas,
ependymomas
Renal, central nervous
system
Breast, ovary
Breast
Adapted from Brown, 1997; Haber and Fearon, 1998; Bennett et aI., 1999; Robertson et aI., 1999.
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Table 3. Number of HGMD entries by mutation type
Mutation type Number of entries (% total)
Single base-pair substitutions 16359 (70.1 %)
Small deletions (~20-bp) 3849 (16.5%)
Small insertions (::=; 20-bp) 1407 (6.0%)
Small indels (~20-bp) 153 (0.70/0)
Repeat variations 30 (0.1 %)
Gross insertions and duplications (~20-bp) 137 (0.6%)
Complex rearrangements (including inversions) 244 (1.0%)
Gross deletions (~ 20-bp) 1166 (5.0%)
Total 23345 (100.0%)
Adapted from Krawczak et aI., 2000 (date of update: Oct., 2001).
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sorted by nucleotides with respect to their propensity to undergo substitution. Table 4
summarizes this hierarchy: G (38.4%) > C (32.2%) > T (17.0%) > A (12.4%) (Krawczak
et aI., 1998). Among these substitutions, transitions (62.5%) are dominant over
transversions (37.50/0) (Krawczak et aI., 1998).
Based on analysis of the HGMD entries, it has been hypothesized that these mutations
are mainly the result of endogenous mutagenic processes (Krawczak et aI., 1998). Such
processes include spontaneous deamination of 5-methylcytosine (5-mC) and
misalignment mutagenesis during DNA synthesis. These processes can potentially
generate point mutations.
Spontaneous deamination of 5-mC has been hypothesized to be a cause of C to T and
G to A transitions at CpG dinucleotides (Krawczak et aI., 1998). These mutations
account for 23% of all HGMD single base-pair substitutions and for 36.90/0 of HGMD
transitions found in gene-coding regions (Krawczak et aI., 1998). In vertebrate genomes,
about 3 to 4% of all cytosines are methylated (5-mC), with 90 to 100% of these 5-mC
occurring in the sequence CpG (Riggs and Jones, 1983; Antequera and Bird, 1993). It
has been shown that 5-mC undergoes spontaneous deamination, forming thymine, at a
rate much higher than the deamination of cytosine, forming uracil (Shen et aI., 1994).
The formed uracil can be removed by uracil-glycosylase (Lindahl, 1982). However, the
formed thymine, when left unrepaired, basepairs with adenine, converting a methyl CpG
sequence into TpG (Antequera and Bird, 1993; Gonzalgo and Jones, 1997). Base
excision repair of U:G mismatches has been shown to be up to 6000-fold more efficient
than that of T:G mismatches when tested with extracts from human tissues (Schmutte et
aI., 1995). In brief, the hypermutability of CpG dinucleotides is likely caused by
spontaneous deamination of 5-mC combined with inefficient repair of the resulting
premutagenic DNA mismatches.
In addition to spontaneous deamination of 5-mC, misalignment mutagenesis during
DNA synthesis has been also hypothesized as a cause of point mutations (Krawczak et
aI., 1998). Eukaryotic DNA polymerases have been shown to generate point mutations in
vitro, presumably as a result of template-primer misalignments in addition to
misincorporation of non-complementary nucleotides (Kunkel, 1990; Kunkel, 1992).
Hotspot mutations have been shown to occur in a given DNA sequence, with mutation
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Table 4. Spectrum of HGMD single base-pair substitutions in gene-coding regionsa
Number of substitutions by
Original T C A G Total (% total)
nucleotide
T 654 271 312 1,237 (17.0%)
C 1,632 (940)b 371 340 2,343 (32.2%)
A 201 163 538 902 (12.40/0)
G 619 453 1,717 (735)C 2,789 (38.40/0)
Total 2,452 1,270 2,359 1,190 7,271 (100.0%)
a Adapted from Krawczak et aI., 1998.
b Number in parentheses is C to T transitions at CpG dinucleotides.
C Number in parenthesis is G to A transitions at CpG dinucleotides.
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rates depending on polymerases and neighboring nucleotides (Kunkel, 1985; Kunkel,
1990; Kunkel, 1992).
Point mutations have also been found to be the major mutation type when germline
mutations associated with human cancer were sorted by type in individual tumor
suppressor genes (Beroud et aI., 2000). Among these point mutations, the predominant
mutations are small deletions in the adenomatous polyposis coli (APC) gene (Laurent-
Puig et aI., 1998; Muniappan, unpublished results) and single base-pair substitutions in
the p53 gene (Beroud and Soussi, 1998), as well as in the von Rippel-Lindau (VHL) gene
(Beroud et al., 1998). These predominant point mutations are distributed throughout each
gene-coding region, as Figure 3 illustrates.
While point mutations are not the only mutation type associated with human disease,
analysis of HGMD entries suggests point mutations as the primary mutation type to be
studied. Thus, methods of measuring point mutations are the methods of choice when
planning analysis of inherited mutations in a variety of human samples.
2.3.2 Somatic mutations
Studied on gene-specific mutations associated with human disease can be used as a
guide when choosing a target gene sequence, in addition to the primary mutation type to
be analyzed. This section reviews studies on nuclear gene-specific mutations found in
somatic cases of human cancer.
2.3.2.1 Gene-specific mutations
Published somatic mutations associated with human disease have been compiled as a
database, the Universal Mutation Database (UMD) (Beroud et aI., 2000). This database
allows creating and analyzing gene-specific mutation databases. The UMD has been
adapted to 13 different nuclear genes, most of which are tumor suppressor genes.
When the UMD somatic mutations in tumor suppressor genes in cancer were analyzed
by mutation type, point mutations were observed to be the major type (Beroud et aI.,
2000). However, differences in gene-specific point mutatiol1s have been found when the
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Figure 3. Distribution of germline point mutations in tumor suppressor genes in
human cancer
Sources: Beroud et aI., 1998; Beroud and Soussi, 1998; Muniappan, unpublished results:
collection of published APe mutations· observed when the entire coding region was analyzed.
UMD somatic entries were sorted by the following two categories: mutations leading to
truncated proteins (MLTP) and missense mutations (Beroud et aI., 2000) (MLTP includes
nonsense mutations, as well as out of frame deletions and insertions). For example,
MLTP accounts for 95% of the APC mutations, 71 % of the VHL mutations, and 77% of
the WT] mutations (Beroud et aI., 1998; Jeanpierre et aI., 1998; Laurent-Puig et aI., 1998;
Gallou et aI., 1999; Beroud et aI., 2000). Missense mutations account for 80% of the p53
mutations (Beroud and Soussi, 1998; Beroud et aI., 2000). These results suggest that
differential gene-inactivating mechanisms playa role in tumor formation.
In addition to gene-specific mutations, differential gene-mutation distribution is also
observed. For example, the majority of ras mutations found in human cancer are
clustered in a small number of codons (Bas, 1989). On the other hand, other cancer-
related gene mutations, such as APC, p53 and VHL, are scattered throughout a larger
number of codons (Beroud et aI., 1998; Laurent-Puig et al., 1998; Hernandez-Boussard et
aI., 1999b). Figure 4 illustrates the distribution of somatic mutations in the APe, p53,
and VHL genes in human cancer.
Analysis of somatic mutations associated with human cancer suggests point mutations
as the primary mutation type to be studied when planning analysis of somatic mutations
in a variety of human samples. In addition, a careful selection of target-gene sequences is
suggested. For certain genes like APe, p53, and VHL, the entire gene-coding regions can
be selected as a target since the observed mutations are scattered throughout each gene-
coding region. On the other hand, analysis should be limited to certain parts of gene-
coding regions for other genes like ras (the observed ras mutations are clustered in a
small number of codons).
2.3.2.2 p53 mutations
The p53 gene has the highest number of mutations among the gene mutations in the
UMD (Beroud et aI., 2000). For this reason, this section reviews studies related to p53
somatic mutations associated with human cancer. This section focuses on hypotheses
made regarding causes of the p53 mutations and discusses limitations of these studies in
understanding human mutagenesis.
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The human tumor suppressor gene p53 lies on chromosome 17p13 (Levine et al.,
1991; Akashi and Koeffler, 1998). This gene is 20-kb in length and consists of 11 exons,
with the gene product being mainly a negative regulator of the cell cycle (Levine et aI.,
1991; Akashi and Koeffler, 1998). Many p53 mutations have been found to be associated
with various cancer types (Hainaut et aI., 1998; Hernandez-Boussard et aI., 1999b). For
most cancer types, 20 to 50% of cases have been shown to carry ap53 mutation(s)
(Greenblatt et aI., 1994).
One of the databases comprising published p53 mutations associated with human
cancer is maintained at the International Agency for Research on Cancer (IARe), the
IARC p53 mutation database (Hainaut et aI., 1998; Hernandez-Boussard et aI., 1999b).
To date, more than 10,000 somatic p53 mutations have been entered into this database.
Most of these mutations are in the gene-coding region. Among IARe mutations 87.2%
are single base-pair substitutions, and the remaining 12.8% are small insertions and
deletions, as well as complex mutations (Hernandez-Bolissard et aI., 1999b). Over 900/0
of all IARe mutations are clustered within the central portion of the p53 gene-coding
region (Soussi et aI., 1990; Hernandez-Boussard et aI., 1999b). This portion is domains
of highly conserved sequences through evolution and consists of the DNA binding
domain of the protein, essential to p53 functional activity (Cho et aI., 1994).
Analysis of published p53 point mutations in all human cancer types has shown that
about 50% of the mutations are G to A transitions, with over 500/0 residing within CpG
dinucleotides (Soussi et al., 2000). Spontaneous deamination of 5-mC has been
hypothesized to be a cause of such transition mutations in epG sequences (Greenblatt et
aI., 1994) (Section 2.3.1 discusses hypermutability of epG dinucleotides). It has been
demonstrated that all of the CpG sites in the human p53 coding sequence investigated are
methylated in all tissue types studied (Tornaletti and Pfeifer, 1995). This demonstration
supports the hypermutability of the epG-dinucleotide hypothesis.
However, analysis by cancer type of these published p53 point mutations has
suggested a link between carcinogen exposure and human cancer (Hussain and Harris,
1998; Soussi et aI., 2000). In these studies, tissue-specific p53 mutations were observed,
suggesting the following three hypotheses: codon 249 mutation (AGG -> AGT) and
dietary aflatoxin B 1 CAF B 1) exposure in liver cancer, G to T transversions and cigarette
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smoke in lung cancer, and CC to TT dipyrimidine mutations and sunlight exposure in
skin cancer.
A G to T transversion at the third position of p53 codon 249 (AGG -> AGT) is the
dominant p53 mutation observed in human liver cancer and has been linked to dietary
AFB 1 (Hussain and Harris, 1998; Hernandez-Boussard et aI., 1999b; Soussi et aI., 2000).
This link has been supported by an observation in which a positive dose-response
correlation was found between estimated dietary AFB} exposure and the frequency of this
mutation in normal-appearing liver samples from hepatocellular carcinoma patients with
different AFB}-exposure levels (Aguilar et al., 1994). AFB} exposure to human cells in
vitro has shown to induce p53 mutations at positions other than the third of codon 249
(Aguilar et aI., 1993; Mace et aI., 1997). In addition, analysis of formed AFB} adducts in
the p53 gene has shown major adduct sites at positions other than codon 249 (Denissenko
et aI., 1998). These studies suggest that additional mechanisms, such as infection with
hepatitis B virus, may be required for selection of the G to T transversion at the third
position of p53 codon 249 in human liver cancer (Denissenko et aI., 1998).
The predominant p53 mutations observed in human lung cancer are G to T
transversions (Hernandez-Boussard et aI., 1999b). This observation is compatible with
the role of exogenous carcinogens present in cigarette smoke, such as BP. The three
most frequently reported p53 mutations of this kind in human lung cancer are at codons
157,248, and 273 (Hernandez-Boussard et aI., 1999b). A G to T transversion at one of
these codons, codon 248 (CGG -> CTG), has been shown to be generated as a result of
BP exposure to human cells in vitro (Cherpillod et aI., 1995). In addition to cigarette-
smoke exposure, formation of many BPDE-DNA adducts has been shown to be strongly
enhanced by methylation of CpG sites in the p53 gene (Denissenko et aI., 1996;
Denissenko et aI., 1997; Chen et aI., 1998). When HeLa cells and human bronchial
epithelial cells were treated with BPDE, this agent selectively induced guanine adduct
formation at CpG sites inp53 codons 157,248, and 273, in accordance with the p53
mutational hotspot codons observed in human lung cancer (Denissenko et aI., 1996).
Thus, two different 5-mC pathways appear to playa role in p53 mutagenesis associated
with human cancer: increased affinity of methylated CpG sites for DNA-reactive
molecules in addition to spontaneous deamination of 5-mC (Pfeifer et aI., 2000).
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Analysis of p53 mutations observed in human lung cancer based on smoking status has
supported the hypothesis that cigarette smoking as a direct cause of these mutations in
Hernandez-Boussard and Hainaut (1998), as well as in Hainaut and Pfeifer (2001).
Another study has supported cigarette smoking as a source of selecting pre-existing
mutations (Rodin and Rodin, 2000).
The commonality of tandem dipyrimidine CC to TT mutations in human squamous
and basal cell skin carcinoma has been observed (Brash et aI., 1991; Ziegler et aI., 1993).
A particular p53 mutation of this kind observed in human skin cancer has been analyzed
in normal-appearing skin samples from skin cancer patients with different sunlight-
exposure levels (Nakazawa et aI., 1994; Ouhtit et aI., 1997). In these studies, a positive
dose-response correlation between the sunlight-exposure level and the frequency of this
mutation was observed. In addition to the indicative role of sunlight exposure,
preferential DNA-adduct formation and differential DNA repair rates appear to playa
role in human skin cancer. Sites where preferential UV-adducts were formed in the p53
gene in human cells have been shown to correlate with the p53 mutational hotspot codons
observed in human skin cancer (Tornaletti et aI., 1993; Tommasi et aI., 1997). The
majority of these hotspots also have been shown to suffer from slow DNA repair of UV-
induced damage in human cells (Tornaletti and Pfeifer, 1994). These studies suggest that
preferential DNA-adduct formation and repair rate have contributed to the p53 mutational
hotspots observed in human skin cancer.
However, hypotheses made based on p53 mutations observed in human cancer should
be evaluated carefully. More than 70% of the molecular studies focus on the central
region of the p53 gene, exons 5 though 8 (Hemandez-Boussard et aI., 1999b; Soussi et
aI., 2000). In addition, many factors may influence detection and reporting of mutations,
including selection of tumor samples, study design, and choice of methods (Hernandez-
Boussard et aI., 1999a; Soussi et aI., 2000). Inter-individual variability in susceptibility
to carcinogens also suggests that a single pathway is highly unlikely (Vineis et aI., 1999).
For example, carcinogens form adducts with DNA, followed by DNA repair and
replication, rather than directly inducing specific point mutations (Vineis et aI., 1999).
Moreover, mutations found in advanced tumors may not be representative of the type of
damage created by an agent in the DNA of the original target cell (Vineis et aI., 1999). In
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addition, these mutations may not play any role in developing tumors (Strauss, 2000).
Thus, mutational analysis in normal tissues must be performed to understand cause-and-
effect relationships between environmental agents and human mutation. For such
analysis, genotype-based methods of measuring mutations in nonnal tissues are
necessary. Such methods should pennit measurement of rare mutations in the presence
of their abundant wild-type and should be general to the human genome.
2.4 Somatic nuclear mutations and mutant fractions in normal human tissues
Studies on mutations and mutant fractions observed in normal human tissues can be
used as a guide when planning further mutational analysis of normal tissues. This section
reviews studies on somatic nuclear mutations, as well as mutant fractions, observed in
normal human tissues. The review focuses on point mutations since these mutations are
the major mutation type observed in both inherited and somatic cases of human disease.
2.4.1 Phenotype-based analysis ofHLA and HPRT mutations
For selectable genes, such as HLA and HPRT, mutation assays based on phenotypic
selection have been developed for analysis of human blood (Albertini et aI., 1982;
Morley et aI., 1983; Albertini et aI., 1985; Janatipour et aI., 1988). Using such assays, a
mutant fraction of about 10-5 has been measured in both the HLA and HPRT genes in T-
lymphocytes of middle-aged healthy individuals (Grist et aI., 1992; Robinson et aI., 1994;
Akiyama et aI., 1995; Podlutsky et aI., 1998). These mutant fractions have been shown to
increase linearly with age (Trainor et aI., 1984; Vijayalaxmi and Evans, 1984; Davis et
aI., 1992; Grist et aI., 1992; Akiyama et aI., 1995; Green et aI., 1995). Figure 5 illustrates
this increase in the HPRT gene.
Assuming a target size of about 1000-bp for both the HLA and HPRT genes, the
expected average mutant fraction per bp in T-lymphocytes of middle-aged healthy
individuals is about 10-8. Any hotspot mutations occurring 10 to 100 times more
frequently than expected by chance would then appear in these genes at fractions between
10-7 and 10-6. Such hotspot mutations in the HPRT gene in cultured human cells have
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Figure 5. HPRT mutant fraction vs. age in T-lymphocytes of healthy individuals
Collection of published HPRT mutant fractions (Tomita-Mitchell, unpublished results); based on
6TG selection and clone-by-clone analysis.
been shown to represent between 10 and 50% of the point mutations that affect the
physiological function of the gene product (Kat, 1992; Tomita-Mitchell, 1999; Tomita-
Mitchell et aI., 2000).
Clone-by-clone analysis of 6TG-resistant HPRT mutants in T-lymphocytes of healthy
individuals has shown that, at birth, the predominant mutation type is large structural
alterations (85%), mostly deletions (McGinniss et aI., 1989). These deletion mutations
are thought to be mediated by V(D)J recombinase acting on sequences within the HPRT
gene that resemble the V(D)J recombinase signal sequences (Fuscoe et aI., 1991; Finette
et aI., 1996~ Fuscoe et aI., 1997). As people age, the predominant mutation type changes
to point mutations (85%), with the remaining 150/0 being large structural alterations
(Albertini et aI., 1990; Lippert et aI., 1990; Albertini et aI., 1993; Cariello and Skopek,
1993a; Albertini and Hayes, 1997). These observations indicate that factors other than
V(D)J recombinase playa role in causing mutations in people as they age.
Published 6TG-resistant HPRT mutations observed in T-lymphocytes of healthy
individuals have been compiled as a database (Cariello et aI., 1998). Table 5 summarizes
these mutations by mutation type and corresponding number. Figure 6 illustrates the
distribution of these mutations. Single base-pair substitutions account for 76% of all
mutations, with the remaining 24% being deletions and insertions. Among single base-
pair substitutions, transversions (41 %) are slightly more common than transitions (36%).
In addition, mutations at GC base pairs (48%) are more common than mutations at AT
base pairs (29%). G to A transitions are the most common type of mutation, accounting
for 27% of all mutations.
The HPRT database does not seem to pinpoint any particular kind of exogenous agent
as the cause for these mutations. For example, when kinds and positions of HPRT
mutations observed in smokers were compared to those of nonsmokers, no significant
differences were observed between the two sub-populations (Vrieling et aI., 1992;
Burkhart-Schultz et aI., 1996; Curry et aI., 1999; Podlutsky et aI., 1999). Thus, these
studies imply that HPRT mutations in healthy populations are endogenous in origin or
induced by ubiquitous environmental exposures (Podlutsky et aI., 1998; Podlutsky et aI.,
1999).
These mutational studies based on phenotypic selection performed on the blood of
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Table 5. Summary of somatic mutations in HPRT gene in T-Iymphocytes of healthy
individuals
Mutation type Number of entries (% total)
G->A 101 (27%)
A->G 34 (9%)
G->C 44 (12%)
G->T 34 (9%)
A->C 36 (10%)
A->T 36 (10%)
Insertion/deletion, 1-bp 53 (14%)
Insertion/deletion, >1-bp 36 (10%)
Total 374 (100%)
Source: Cariello et aI., 1998; courtesy of Dr. A. Tomita-Mitchell; based on 6TG selection and
clone-by-clone analysis.
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Figure 6. Distribution of somatic mutations in HPRT gene in T-Iymphocytes of healthy
individuals
Source: Cariello et aI., 1998; courtesy of Dr. A. Tomita-Mitchell; based on 6TG selection and
clone-by-clone analysis.
healthy individuals suggest the spontaneous origin of human HPRT mutation. While
mutational studies of other nuclear genes in normal human tissues remain to be
completed, such studies are hindered by the lack of general and sensitive methods of
measuring mutations based on their genotype. Mutation detection methods based on
phenotypic selection are limited to selectable genes, such as HPRT, and certain tissue
types, such as blood. For these reasons, genotype-based methods are the methods of
choice.
2.4.2 Phenotype-based analysis ofp53 mutations
Mutant forms of the p53 protein have been detected in skin tissues of healthy
individuals (Ponten et aI., 1995; Jonason et aI., 1996; Tabata et aI., 1999). By using
antibodies specific to p53, the mutant forms can be stained as individual patches (Gannon
et aI., 1990; Iggo et aI., 1990; Baas et aI., 1994). In this assay,p53 mutants are
distinguished from the wild-type by their longer half life (Finlay et aI., 1988; Harris and
Hollstein, 1993). Each compact pattern of the stained patches, a contiguous area of
homogeneously stained cells, represents clones derived from a single cell with a p53
mutation (Jonason et aI., 1996; Ren et aI., 1996; Ren et aI., 1997). Between 50 and 70%
of the patches have been shown to contain such clones (Jonason et aI., 1996; Ponten et
aI., 1997; Ren et aI., 1997).
Using such a phenotype-based assay, p53 mutant fractions in skin tissues of healthy
individuals can be estimated. Table 6 summarizes the estimated mutant fractions. On
average, 33 and 3 p53-immunopositive patches per cm2 of human skin have been
observed in sun-exposed and sun-shielded areas, respectively (Jonason et aI., 1996). By
dividing these observed values by the stem cell number per cm2 of skin, the p53 stem cell
mutant fractions can be estimated. About 4.5 x 106 keratinocytes have been estimated per
cm2 of normal human skin (Pinkus, 1952; Bergstresser et aI., 1978; Weinstein et al.,
1984). And among these keratinocytes, between 2 and 10% have been found to be stem
cells (Pinkus, 1952; Potten and Hendry, 1973; Potten, 1981; Potten and Morris, 1988).
Using the stem cell number of 2.7 x 105 per cm2 of human skin (median value: (4.5 x 106)
X 0.06), the p53 stem cell mutant fractions can be estimated to be about 1.2 x 10-4 (33 +
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Table 6. Summary of p53 mutant fractions in skin tissues of healthy individuals
Level of sun
exposure
Low/sun-shielded
Stem cell mutant
fractiona
1.1 X 10-5
Total mutant
fractionb
Average mutant
fractionlbpC
High/sun-exposed 1.2 x 10-4 10-3 to 4 X 10-2 10-6 to 4 X 10-5
a On average, 33 and 3 p53-immunopositive patches per cm2 of human skin have been observed
in sun-exposed and sun-shielded areas, respectively (Jonason et aI., 1996). The stem cell mutant
fractions were estimated by dividing these observed values by the stem cell number per cm2 of
human skin, 2.7 x 105.
b Jonason et aI., 1996.
C Assuming a target size of about 1000-bp for the p53 gene, the average mutant fractions per bp
were estimated by dividing the total mutant fractions by 1000.
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(2.7 X 105)) and 1.1 x 10-5 (3 + (2.7 x 105)) for sun-exposed and sun-shielded areas,
respectively. In this estimation, all irnrnunopositive patches are assumed to be clones,
each representing an individual mutant.
The total p53 mutant fractions are expected to be higher than the stem cell mutant
fractions because of the clonally-derived nature of the immuopositive p53 mutant patches
(Jonason et aI., 1996~ Ren et aI., 1996~ Ren et aI., 1997). The total mutant fractions in
skin tissues of healthy individuals have been estimated to be 10-3 to 4 X 10-2 and 10-4 to
10-3 in sun-exposed and sun-shielded areas, respectively (Jonason et al., 1996) (see Table
6). In this estimation, the total mutant fraction was estimated by averaging the measured
area of clones and then multiplying by the number of clones per cm2.
Assuming a target size of about 1000-bp for the p53 gene, the average mutant
fractions per bp in skin tissues of healthy individuals are expected to be 10-6 to 4 X 10-5 in
sun-exposed areas and 10-7 to 10-6 in sun-shielded areas (see Table 6). Any hotspot
mutations occurring 10 times more frequently than expected by chance would then
appear in this gene at fractions 10 times higher than the expected average mutant
fractions for both sun-shielded and sun-exposed areas.
When the average p53 mutant fractions per bp were compared, up to a 400-fold higher
mutant fraction has been observed in sun-exposed relative to sun-shielded skin (Jonason
et aI., 1996). On the other hand, another study showed no such difference (Guhtit et aI.,
1998). This discrepancy is perhaps because one study was based on a particular p53
mutant (Ouhtit et aI., 1998), while the other was based on mutations in the entire p53
gene (Jonason et aI., 1996). Further mutational analysis in normal human skin is
necessary to validate either study.
2.4.3 Genotype-based analysis of ras and p53 mutations
Several nuclear point mutations have been observed in tissues of healthy individuals
without reference to phenotypic selection (Wilson et aI., 1999~ Ouhtit et aI., 1999; Wilson
et aI., 2000; Li-Sucholeiki et aI., unpublished results). Either allele-specific PCR or
restriction fragment length polymorphism (RFLP)/PCR (see Section 2.5.3.2) was used as
the genotype-based means for such observation. All of these mutations had been
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previously observed in human tumors (Bas, 1989; Hainaut et aI., 1998; Hernandez-
Boussard et al., 1999b).
Table 7 summarizes the position, kind, mutant fraction, and observed number of cases
for each mutation detected in normal human tissues. Among these mutations, about a 50-
fold higher average mutant fraction was found in lungs compared to that in either blood
or skin (5 x 10-5 vs. 10-6). However, this comparison is based on mutations in different
genes, as well as mutations in the same gene but at different base-pair positions. When a
particular p53 mutation in normal human skin tissues of different sun-exposure levels
was compared, no statistically significant relationship was found between levels of sun
exposure and mutant fractions (Ouhtit et aI., 1998). In addition, no significant
differences were observed in the level of this mutation among people of different ages or
genders (Ouhtit et aI., 1998).
A similar level of mutant fractions has also been observed in normal-appearing
smokers' lungs compared to those of non-smokers' (Li-Sucholeiki et aI., unpublished
results). In this study, two G to T transversions in the p53 gene were detected in two
smokers' and two nonsmokers' lungs, with an average mutant fraction of 5 x 10-5 for
each, in smokers' and nonsmokers' lungs. These results indicate that cigarette smoking
does not affect the kind or number of nuclear point mutations in human bronchial
epithelial cells. These results confirm a previous observation made in human
mitochondrial DNA (Coller et aI., 1998).
These genotype-based mutational studies performed on normal human tissues do not
pinpoint any particular exogenous agent as a cause for these mutations. However, these
studies are few. Therefore, additional studies analyzing more genes, tissue types, and
individuals are necessary to validate any observations made in these previous studies.
2.5 Criteria for measuring point mutational spectra in normal human tissues
Analysis of somatic point mutational spectra in nonnal human tissues allows direct
testing of the hypothesis that environmental agents are the primary cause of human
mutation. Comparison of mutational spectra in smokers' and non-smokers' lungs reveals
effects of cigarette smoke on human mutation. The same type of comparison can be
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Table 7. Summary of nuclear point mutations in normal human tissues*
Tissue Gene Position and kind Mutant fraction (mf) Number of
type cases
Codon 12.2,
H-ras G->T ~ 10-6 3
Codon 12.1,
G->T ~ 10-6 3
Bloodu&b Codon 12.2,
N-ras G->T ~ 10-6 6
Codon 13.1,
G->A ~ 10-6 1
Codon 248.1,
C->A ~ 10-6 1
Codon 248.1
p53 (eDNA bp 742), ~ 10-6 6
C->T
Codon 249.2
p53 (eDNA bp 746) :::::5 x 10-5d ~200e
Lunge G->T
Codon 249.3
p53 (eDNA bp 747) :::::5 x 10-5d ~200e
G->T
< 0.5 x 10-6 58
0.5 ::; mf ~ 0.99 x 10-6 8
Skinf p53 Codon 247.3&248.1
(eDNA bp 741&742), 1.0~mf::; 1.49x 10~6 4
CC ->TT
1.5 ::; mf ::; 2.49 x 10-6 2
2:: 2.5 x 10-6 3
* Genotype-based mutational analysis.
a Wilson et aI., 1999.
b Wilson et aI., 2000.
e Li-Sucholeiki et aI., unpublished results: tracheal bronchial epithelial cells of deceased middle-
aged individuals, considered as healthy individuals, were analyzed. These individuals died of
either stroke or subarachnoid hemorrhage cerebrovascular disease.
d Average mutant fraction.
e Two smokers' and two nonmokers' lungs were microdissected into about 200 sectors.
f Ouhtit et aI., 1998.
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performed in sun-exposed and un-exposed human skin. However, detection of mutations
in normal tissues with statistical significance requires a careful planning since these
mutations are present as a much smaller copy number compared to the wild-type copy
number (mutations in normal tissues are rare mutations). This section reviews studies on
criteria for measuring rare mutations with statistical significance. This review includes
stem cell turnover unit size, sample size, and method of analysis.
2.5.1 Turnover unit size
A stem cell gives rise to descendent transition and terminal cells (Potten, 1981; Patten
and Morris, 1988; Potten and Loeffler, 1990), generating a stem cell compartment, or a
turnover unit. Thus, a mutation in a stem cell leads to a clonally-derived mutant turnover
unit. Existence of such mutant turnover units in normal human tissues has been
suggested and demonstrated (Jonason et aI., 1996; Khrapko et aI., 1997a; Coller et aI.,
1998; Li-Sucholeiki et aI., unpublished results).
DNA sequencing analysis of immunopositive p53 mutant patches has shown that these
patches are clonally-derived, each patch representing a particular p53 mutation, in skin
tissues of healthy individuals (Ponten et al., 1995; Jonason et al., 1996; Tabata et al.,
1999). The turnover unit size for these p53 mutations was observed to be between 60 and
3000 cells, with different average unit sizes in tissues of different sun exposure levels:
0.014 mrn2 in sun-shielded tissues and 0.040 mm2 in sun-exposed tissues (Jonason et aI.,
1996). These unit sizes are equivalent to 630 cells (0.014 mm2 x (4.5 x 106/cm2)) and
1800 cells (0.040 mm2 x (4.5 x 106/cm2)) using the cell number of 4.5 x 106 per cm2 of
normal human epidermis (Pinkus, 1952; Bergstresser et aI., 1978; Weinstein et aI., 1984).
Using allele-specific peR, particular p53 mutations have been detected as mutant-rich
clusters in normal-appearing human bronchial epithelial cells (Li-Sucholeiki et aI.,
unpublished results). These clusters are thought to be clonally derived. In this study, no
difference in mutant turnover unit size was observed, determined to be about 32 cells in
both smokers' and non-smokers' lungs. These results contradict the study of Jonason et
ai. (1996) in which, on average, about a 3-fold higher mutant turnover unit size was
observed in mutagen-exposed (sun-exposed) relative to un-exposed (sun-shielded) areas
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of normal human skin. This study suggests sunlight as the cause for this increase. This
contradiction is probably because two different tissue types, lung vs. skin, and two
different mutagens, cigarette vs. sunlight, were compared.
While turnover unit size has not been detennined for all tissue types, this factor should
guide planning somatic mutational analysis in nonnal human tissues. For example, in a
sample containing 108 cells with a turnover unit size of 32 cells, the expected number of
turnover units is about 3 x 106 (108 + 32). Using the observed HPRT and HLA mutant
fractions, 10-5 (see section 2.4.1),30 stem cell mutations (10-5 x (3 X 106) =30) would
appear in each gene. Thus, the expected number of mutations per 100-bp sequence is 3,
assuming a target size of 1000-bp for these genes. This expectation predicts that to
observe 30 mutations, either a 100-bp sequence in 10 tissue samples, each containing 108
cells, or 10 sequences, each containing 100-bp in the same sample of 108 cells, must be
analyzed.
2.5.2 Sample size
When planning detection of somatic mutations in normal tissues, sample size must be
examined. Sample size can be limited by choice of mutation detection method, thereby
limiting the copy number of any particular mutant to be analyzed. For example, for a
sample size of 105 diploid human cells containing a mutation at a fraction of 5 x 10-6 in a
single copy sequence, one mutant copy (105 X 2 x (5 X 10.6)) would be available for
analysis. Based on the Poisson distribution, the probability of not detecting this mutation
is 0.37 (e- l ). Thus, this sample would generate false negatives 37% of the time,
confounding mutational analysis.
Mutation detection with sufficient precision, such as ±20%, requires a statistically
significant copy number of any particular mutant, at least 100 copies (Leong et aI., 1985;
Keohavong and Thilly, 1992a; Chen and Thilly, 1994). Thus, for example, a sample size
of at least 107 cells ((~107) x 2 x (5 x 10-6) =(2100)) is required for a mutation occurring
at a fraction of 5 x 10-6 in a single copy sequence. To sum up, reproducible outcomes
have been demonstrated in which at least 100 copies of any particular mutant were
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detected in various human cell and tissue samples (Keohavong and Thilly, 1992b;
Khrapko et aI., 1997a; Coller et al., 1998; Li-Sucholeiki and Thilly, 2000).
2.5.3 Methods
Detection of mutations present as abundant copies, representing mutations in diseased
tissues, can be as simple as DNA sequencing (Cooper and Krawczak, 1993). However,
somatic mutations in normal tissues are rare mutations, and analysis of these mutations
requires more sophisticated methods. This section reviews available methods of
analyzing rare mutations in human genomic DNA.
2.5.3.1 Hifi-PCR
Introduction of thermostable DNA polymerases to irl vitro DNA amplification, PCR,
has simplified the amplification by allowing it to be automated (Saiki et aI., 1988).
However, careful selection of a polymerase is necessary for analysis of amplified
products since different polymerases generate mutations in a chosen target at various
rates during PCR (Keohavong and Thilly, 1989; Cariello et al., 1991; Mattila et al., 1991;
Ling et aI., 1991; Flarnan et aI., 1994; Cline et aI., 1996). Table 8 summarizes the
fidelities of, as well as predominant mutations generated by, three thermostable DNA
polymerases commercially available, Thermus aquaticus (Taq), Thermococcus litoralis
(Vent), and Pyrococcus furiosus (Pfu).
While for certain applications of PCR products, such as DNA sequencing, the levels
and kinds of mutations generated by a polymerase are not a concern, application to
analysis of rare mutations requires a polymerase with high fidelity. To date, Pfu offers
the highest fidelity among the thermostable DNA polymerases available commercially
(Flaman et aI., 1994; Cline et aI., 1996; Andre et aI., 1997). Thus, it is the enzyme of
choice for rare event analysis. The fidelity of Pfu has been determined to be about
10-6/bp/doubling (see Table 8), a factor which can guide planning of mutational analysis.
A typical template target copy number for PCR is about 105 to 106 (:=::; 1 to 10 ~g) and a
chosen target can be amplified up to about 10]2 copies (106- to 107-fold amplification or
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Table 8. Characteristics of thermostable DNA polymerases
DNA polymerase
Taq
Vent
Fidelitylbp/doubling*
0.72 - 2.4 x 10-4 (8/13)a
2.4 - 4.5 x 10-5 (5/7)b
Predomina~t mutation type**
A -> G (84/157)d
A -> G (16/18)e
Pfu 0.65 - 2 x 10~6 (8/10)C G -> T (15/19)f
* Reported fidelities were gathered and each was counted as one. The range indicated is based on
the reported fidelities in close agreement. For example, 8 out of 13 were in the range indicated
for Taq.
**·Reported mutations were gathered and each was counted as one. For example, 84 out of 157
were A -> G transitions for Taq.
a Saiki et aI., 1988; Tindall and Kunkel, 1988; Keohavong and Thilly, 1989; Eckert and Kunkel,
1990; Cariello et aI., 1991; Chen et aI., 1991; Ling et a1., 1991; Lundberg et a1., 1991; Keohavong
et aI., 1993; Flaman et aI., 1994; Cline et aI., 1996; Huang and Keohavong, 1996; Smith and
Modrich, 1996.
b Cariello et aI., 1991; Ling et aI., 1991; Mattila et aI., 1991; Keohavong et aI., 1993; Cline et aI.,
1996; Smith and Modrich, 1996.
C Lundberg et aI., 1991; Brail et aI., 1993; Cariello and Skopek, 1993b; Barnes, 1994; Flaman et
aI., 1994; Cline et aI., 1996; Smith and Modrich, 1996; Andre et aI., 1997; Parsons and Heflich,
1998; Li-Sucholeiki and Thilly, 2000.
d Dunning et aI., 1988; Saiki et aI., 1988; Keohavong and Thilly, 1989; Ennis et aI., 1990; Chen et
aI., 1991.
e Keohavong et aI., 1993.
f Andre et aI., 1997~ Li-Sucholeiki and Thilly, 2000.
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20 to 23 doublings) (Saiki et aI., 1988; Cha and Thilly, 1993). For this reason, Pfu-
generated mutations in a chosen target after 20 doublings are discussed in this section.
After 20 doublings are performed with a sample using Pfu, any hotspot mutations of Pfu
origin occurring 10 times more frequently than expected by chance would appear in the
amplified target at a fraction of 2 x 10-4 (10-6/bp/doubling x 20 doublings x 10). If, for
example, the initial sample contained mutations at a fraction of about 2 x 10-4, the level of
these mutations would be indistinguishable from the Pfu-hotspot mutations, which would
interfere with the sample analysis. Especially if this sample contained mostly G to T
transversions, the analysis would be even more confounded since the predominant
mutation generated by Pfu is a G to T transversion (see Table 8). Thus, either mutations
at initial fractions of above 2 x 10-4 should be analyzed or pre-PCR mutant enrichment
must be performed when analyzing mutations at initial fractions at or below 2 x 10-4•
2.5.3.2 Genotype-based point mutation detection
This section reviews studies on genotype-based methods of analyzing rare point
mutations, representing somatic point mutations in normal tissues. Unlike phenotype-
based methods, which can be applied to selectable genes and certain tissue types,
genotype-based methods offer analysis of any gene and tissue type of interest. However,
detection of rare mutations requires enrichment of mutant sequences relative to the
abundant wild-type sequence. Mutant enrichment can be achieved by selectively
amplifying a particular mutant sequence (allele-specific PCR), selectively destroying the
wild-type sequence (RFLPIPCR), or spatially separating mutant from wild-type
sequences (target isolation/CDCE/hifi-PCR) (Parsons and Heflich, 1997b). Table 9
summarizes sensitivities, target sizes, and analysis limitations of these genotype-based
methods of analyzing point mutations at fractions at or below 5 x 10-5 in human genomic
DNA. All of these assays use an internal standard to determine the level of mutations in
initial samples.
56
Table 9. Characteristics of genotype-based methods of rare point mutational analysis
Method*
Allele-specific PCRa
RFLPIPCRb
Sensitivity** Target size
(bp)
1
~4-6
Analysis limitation
Small target size
Mutations in restriction
recognition sequences
Target isolation Mutations in sequences with
/CDCE/hifi-PCRc 10-6 ~ 100 neighboring natural clamp
* Two point mutation detection methods, MutEx/ACB-PCR (Parsons and Heflich, 1998) and
MutEx/PCR/SNuPE (Parsons and Heflich, 1997b), with sensitivities of 10-7 and 2 x 10-5/bp,
respectively, are not included in this table since these sensitivities have not been demonstrated in
human genomic DNA.
** Sensitivities in human genomic DNA are based on the mutant copy number detected, x, in the
presence of the wild-type copy number, y: x 7 y ("Chen and Zarbl, 1997; bChiocca et aI., 1992;
cLi-Sucholeiki and Thilly, 2000).
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2.5.3.2.1 Allele-specific peR
Detection of a point mutant by allele-specific PCR is based on preferential
amplification of a known mutant sequence using mismatched primers. Primers that
contain one mismatch to a mutant at the 3'end but two mismatches to the wild-type can
preferentially amplify the mutant relative to the wild-type in a PCR reaction mixture (Cha
et aI., 1992). The amplified mutant in a polyacrylamide gel can then be quantified by
comparing its signal intensity to the control PCR samples in which initial mutant
fractions are varied. Recently, such analysis has been performed by capillary
electrophoresis coupled with laser-induced fluorescence detection, and the initial mutant
copy number was measured using an internal standard (Li-Sucholeiki et aI., unpublished
results).
The sensitivity of allele-specific peR, 10-6, has been demonstrated in human genomic
DNA (~10 J-lg) in which 5 copies of a mutant were detected in the presence of 3 x 106
copies of the wild-type (Chen and Zarbl, 1997). This method has been applied to
analysis of nuclear point mutations in normal human skin and lung tissues (Nakazawa et
aI., 1994~ Guhtit et aI., 1997; Ouhtit et aI., 1998; Li-Sucholeiki et aI., unpublished
results).
The advantages of allele-specific PCR over RFLP/PCR and target
isolation/CDCE/hifi-PCR are its rapidity and simplicity. However, this method offers the
smallest target size, 1-bp, and detection of a single mutant at a time. Thus, analysis of
various point mutations in the same target of I-bp requires multiple assays to be
optimized and performed, thereby eliminating its advantages especially when a larger
target, such as 100-bp, needs to be analyzed.
2.5.3.2.2 RFLP/PCR
RFLP, when coupled with peR, allows detection of point mutations in restriction
recognition sequences (Parry et aI., 1990; Zijlstra et aI., 1990; Felley-Bosco et aI., 1991).
Genomic DNA is restriction digested during which mutant sequences in the recognition
site of the chosen restriction endonuclease are not cleaved, while the wild-type is cleaved,
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enriching for mutants. The uncleaved sequences are then PCR amplified. To generate
the majority of the amplified products belonging to the mutants, as opposed to the un-
cleaved wild-type, restriction digestion and PCR are repeated 2 to 3 times prior to
analysis. The amplified mutants are identified by DNA sequencing or are quantified by
oligonucleotide plaque hybridization using sequence-specific probes.
The sensitivity of RFLP/PCR, 4 x 10-7, has been demonstrated in human cells in which
4 copies of each mutant were detected in the presence of 107 copies of the wild-type
(Chiocca et al., 1992). This method has been applied to analysis of nuclear point
mutations in mutagen-treated human cells (Chiocca et aI., 1992; Palombo et aI., 1992;
Pourzand and Cerutti, 1993a, b; Hussain et aI., 1994) and normal human tissues (Aguilar
et al., 1994; Hussain et al., 1994). The sensitivity of the combined method of RFLP/PCR
and ligation chain reaction (LCR) has also been demonstrated in human cells in which 1
copy of each mutant was detected in the presence of 107 copies of the wild-type (10-7)
(Wilson et aI., 1999). RFLPIPCR/LCR has been applied to point mutational analysis in
peripheral blood of healthy individuals (Wilson et aI., 1999; Wilson et aI., 2000).
To date, RFLP/PCR and RFLPIPCR/LCR offer the highest sensitivity among the point
mutation detection methods available for analysis of human cells and tissues without
phenotypic selection. However, these methods not only have a small target size of about
4 to 6-bp but are prone to generating polymerase-created false positives. Assuming that
the efficiency of the first restriction digestion is 100%, the target copy numbers in the
initial sample, 1 and 107 of each mutant and of the wild-type (initial mutant fraction =
10-7), respectively, change to 1 and 105 (enriched mutant fraction =10-5) after digestion.
If, for example, a 106-fold amplification (20 doublings) is performed with this sample
using Pfu DNA polymerase, any Pfu-hotspot mutations occurring 10 times more
frequently than expected by chance would appear in the anlplified target at a fraction of
about 2 x 10-4 (see Section 2.5.3.1). This mutant fraction is about 10 times higher than
the level of mutations in the restriction digested target (2 x 10-4 vs. 10-5), which would
interfere with the sample analysis. Since such Pfu-generated hotspot mutations would
not appear in every restriction recognition sequence of about 4- to 6-bp, the sensitivity of
RFLP/PCR or RFLP/PCR/LCR would vary for different restriction recognition
sequences. Indeed, a 1000-fold difference in sensitivity has been reported using two
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different sequences (Pelley-Bosco et at, 1991). Thus, the demonstrated sensitivity of
about 10-7 (Chiocca et aI., 1992; Wildson et aI., 1999) is valid for certain, but not all,
sequences.
2.5.3.2.3 Target isolation/CDCE/hifi-PCR
CDCE is a DNA separation technique by which point mutations in a chosen target can
be differentiated from the wild-type based on differences in their melting temperatures.
CDCE is in a capillary gel format (Khrapko et aI., 1994a), derived from slab gel formats
using the same separation principle: DGGE (Fischer and Lerman, 1983) and CDGE
(Hovig et aI., 1991). The advantages of CDCE over DGGE or eDGE are rapidity (min
vs. hr, Khrapko et aI., 1994a, b) and higher sensitivity (3 x 10-4 (Khrapko et aI., 1994a)
vs. 1 to 10 X 10-3 (Cariello et aI., 1990; Keohavonget aI., 1992b) without prior mutant
enrichment). In addition, CDCE offers DNA separation with high resolution (Khrapko et
aI., 1994b). Especially for the purpose of analyzing rare mutations, CDCE is the method
of choice since it avoids interfering factors associated with the slab gel techniques, such
as heat-induced DNA damage due to extensive incubation at high temperature and DNA
radiolysis caused by radioactive labels used for detection (Hanekamp, 1993).
Figure 7 depicts the CDCE separation principle with a hypothetical melting profile of
a DNA fragment suitable for CDCE separation. A melting profile is defined as a plot
which shows the calculated temperature at which each base pair has an equal chance of
being in a helix (un-melted) or random (melted) form (Fischer and Lerman, 1983).
CDCE, when combined with target isolation and hifi-PCR, allows detection of point
mutations at fractions as low as 10-6 (Li-Sucholeiki and Thilly, 2000). Figure 8 illustrates
a flow diagram of this combined method. This method has been applied to analysis of
point mutations in a 121-bp nuclear single copy sequence in mutagen-treated human cells
(Li-Sucholeiki and Thilly, 2000). In this application, a sensitivity of 10-6 was
demonstrated in which at least 102 copies of each mutant were detected in the presence of
108 copies of the wild-type. This sensitivity is limited by the fidelity of Pfu DNA
polymerase used for PCR.
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Figure 7. DNA separation by CDCE
A. A fragment suitable for CDCE separation contains a low-melting, or target, domain of
about lOO-bp juxtaposed with a domain of a higher melting temperature, or a clamp.
B. Since the melting temperature of the clamp is higher than that of the target, a
partially-melted intermediate can be formed under a certain range of denaturant
concentrations or temperatures. Introducing point mutations to the target generates
differential equilibria between partially-melted and un-melted forms, resulting in
different electrophoretic mobilities from that of the wild-type. Thus, these point
mutations can be CDCE separated from the wild-type under optimal denaturing
conditions.
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Restriction-digested human genomic DNA
Initial sample size: 108 cells (~600 J-lg gDNA)
Initial target DNA copy number: 2 x 108
Initial mutant fraction: 10-6
Target isolation by probes
(Efficiency: 104-fold)
Sample size: ~ 60 fig gDNA
Target DNA copy number: ~2 x 108
Mutant fraction: 10-6
+
Pre-PCR mutant enrichment by CDCE and CE
(Efficiency: ~ 10G-200-fold)
Mutant fraction: ~1-2 x 10-4
,
Hifi-PCR followed by post-peR mutant enrichment by CDCE
(Two rounds, total efficiency::::; 10O-fold)
Final mutant fraction: ~ 1-2 x 10-2
,
Mutational analysis by CDCE
Individual mutant purification by CDCE for sequencing
Figure 8. Flow diagram of target isolation/CDCE/hifi-PCR
A chosen target is isolated from a genomic DNA digest using biotin-labeled probes.
For this procedure, sequence-specific hybridization is coupled with a biotin-streptavidin
capture system. This procedure is followed by pre-peR mutant enrichment, performed
first by separating mutant from wild-type sequences by CDCE and then by eluting these
separated mutants. Capillary electrophoresis (CE) is then performed as an additional
means to enrich for mutants; CE differentiates mutants from wild-type containing
species, such as single strands, in CDCE mutant-enriched samples. Post-PCR mutant
enrichment is also performed by CDCE separation and elution. Hifi-PCR and post-peR
mutant enrichment, repeated in two rounds, are performed prior to mutational analysis by
CDCE. At this stage, each individual mutant is CDCE purified for sequencing.
Source: Li-Sucholeiki and Thilly, 2000.
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To date, target isolation/CDCE/hifi-PCR offers the largest target size over allele-
specific PCR and RFLPIPCR. In addition, this method allows detection of point
mutations at fractions as low as 10-6 with a statistical significance, such as ±20%
precision, through its ability to handle large sample sizes of up to about 108 human cells
(~600 Ilg genomic DNA). Analysis of such a large sample size is permitted by target
isolation by which an initial sample size of 600 Ilg of human genomic DNA can be
reduced to 60 ng, while retaining the same copy number of a chosen target.
One major drawback of target isolation/CDCE/hifi-PCR is that it can be applied only
to DNA sequences with a neighboring natural clamp. To increase the pool of target
sequences in the human genome, a means of attaching a clamp to any sequence of interest
needs to be included in this method. Available methods of clamp attachment are
reviewed in the following section.
2.5.3.3 Clamp attachment
Point mutational analysis by DGGE, eDGE, or CDCE requires DNA sequences with
a clamp. While sequences with a natural clamp can be directly analyzed by these
methods, clamp attachment is necessary for those sequences without a natural clamp.
Three methods are available for attaching a clamp to a DNA sequence of interest (Myers
et aI., 1985b; Sheffield et aI., 1989; Abrams et aI., 1990). The principle of each method
with limitations is reviewed in this section.
2.5.3.3.1 Cloning-based method
Myers et aI. (1985a) first predicted and demonstrated that the melting property of a
DNA sequence can be changed by clamp attachment. A clamp, rich in GC bases, is
attached to a target sequence of interest by inserting the target into a plasmid vector
containing the clamp. For this insertion, linkers of restriction ends are ligated to both
ends of the target and the clamp: BamH I (5'GATC3') and Bgl II (5'GATC3') to the
target, and BamH I and Hind III (5'AGCT3') to the clamp. Thus, the clamp can be
ligated to the plasmid after digesting the plasmid with BanlH I and Hind III, and either
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end of the target can be ligated to the BamH I end of the clamp after digesting the clamp-
ligated plasmid with BamH I.
While point mutations in a chosen target with the attached clamp have been shown to
be separated by DGGE, the same demonstration could not be performed using the same
target without a clamp (Myers et aI., 1985b). This demonstration shows that clamp
attachment can make DNA sequences without a natural clamp suitable for point
mutational analysis by DGGE, CDGE, or CDCE. However, this cloning-based method
of clamp attachment has not been demonstrated with genomic DNA. Thus, this method
as it is cannot be applied to mutational analysis in human cells and tissues.
2.5.3.3.2 PCR-based method
Two PeR-based methods of clamp attachment have been developed. The primary
method has been demonstrated using genomic DNA as a template and using primers to
which an additionaI40-45-bp sequence is added at the 5' end (Sheffield et aI., 1989).
This added sequence is non-complementary to the target and rich in GC bases. A clamp
is attached to one end of the amplified sequence by the GC-rich primers during PCR.
The second method is rather an alternative to clamp attachment, called chemiclamping
(Girodon et aI., 1993; Gille et aI., 1998). This method uses PCR primers with a psoralen
derivative at the 5' end, combined with UV irradiation of the PCR products. As a result,
cross-linking is induced, forming the covalent bond between the two target strands of the
peR products. Depending on whether the cross-linking is desired at one or both ends of
a target, the 5' modified primers can be designed for one (Girodon et aI., 1993) or both
ends (Gille et aI., 1998). Although a GC-rich sequence is not added to the primers, point
mutations in a cross-linked target have been demonstrated to be suitable for DGGE
separation (Girodon et aI., 1993; Gille et aI., 1998).
The major advantage of the PeR-based methods of clamp attachment over cloning-
and probe-based methods is their simplicity. However, these methods cannot be applied
to analysis of point mutations at fractions below 2 x 10-4. Detection of mutations at such
low fractions requires pre-PeR mutant enrichment, as Section 2.5.3.1 discusses and
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Figure 8 in Section 2.5.3.2.3 illustrates. Therefore, clamp attachment must be performed
without peR.
2.5.3.3.3 Probe-based method
Figure 9 illustrates the probe-based method of clamp attachment (Abrams et aI.,
1990). This method is the only available method of clamp attachment, which can
potentially be applied to target isolation/CDCE/hifi-PCR. Such an application would
allow analysis of point mutations at fractions below 2 x 10-4 in any DNA sequence of
interest in the human genome.
However, two factors regarding this probe-based method should be noted. The first is
the preparation procedllre of the probes. The probes are prepared by constructing single-
stranded plasmid vectors containing a clamp and inserting a chosen target sequence into
the vectors. These vectors are used as a template for generating biotin-labeled probes by
primer extension using biotin-labeled primers. These primer-extended vectors are then
restriction digested and denatured with NaOH. The strand with the biotin-label is
purified by aVidin-agarose chromatography, which distinguishes biotin-labeled from
unlabeled fragments. This procedure is followed by alkaline-agarose gel electrophoresis,
which differentiates single-stranded DNA fragments based on their length (McDonell et
aI., 1977).
This probe preparation procedure is not only labariolls but introduces mutations to the
probes at the same time. Klenow DNA polymerase, used for primer extension, has been
shown to create small deletions and single base-pair substitutions (Scharf et aI., 1986; de
Boer and Ripley, 1988; Keohavong et aI., 1989; Bell et aI., 1997) at a rate of about
10-4/bp/doubling (Scharf et aI., 1986; Keohavong et aI., 1989). Thus, any Klenow hotspot
mutations occurring 10 times more frequently than expected by chance (1 % hotspots)
would be generated at a rate of about 10-3/doubling. These 1% hotspot mutations are
expected in the probes at a fraction of 10-3 after primer extension. Thus, unless the
probes are purified for the wild-type, the probes cannot be applied to analysis of point
mutations at fractions below 10-3, assuming Klenow hotspot mutations are not generated
any higher than 1%.
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Digestion
......
Target
Probe
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Probe (1: Clamp, 2: Target)
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Polymerase,
dNTPs
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Figure 9. Probe-based method of clamp attachment
Human genomic DNA is restriction digested to liberate a chosen target. This DNA is
then denatured, mixed with probes, and allowed to form probe-target hybrids. The
probes contain the sequence complementary to the entire target of choice with an
additional sequence belonging to a clamp, rich in GC bases, at the 5'end. These hybrids
of partial double strands are treated with DNA polymerase and four dNTPs to generate
fully double-stranded fragments.
Source: Abrams et aL, 1990.
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The second factor that should be noted regarding the probe-based method is the
efficiency of clamp attachment to a chosen target. Assuming 100% of a chosen target in
a genomic DNA digest forms hybrids with the probes, the clamp attachment efficiency
would be equal to the efficiency of the probe-target hybrids converting to fully base-
paired fragments (see Figure 9). It is desirable to have a clamp sequence rich in GC
bases, but increase in the GC content of a template DNA has been shown to reduce the
template amplification efficiency (McDowell et aI., 1998). Thus, the efficiency of the
hybrids converting to fully base-paired fragments may be low. This efficiency can be
increased to some degree by introducing additives such as formamide (Sarkar et aI.,
1990; Varadaraj and Skinner, 1994), DMSO (Winship, 1989; Bookstein et aI., 1990; Sun
et aI., 1993), and betaine (Henke et aI., 1997). However, the clamp attachment efficiency
of the probe-based method has not been determined. Especially when DNA sample size
is a limiting factor for analysis of point mutations at low fractions, achieving high
efficiency clamp attachment is critical.
The clamp attachment method developed in this thesis generates a clamp attachment
efficiency of greater than 95%. This method is based on enzymatic ligation coupled with
mass action. Since clamp attachment is performed without peR, this method can be
combined with target isolation/CDCElhifi-PCR for analysis of point mutations at
fractions below 2 x 10-4. This combination increases the scanning range for the human
genome. Target isolation/CDCE/hifi-PCR alone can be applied to only those DNA
sequences with a natural clamp, representing about 9% of the human genome. In
addition, none of gene-coding regions for certain genes like p53 and BRCA 1 can be
studied by this method. However, the combined method of clamp ligation and target
isolation/CDCE/hifi-PCR allows analysis of the majority, if not all, of gene-coding
regions.
2.6 Criteria for measuring inherited point mutational spectra in human populations
Studies of inherited point mutational spectra in human populations allow testing of the
relationship of genes to diseases and the discovery of causative alleles over the entire
gene, as Figure 10 summarizes. However, such studies require analysis of a large
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Figure 10. Analysis of inherited point mutational spectra in human populations
A. Age-specific decline ~n sum of alleles coding for risk of disease is expected in human
populations since carriers would die earlier in life than non-carriers.
B. If the hypothesis illustrated in Figure lOA is true, analysis of the entire set of a
gene's alleles (inherited point mutational spectra) in human popll1atio~s as a function
of age can be used as a means to identify causative alleles. Allele-specific decline is
expected for causative alleles as people age, while non-causative allele fractions are
expected to stay the same.
S9urce: TOlnita-Mitchell et aI., 1998.
number of individuals to generate observed mutations with statistical significance.
Fulfilling such a requirement demands sensitive and general methods to detect mutations
in a large number of individuals.
To analyze alleles at fractions as low as 1% hotspots belonging to non-deleterious
genes, methods of detecting mutations at a fraction of 5 x 10-5 in human populations are
necessary. For example, in a sample size of 107ceils (2 x 107 allele copies), derived from
105 persons, each person is represented by 100 cells. Alleles at a fraction of 5 x 10-5 in
this sample are present as 103 copies ((2 x 107) + (5 x 10-5)), which can be detected with
statistical significance using mutation detection methods with a sensitivity of 5 x
10-5• A total gene-inactivating allele fraction of 3 x 10-1 for non-deleterious genes is
expected in human populations, and a fraction of 5 x 10-3 for recessive deleterious genes
(William G. Thilly, personal communication). 1% hotspot alleles in non-deleterious
genes is then expected to appear at a fraction of 5 x 10-5.
To sum up, sensitive and general methods of measuring mutations based on their
genotype can be applied to analysis of inherited mutations in human populations, in
addition to analysis of somatic mutations in normal human tissues. These analyses may
allow an understanding of human mutagenesis.
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3 MATERIALS AND METHODS
3.1 Construction of melting profiles
Sequence-specific melting profiles were constructed using WinMelt™ 2.0 (Medprobe,
Norway), software based on a previous work (Lerman and Silverstein, 1987). WinMelt™
2.0 constructs melting profiles of known sequences as a function of sequence and
temperature. This software uses an algorithm for calculating the equilibrium melting
transition probability (Fixman and Freire, 1977), combined with the neighbor base-pair
doublet parameters (Gotoh and Tagashira, 1981). A close correlation between calculated
and experimental measurements has been demonstrated (Myers et al., 1985a, b), ensuring
that the algorithm is accurate.
3.2 Proposed method of clamp attachment
3.2.1 Ligation-based methodology
Figure 11 illustrates the proposed method of attaching a clamp to any 100-bp sequence
in the human genome. High efficiency clamp ligation to the restriction ends of a chosen
target by mass action is expected in a ligation reaction mixture containing at least a 10-
fold molar excess of the clamp.
About 3000 restriction enzymes have been found, exhibiting over 200 different
specificities (New England BioLabs, 2000-2001; Roberts and Macelis, 2001). Each
enzyme recognizes a specific DNA sequence of 4-6-bp (recognition site), cleaves within
or next to the recognition site, and generates either blunt or cohesive ends (reviewed in
Pingoud and Ieltsch, 1997).
DNA ligase joins DNA by catalyzing the formation of phosphodiester bonds between
juxtaposed 5'-phosphoryl and 3'-hydroxyl termini (Kellenberger et aI., 1961; Gellert,
1966; Cozzarelli et aI., 1967; Gefter et aI., 1967; Gellert, 1967; Olivera and Lehman,
1967; Weiss and Richardson, 1967; Zimmerman et al., 1967) (DNA ligase is reviewed in
Lehman, 1974; Higgins and Cossarelli, 1979; Engler and Richardson, 1982). Thus,
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restriction end Y
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> Target restriction fragment (Ix)
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Figure 11. Proposed method of clamp attachment
One end of a desired target is liberated from genomic DNA using a restriction enzyme
of choice. For each restriction enzyme chosen, a clamp, with an end complementary to
the one generated by the chosen enzyme, is prepared. This clamp is then covalently
joined to the target restriction end by DNA ligase. High efficiency clamp ligation by
mass action is expected in a ligation reaction mixture containing at least a 10-fold molar
excess of the clamp.
Source: Kim et aI., 2001.
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restriction enzymes produce suitable substrates for ligation since they cleave DNA in
both strands by hydrolyzing phosphodiester bonds (Connolly et aI., 1984; Grasby and
Connolly, 1992; leltsch et aI., 1992). Ligation of restriction-generated ends was first
demonstrated with cohesive ends of 4 and 6 nucleotides (Mertz and Davis, 1972). Since
then, ligation of ends as short as one nucleotide (Hung and Wensick, 1984), as well as
fully base-paired, or blunt ends (Ehrlich et aI., 1977; Mottes et aI., 1977; Sgaramella and
Ehrlich, 1978), has been demonstrated.
3.2.2 Method of estimating number of chosen restriction ends per human cell
The theoretical number of chosen restriction ends per diploid human cell was
estimated based on three factors. First, a haploid human genome contains about 3 x 109-
bp (Current protocols in molecular biology, 1987; Lander et aI., 2001; Venter et aI.,
2001). Second, two ends are generated each time a restriction endonuclease cleaves its
recognition site. Third, depending on the size of the recognition site, the frequency with
which an enzyme cleaves would vary, producing fragments with different expected
average lengths. For example, an enzyme with a 4-base recognition site would cleave
every 256 bases, assuming the human genome is comprised of 50% GC bases. Although
the GC content determined for humans is 41 % (Marmur and Doty, 1962; Lander et al.,
2001), 50% was used instead to simplify the estimation. Thus, the cleavage frequency in
bases was estimated as follows: 4x.
3.2.3 Preparation of clamp for Apo I restriction end
Figure 12 illustrates the characteristics of the clamp prepared for the restriction end
generated by Apo I restriction endonuclease. Apo I has a 6-base recognition sequence
and cleaves after the first base pair, generating a 5' -AATT-3' cohesive end (Polisson and
Robinson, 1992), as Figure 13 shows.
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S'FITC~
3'OH
3'OH/
cgcccgccgc gccccgcgcc cgtcccgccg cccccgcccg ataataa(c)*
gcgggcggcg cggggcgcgg gcagggcggc gggggcgggc tattatt(g)*ttaa
J t '-S'P
Complementary to Apo I restriction end
Figure 12. Characteristics of clamp for Apo I restriction end
The first 40-bp sequence of the clamp is from a previous study (Sheffield et aI., 1989).
This clamp has an end that is complementary to, or the same as, the Apo I. This end
contains 5'-phosphoryl and 3'-hydroxyl residues, allowing clamp self-ligation, as well as
clamp ligation to the restriction end generated by Apo II
* The base pair in parentheses was omitted when preparing the clamp using the second approach
(see Section 3.2.3.2). This omission was necessary to generate Apo I restriction recognition site,
where the clamp was ligated to the chosen HPRTtarget.
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Figure 13. Recognition sequence of Apo I restriction endonuclease
..
5'-Pu AATT Py-3'
3'-Py TTAA,fu-5'
3.2.3.1 First approach: direct hybridization
As a first means of preparing the clamp, a pair of complementary oligonucleotides
were synthesized (Synthetic Genetics, San Diego, CA), polyacrylamide gel
electrophoresis (PAGE)-purified (Synthetic Genetics), and hybridized to each other.
During the synthesis, one strand of the clamp was fluorescein labeled at the 5' end
(5'FITC), and a phosphate group was attached at the 5' end (5P') of the other strand, as
Figure 12 illustrates. Clamp hybridization was performed at 75°C for 15 min in a buffer
containing 0.2 M NaCI, 10 mM Tris-HCI (pH. 7.6), and 2 mM EDTA.
3.2.3.2 Second approach: purification by CDCE
As a second means of preparing the clamp, the chosen HPRT target with the ligated
clamp was PCR amplified using the GCl/Pl primer pair. This procedure was followed
by CDCE purification of the wild-type DNA. This DNA was then restriction digested by
Apo I prior to CE purification of the target-cleaved clamp.
3.3 Overview of proposed point mutation detection method
Figure 14 shows a flow diagram of the proposed method, which allows analysis of
rare point mutations at fractions below 2 x 10-4 in almost the entire human genome.
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Figure 14. Flow diagram of proposed point mutation detection method:
natural vs. ligated clamp
Natural clamp: For analysis of DNA sequences with a natural clamp, a chosen target is
isolated from a genomic DNA digest using biotin-labeled probes. For this procedure,
sequence-specific hybridization is coupled with a biotin-streptavidin capture system.
This procedure is followed by pre-PeR mutant enrichment, performed first by separating
mutant from wild-type sequences by CDCE and then by eluting these separated mutants.
CE is performed as an additional means to enrich for mutants; CE differentiates mutants
from wild-type containing species, such as single strands, in CDCE mutant-enriched
samples. After hifi-PCR, CDCE is performed for further mutant enrichment. Final
mutant-enriched samples are then peR amplified prior to mutational analysis by CDCE.
At this stage, each individual mutant is CDCE purified for sequencing.
Ligated clamp: For analysis of DNA sequences without a natural clamp, restriction
digestion and clamp ligation are performed prior to pre-peR mutant enrichment by
CDCE.
Source: Kim et a!., 2001.
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3.4 Test target sequence: HPRT exon 3
A part of the human HPRT gene (eDNA bp 223-318) was chosen as a test target to
discover if the proposed point mutation detection method is as sensitive as the one
established for DNA sequences with a natural clamp. This target is comprised of 52% of
the HPRT exon 3 (cDNA bp 135-318) and is juxtaposed with a domain of a higher
melting temperature, a natural clamp (eDNA bp 141-216). Thus, the chosen target allows
a direct sensitivity comparison of the proposed mutation detection method using the
ligated clamp to that of the established method using the natural clamp.
Figure 15 illustrates the melting profiles of the chosen target. These melting profiles
suggest that the chosen target with either the natural or ligated clamp is suitable for
CDCE separation.
3.5 Preparation of internal standards
3.5.1 Homoduplex mutant of genomic DNA
A homoduplex mutant of genomic DNA carrying a G -> T transversion at HPRT
cDNA bp 312 was isolated from HPRTMunich cells. HPRTMunich cells are a lymphoblast
line, isolated from a male patient with gout (Wilson and Kelley, 1984). Separation of this
mutation in the chosen HPRT target from the wild-type has been demonstrated by DGGE
(Cariello et al., 1988).
3.5.2 Homoduplex mutant of peR products (438-bp)
A 438-bp homoduplex mutant carrying a G -> A transition at HPRT cDNA bp 309
was constructed by peR. This mutant is compatible with the chosen HPRTtarget-
embedded fragment liberated from genomic DNA by BstN I and Dra I restriction
endonucleases.
To construct this mutant, three sets of PCR were performed. The first was performed
using the lSI/PI-unstable primer pair and using human wild-type genomic DNA as a
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Figure 15. Melting profiles of human HPRTexon 3: natural vs. ligated clamp
The solid line represents the· melting profile of the target wild-type with the natural
clamp, whereas the dotted line represents the melting profile of the same target withthe
ligated clamp. Restriction digestion by Ahd I and HinfI liberates the chosen target with
the natural clamp, suitable for CDCE separation. Restriction digestion by Apo· I liberates
the natural clamp from the chosen target with the generation of the Apo I restriction end
(5' AATT3', HPRT eDNA bp 218-221). The prepared clamp for the Apo I restriction end
can be ligated to this target end, making the Apo I-digested target suitable for CDCE
separation.
template to generate a 295-bp mutant fragment. The amplified fragment was then used as
a primer, together with 182, for the second set of PCR; human wild-type genomic DNA
was used as a template, and the 438-bp mutant fragment was generated. This fragment
was purified by CE, performed using a 75-~m id capillary at a constant current of 9 JlA.
The purified fragment was then used as a template for the third set of peR; the IS 1/152
primer pair was used, and enough cycles were applied to convert all the primers into
products. Upon this conversion, the expected concentration of the amplified mutant was
about lOll copies/~l, equivalent to the initial primer copy number. The known
concentrations of the mutant to be used as stock were then made by subsequently diluting
the peR products with dH20, 10-fold each time.
3.5.3 Homoduplex mutant ofpeR products (198-bp/169-bp)
A 198-bp or l69-bp homoduplex mutant carrying a G -> A transition at HPRT cDNA
bp 309 was constructed by peR. This mutant is compatible with the chosen HPRTtarget
with the natural clamp (198-bp) after Ahd I and HinfI restriction digestion or with the
ligated clamp (169-bp) after clamp ligation.
The mutant with the natural clamp was amplified using the P3/Pl-unstable primer pair
and using human wild-type genomic DNA as a template. The same mutant with the
ligated clamp was amplified using the GC l/Pl-unstable primer pair and using the clamp-
ligated wild-type DNA of the chosen HPRT target as a template. The known
concentrations of the mutant to be used as stock were prepared as described in Section
3.5.2.
3.5.4 Heteroduplex mutant ofpeR products (198-bp)
To create a mutant in mutant/wild-type heteroduplexes, first, a homoduplex mutant
with the natural clamp (G -> A at HPRT cDNA bp 309) was prepared as described in
Section 3.5.3. Second, the wild-type and the mutant, each in a homoduplex form at a
molar ratio of 100 to 1 were co-amplified using the P3IPI primer pair. Enough cycles
were applied to this peR in which the homoduplex mutant formed heteroduplexes with
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the wild-type by mass action. The known concentrations of the mlltant in heteroduplexes
to be used as stock were prepared as described in Section 3.5.2.
3.6 peR
3.6.1 Primers
Figure 16 and Table 10 summarize the sequences and sites of the primers used in this
study analyzing the chosen HPRT target.
The names and sequences of the primers used in this study analyzing the chosen p53
target are as follows:
Ge2: 5'FITC-GCCGC CTGCA GCCCG CGCCC CCCGT GCCCC CGCCC CGCCG
CCGGC CCGGG CGCCT T-3'
BS: 5'-TGACC TGGAG TCTTC C-3'
BS-stable: 5'-TGACC TGGAG TCTTC CAGTG TGACGATG-3', underlined is an AT
-> GC transition at cDNA bp 763
HH: 5'FITC-CTTGC CACAG GTCTC CCCAA-3'
AP: 5'-TATGG AAGAA ATCGG TAAGA-3'
Each primer was synthesized and PAGE-purified by Synthetic Genetics (San Diego,
CA).
3.6.2 Reaction conditions
peR was performed inside closed glass capillaries using an Air Thermo Cycler (Idaho
Technologies, Idaho Falls, ID). Each reaction mixture of 10 to 50 ~l contained 20 mM
Tris-HCI (pH 8.0), 2 mM MgCI2, 10 mM KCI, 6mM (NH4)2S04,0.1 % Triton X-100, 100
~g/ml nuclease-free BSA, 0.2 ~M each primer, 0.1 mM dNTPs (Pharmacia, Piscataway,
NJ), and 0.1 U/~l Pfu Turbo™ DNA polymerase (Stratagene, La Jolla, CA). Each PCR
cycle consisted of 7 s of template denaturation at 94°C, 30 s of template-primer annealing
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5' - bGGTTGGTGTG GAAGTTTAAT GACTAAGAGG Ctgtttgttat
1
aaagtttaat gtatgaaact TTCTATTAAA TTdcctgattt
tatttctgta ggactgaeRcg tcTTGCTCGA GATGTGATGA
2
AGGAGATGGG AGGCCATCAC ATTGTAGCCC TCTGTGTGCT
CAAGGGGGGC TATA~ATTCT TTGCTGACCT GCTGGATTAC
ATCAAAGCAC TGAATAGAAA TAGTGATAGA TCCATTCCTA
TGACTGTAGA TTTTATCAGA CTGAAGAGCT ATTGTGTGAG
TATATTT AAT ATATGgATTCT TTTTAGTGGC AACAGTAGGT
3
TTTCTTATAT TTTCTTTGAA TCTCTGCAAA CCATACTTGC
TTTCATTTCA CTTGGTTACA GTGAGATTTT TCTAACATAT
TCACTAGTAC TTTACATCAA AGCCAATACT GTTTTTTIh -3'
4
Figure 16. Primer sites for chosen HPRT targeta
a For each primer, the position of the first base is underlined with a number below (see Table 10
for the name and sequence infonnation).
b BstN I restriction end.
c&d Two groups of bases in lowercase letters represent sites for Probe 1C and Probe 2d . These
probes were used for target isolation.
e Ahd I restriction end.
f Apo I restriction end.
g HinfI restriction end.
h Dra I restriction end.
* The group of bases in bold represents the entire sequence of HPRTexon 3 (eDNA bp 135-318).
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Name
Table 10. Sequences of primers for chosen HPRT target
Sequence
GCIb,c
PI
PI-stable
PI-unstable
1
2
3
3
3
5'-GGTTG GTGTG GAAGT TTAAT GAC-3'
5'-ACGTC TTGCT CGAGA TGTGA-3'
5'-CGCCC GCCGC GCCCC GCGCC CGTCC
CGCCG CCCCC GCCCG ATAAT AA-3'
5'-CATAT ATTAA ATATA CTCAC-3'
5'-CATAT ATTAA ATATA CTCAC ACGAT
AGCTC TTCAG-3' (underlined is an AT -> GC transition
at cDNA bp 316)
5'-CATAT ATTAA ATATA CTCAC ACAAT AGCTT
TTC AG-3' (underlined is a GC -> AT transition at cDNA
bp 309)
IS2 4 5'-AAAAA AACAG TATTG GCTTT-3'
a See Figure 16.
b 5'end fluorescein-labeled primers.
C This primer, together with PI, was used to amplify the chosen HPRT target with the ligated
clamp.
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at 45°C, and 10 s of primer extension at 72°C. After a desired number of cycles,
incubation followed, at 72°C for 2 min and at 45°C for 15 min. Under the reaction
conditions specified, about 60% PCR efficiency was observed for the chosen HPRT
target with either the natural (the P3fPl primer pair) or ligated (the GCIIPI primer pair)
clamp.
When amplifying the chosen HPRT target with the ligated clamp, byproducts,
representing between 5 and 20% of the total amplified products, were formed. This is
thought to be the result of using the high GC-content primer, GC 1 (83%). These
byproducts, discovered to be a form of the wild-type, had slower electrophoretic
mobilities that that of the wild-type under optimal CDCE-separating conditions, which
separated mutant from wild-type sequences. This confounded quantitative analysis of the
amplified products by CDCE. However, this problem was nlinimized by incubating the
PCR sample with 0.05 D/1l1 Exo· Pfu DNA polymerase (Stratagene, La Jolla, CA) for 5
min at 72°C prior to CDCE analysis.
3.7 CDCE and CE
3.7.1 Instrumentation and operating conditions
Figure 17 depicts a CDCE apparatus. CDCE uses elevated temperatures to permit
separation of mutant from wild-type sequences (Khrapko et aI., 1994a). A portion of the
capillary is inserted into a water jacket, a regulated-temperature zone where the
separation takes place; the temperature of the water jacket is controlled by a constant
temperature water circulator. CE is performed at room tenlperature to separate DNA
molecules based on their length and to separate double- from single-stranded DNA of the
same length.
Depending on DNA separation efficiency or loading capacity desired, CDCE or CE
was performed differently: using a capillary of different inner diameter (id) (e.g., 75 to
540 ~m), a capillary of various lengths (e.g., 15 to 30 em), or a water jacket of various
lengths (e.g., 6 to 20 em). DNA loading capacity has been shown to be increased up to
about 100-fold (100 ng vs. 10 Ilg) as the id of a capillary is increased from 75 to 540 ~m
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Figure 17. Diagram of CDCE apparatus
CDCE apparatus consists of a CE apparatus (Cohen et aI., 1990), a heated zone of
constant temperature, and a detector (Khrapko et aI., 1994a). Fluorescently-Iabeled
molecules are detected as they pass through a single point of a capillary where an argon
laser beam is focused. The emitted fluorescence signal is collected by a microscope
objective and directed through filters into a photomultiplier. The signal is then amplified
by a current preamplifier and recorded by a computerized data acquisition system. Both
ends of the capillary are bathed in buffer reservoirs filled with 1 x TBE (89 mM Tris-
borate (pH. 8.0),1 mM EDTA).
Adapted from Khrapko et aI., 1994a; Muniappan and ThiIly, 1999; Li-Sucholeiki et aI., 1999.
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1. Power supply (Model CZE 1000R-2032; Spellman, Hauppauge, NY).
2. Argon ion laser (Model 5425ASL; Ion Laser Technology, Salt Lake City, UT).
3. 488 nm filter (Corion, Franklin, MA).
4. Microscope objective (Newport, Irvine, CA).
5. 540 and 530 nrn filters (Corion).
6. Photomultiplier (Oriel Instruments, Stratford, CT).
7. Current preamplifier (Oriel Instruments).
8. Data acquisition system (ACM2-16-8AfTSIBI; Strawberry Tree Computers,
Sunnyvale, CA).
9. Computer.
10. Constant temperature water circulator.
11. Water jacket.
12. Buffer reservoirs.
13 . Capillary.
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(Li and Thilly, 1996). Using a longer water jacket increases separation efficiency of
different mutant sequences, as well as of mutant from wild-type sequences. Experiments
performed in this study showed that when DNA separation was performed at room
temperature, increase in the length of a capillary increased· separation efficiency of DNA
molecules of different lengths.
Desired CDCE and CE separation conditions were determined by performing test runs
with DNA molecules, labeled with fluorescein. For example, desired CDCE separation
conditions were determined using PCR products containing both mutant and wild-type
sequences.
For purification of desired DNA molecules, electro-elution was performed in 0.1 x to
0.8 x TBEB (0.1 x TBEB: 0.1 x TBE, 0.03 mg/ml BSA) as they reached the anodic end
of the capillary after CDCE or CE separation.
3.7.2 Coating of capillaries
The inner surface of capillaries was coated with linear polyacrylamide prior to use.
This procedure was necessary to prevent electro-osmotic flow, which otherwise limits
separation efficiency of desired molecules (Hjerten 1985). The capillaries were coated as
described in previous studies (Hanekamp et aI., 1996; Khrapko et aI., 1997b; Khrapko et
aI., 2001) (adapted from Hjerten (1985)):
For each procedure, a fused-silica capillary (~12 m) of a desired id (Polymicro
Technologies, Phoenix, AZ) was filled with 1 M NaOH (using a high-pressure syringe
with the needle end inserted into a piece of Teflon tubing). This capillary was incubated
at room temperature for 1 hr. The capillary was then washed with dH20, filled with 1 M
Hel, and incubated at room temperature for 10 min. After another washing with dH20,
the capillary was washed again with 100% methanol. The washed capillary was filled
with y-methacryloyloxypropyltrimethoxysilane (Sigma, St Louis, MO) and was incubated
at room temperature overnight. Washing with 100% methanol was repeated, and the
capillary was filled with 6% acrylamide solution in 1 x TEE containing 0.1 % N, N, N',
N'-tetramethylethylenediamine (TEMED) and 0.025% ammonium persulfate (APS). The
capillary was incubated at room temperature overnight before using.
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3.7.3 Preparation of separation matrix
For improved resolution and reproducible DNA separation by CDCE and CE, a
replaceable linear polyacrylamide matrix was prepared as described in previous studies
(Ruiz-Martinez et aI., 1993; Hanekamp et aI., 1996; Khrapko et aI., 1997b; Khrapko et
aI., 2001). Preparation of such a sieving matrix was permitted by low concentrations of
oxygen, radical initiator CAPS), and catalyst (TEMED) in a monomer solution with
polymerization allowed at low temperatures (Ruiz-Martinez et aI., 1993). This procedure
was performed as follows:
5% acrylamide solution in 1 x TBE containing 0.030/0 TEMED was prepared in a flask
with the top sealed with multiple layers of Parafilm. Throughout the procedure, the flask
was kept in an ice bath, and a stir bar placed in the flask was left in motion. A stainless
steel needle, connected to an argon cylinder by silicone tubing, was dipped into the
solution through the Parafilm. This solution was deoxygenated by argon bubbling for 1
hr. The tip of the needle was then taken out of the solution but was kept within the flask
during the rest of the procedure. 0.003% of APS was added to the solution using a 100-
fll high-pressure syringe through the Parafilm. After a brief mixing, needles were
inserted into pre-chilled 10- to 50-ml glass syringes. Each needle was put in the flask
through Parafilm but was kept out of the solution. The syringe was then filled with argon
gas, which was flushed out into the air. Similarity, the syringe was rinsed with a small
volume of the solution. The rinsed syringe was filled with the solution, and the syringe
needle was replaced with a 200-1l1 pipet tip with a sealed end. The filled syringe was
placed in vertical position and was kept at 4°C to allow the acrylamide to polymerize and
also for storing.
The polymerized matrix was dispensed into IOO-lll high-pressure syringes. A piece of
Teflon tubing was inserted into each syringe needle end to replace the matrix in a
capillary before each CDCE and CE separation. Such a replacement procedure has been
shown to be critical in generating reproducibility in DNA separation (Khrapko et aI.,
1994a).
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3.7.4 Sample loading
3.7.4.1 Diluted sample
Each PCR-amplified sample was diluted 10-fold with dH20 prior to loading into a
capillary for CDCE or CE separation. Dilution was necessary since sample injection into
a capillary is inhibited by the high salt concentration in the peR sample. A piece of
platinum wire and the cathodic end of the capillary were dipped into the diluted sample
solution tube, and the sample was electro-kinetically injected by applying a constant
current of 21lA for 30 s. Typically, about 108 copies of a PCR sample are loaded into a
75-llm id capillary by this procedure (Hanekamp et al., 1996; Khrapko et aI., 2001).
3.7.4.2 Dialyzed sample
To load the entire DNA sample into a capillary, each desired sample was dialyzed by
drop dialysis. Drop dialysis is a simple and rapid method of dialyzing small-volumn
samples, smaller than 100 fll (Marusyk and Sergeant, 1980). For this procedure, a 0.025-
11m membrane filter (Millipore, Bedford, MA) was floated on the surface of 0.001 to
0.01 x TBE poured into a container (e.g., plastic Petri dish). A desired sample was then
transferred to the surface of the floating membrane filter by pipeting and was dialyzed
against the buffer by leaving a stir bar in motion for 2 hr. The dialyzed sample was then
transferred to a tube by pipeting, and its volume was condensed to about 2 to 4 III by
lyophilizer.
The yield of drop dialysis was determined by comparing the copy number of a chosen
sequence before and after the procedure; the copy number was measured by quantitative
PCR, followed by CDCE. The range of the yields was between 80 and close to 100% as
long as the samples contained 50 mM salt (e.g., NaCI).
The use of TBE at low concentrations as a dialysis buffer is to prevent the ionic
strength of the condensed sample solution from being higher than that of 1 x TBE. Such
consideration was necessary for electro-kinetic injection of the entire DNA sample into a
capillary since ions are preferentially loaded before DNA. For sample injection, the
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dialyzed and condensed sample was transferred to a piece of Teflon tubing. One end of
the tubing was mounted onto the cathodic end of the capillary, and the other end of the
tubing was inserted into a buffer reservoir. By applying a desired current (50 JlA for a
320-Jlm id capillary and 80 JlA for a 540-Jlm id capillary) for 2 min, the sample was
injected into the capillary. This injection procedure has been demonstrated to be suitable
for loading between 85 and close to 100% of sample DNA into a capillary (Khrapko et
aI., 1994a; Li-Sucholeiki, 1999); close to 100% sample loading was observed in
experiments performed in this study.
3.7.5 Methods of quantitative analysis
Quantitative analyses of fluorescently-Iabeled DNA molecules were performed by
CDCEandCE:
To estimate the copy number of a chosen DNA sequence at any stage throughout the
procedure outlined in Section 3.3, quantitative PCR was performed as described in
previous studies: a known copy number of an internal standard was co-amplified with an
aliquot of each sample desired (Khrapko et aI., 1997b; Marcelino et aI., 1998; Kim et aI.,
2001; Lim et aI., 2001). This peR sample was then separated by CDCE. The areas
under the separated peaks, which represented the wild-type homoduplex CAw), mutant
homoduplex (AM)' and wild-type/mutant heteroduplexes (AH), were measured, and the
chosen sequence copy number was estimated as follows:
([Aw + (AH -7- 2)] -7- [AM + (AH + 2)] XCIS) =# of chosen sequence copies/JlI (1)
where CIS is the concentration of the mutant internal standard used for the quantitative
PCR.
Similarly, enumeration of individual mutant sequences in initial samples (initial
mutant fractions) were measured by CDCE. The areas under the CDCE-separated peaks,
which represented individual mutants in an initial sample (AMs) and an added mutant
internal standard (AMI) at a known fraction (IMF), were measured. These areas were then
compared to measure the initial mutant fractions: (AMS + AMI) X IMFo
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The fidelity of Pfu DNA polymerase was estimated as follows:
fidelitylbp/doubling =([(AMs + AMI) x IMF] + T) + D (2)
where T is the target size in bases and D is the applied number of doublings used for
target amplification.
The areas under the CE-separated peaks, which represented DNA molecules differing
in length, were measured for different purposes, such as estimating efficiency of clamp
ligation and of restriction digestion.
3.8 Mutational analysis: ligated vs. natural clamp
3.8.1 Procedure of genomic DNA isolation
Genomic DNA from human cells was isolated as described in previous studies
(Khrapko et aI., 1997b; Kim et aI., 2001):
Cells were thawed, centrifuged at 1500 g for 10 min, and washed twice with
phosphate-buffered saline (PBS) at a concentration of 107 celis/illl. These cells were
resuspended in 1 x TE buffer (50 mM Tris-HCI (pH 8.0), 10 mM EDTA) at a
concentration of 107 cells/mI. 20 mg/ml of Proteinase K (Roche Molecular
Biochemicals, Indianapolis, IN) and 10% SDS were then added to the final
concentrations of 1 mg/ml and 0.5%, respectively. This sample mixture was incubated in
a water-bath shaker (100-200 rpm) at SO°C for 3 hr. 30 mg/ml RNase A (Sigma-Aldrich,
Inc. Saint Louis, MO) was then added to a final concentration of 20 flg/ml, followed by
incubation in a water-bath shaker (100-200 rpm) at 37°C for 1 hr.
This sample was centrifuged at 10,000 g at 4°C for 15 min, followed by the transfer of
the central portion of the supernatant into a new tube by pipeting. This step was repeated
two to three times to get as much of the supernatant as possible. To the transferred
supernatant, 2.5 M NaCI was added to a final concentration of 250 mM, followed by
addition of two volumes of chilled 100% ethanol. A DNA spool was then formed upon
mixing of the sample solution and was washed twice with chilled 70% ethanol. After
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discarding as much of the 70% ethanol as possible, the spool was air-dried for
approximately 30 min. 0.1 x TE buffer was then added to a DNA concentration of 1 to 4
mg/ml, and the spool was dissolved by gently rotating the sample tube.
Absorbencies by a UV spectrophotometer at wavelengths of 260 and 280 nm were
measured to estimate the quantity and quality of the isolated DNA. As an additional
means to quantify the isolated DNA, the copy number of the chosen HPRTtarget was
measured by quantitative PCR, followed by CDCE. For this measurement, an aliquot of
each genomic DNA sample, together with a known copy number of the 438-bp mutant
internal standard, was restriction digested with BstN I and Dra I. An aliquot of this
digested sample was then amplified using the P31P1 primer pair, followed by CDCE
separation.
Based on these quantitative analyses, the HPRTMunich genomic DNA (see Section 3.5.1)
was added to the HPRTwild-type genomic DNA at a desired fraction prior to restriction
digestion by BstN I and Dra I.
3.8.2 First restriction digestion: BstN I and Dra I
The reaction mixture of BstN I and Dra I restriction enzymes (New England Biolabs,
Beverly, MA) contained 10 mM Tris-HCl, 10 mM MgClz, 50 mM NaCI, and 1 mM
dithiothreitol (pH 7.9 at 25°C). 10 mg/ml of BSA was added to a final concentration of
0.1 mg/ml, which was incubated at 37°C for 4 hr with an enzyme/DNA ratio of 1 U/llg.
The efficiency of BstN I and Dra I restriction digestion was assessed by 2% agarose
gel electrophoresis; human genomic DNA digested with BstN I and Dra I multiple times
under the specified reaction conditions was used as a reference to indicate complete
digestion.
To each restriction-digested sample, the 438-bpmutant internal standard was added at
a desired fraction prior to target isolation.
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3.8.3 Target isolation
3.8.3.1 Procedure
Isolation of the chosen HPRT target was performed with each BstN I and Dra I
restriction-digested sample. This procedure is based on probe-target hybridization
coupled with a biotin-streptavidin capture system, as Figure 18 illustrates. The procedure
was performed as described in previous studies with modifications (Li-Sucholeiki and
Thilly, 2000; Kim et aI., 2001). These modifications made the procedure optimal for the
chosen target and minimized sample exposure to heat during the procedure:
To each BstN I/Dra I restriction-digested sample, Probe 1 (5' TGTGG AAGTT
TAATG ACTAA GAGGT GTTTG 3') and Probe 2 (5' GACGT TCAGT CCTAC
AGAAA TAAAA TCAGG 3') (Synthetic Genetics, San Diego, CA) were added at a
probe/target molar ratio of 5 x 104 each (the probes were biotinylated at the 5' end by an
IS-carbon spacer arm with a 6-carbon linker and were PAGE-purified prior to use)
(Figure 15 in Section 3.6.1 indicates the probe sites in the target-embeded BstN I and Dra
I restriction fragment). This mixture was boiled for 1 min for target denaturation and
immediately chilled in an ice bath for 10 min. The chilled sample was incubated at 60°C
for 2 hr in 6 x SSPE (0.894 M NaCl, 60 mM sodium phosphate (pH 7.4),6 mM EDTA)
for probe-target hybridization.
Streptavidin-coated glass paramagnetic beads (CPG, Lincoln Park, NJ) were pre-
washed twice with 3 x SSPE at a concentration of 10 mg/mL. The washing was
performed first by magnetically separating the beads from the supernatant and second by
removing the supernatant. The pre-washed beads were added to the probe-target
hybridized sample at 0.4 mg of beads/108 copies of the target. This mixture was
incubated at 50°C for 30 min to allow the binding of the beads to the probe-target
hybrids. The beads were then washed with 6 xSSPE at a concentration of 5 mg/mL at
room temperature to remove non-specific bead-DNA bindings. This washing step was
repeated three times, once with 6 x SSPE and twice with 3 x SSPE. The final washing
was performed with a buffer containing 50 mM NaCI, and 1 mM Tris-HCI (pH 7.4) to
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Figure 18. Procedure of target isolation
Human genomic DNA is restriction digested to liberate a chosen target. This DNA is
then denatured, mixed with biotin-labeled probes, and allowed to form probe-target
hybrids. Streptavidin-coated beads are added to this mixture of hybrids, followed by
incubation, to allow the binding of the beads to the probe-target hybrids. After washing,
the target is eluted in single strands. Target isolation is followed by target renaturation
during which mutant sequences formed heteroduplexes with the wild-type by mass
action.
Source: Li-Sucholeiki and Thilly, 2000.
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minimize the salt, which could have been carried over by the beads. ··All the supernatant
transferred up to this point was combined for estimating the target DNA yield.
The target was released from the probe-bound beads twice in dH20 at 20 mg
beads/mL at 70°C for 2 min. The released target was magnetically separated from the
beads and transferred to a new tube, and its volume was condensed to about 10 III by
lyophilizer prior to target renaturation.
3.8.3.2 Methods of estimating yield and isolation efficiency
The yield and efficiency of target isolation were estimated by quantitative peR,
followed by CDCE. To estimate the target DNA yield, the wild-type copy number of the
chosen HPRT target in both samples of the final target-isolated (CE) and combined
supernatant (Cs) was measured using the 438-bp mutant internal standard and the P31P1
primer pair. The ratio of CE to CE+ Cs was then estimated to determine the target DNA
yield ([CE + (CE+ Cs)] x 100).
The isolation efficiency of the chosen HPRT target relative to non-target sequences in
the pool of genomic DNA digest (BstN I/Dra I) was estimated using a part of human
mitochondrial DNA (DNA bp 10011-10215) as a non-target reference. CDCE separation
of mutations in the chosen mitochondrial target from the wild-type has been
demonstrated (Khrapko et aI., 1994a; Khrapko et aI., 1997a, b Coller et aI., 1998;
Marcelino et aI., 1998). Thus, this sequence allows measurement of the sequence copy
number by quantitative PCR, followed by CDCE. For this quantitative PCR, an internal
standard containing a mutation in the chosen mitochondrial target (A -> G transition at bp
10072) was obtained from a previous study (Khrapko et aI., 1997b); CW7 (5' ACCGT
TAACT TCCAA TTAAC 3', bp 10,011-10031) and J3 (5'FITC GCOGG CGCAG
GGAAA GAGGT 3', complementary to bp 10196-10215) primers (Synthetic Genetic, La
Jolla, CA) were used. To estimate the isolation efficiency of the chosen HPRT target, the
measured wild-type molar ratio of the chosen mitochondrial (M) to HPRT (T) targets in
the initial sample (Mr + T1 = IR) was compared to that of in the final target-isolated
sample (Mp + Tp =FR) (isolation efficiency =IR + FR).
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As a second means to estimate the isolation efficiency of the chosen HPRT target,
absorbencies of desired samples were measured by a UV spectrophotometer at a
wavelength of 260 nm. Sample DNA concentrations per a given HPRT target copy
number before (AI) and after (AF) the procedure were then compared to estimate the
isolation efficiency (AI -:- AF).
3.8.4 Target renaturation
To allow renaturation of the chosen HPRT target, isolated in single strands from the
pool of genomic DNA digest, incubation was perfonned either at 55°C in a renaturation
buffer (0.2 M NaCI, 10 mM Tris-HCl (pH 7.6),2 mM EDTA) or at28°C in the presence
of 40% dimethyl sulfoxide (DMSO) in the renaturation buffer. Incubation was
performed for 16 hr during which mutant sequences formed heteroduplexes with the
wild-type by mass action. Each renatured sample was desalted by drop dialysis (see
Section 3.7.4.2) prior to second restriction digestion.
3.8.5 Second restriction digestion
3.8.5.1 Ahd IJHinjI: natural clamp
To liberate the chosen HPRTtarget with the natural clamp (eDNA bp 141-318) from
the 438-bp restriction fragment of BstN I and Dra I, each target-renatured sample was
restriction digested with Ahd I and Hin!I (New England Biolabs, Beverly, MA). The
reaction mixture of Ahd I and HinjI contained 50 mM potassium acetate, 20 mM Tris-
acetate, 10 mM magnesium acetate, and 1 mM dithiothreitol (pH 7.9 at 25°C). 10 mg/ml
BSA was added to a final concentration of 0.1 mg/ml, which was incubated at 37°C for 2
hr with 10 U of each restriction enzyme. The efficiency of Ahd I/HinjI restriction
digestion was estimated as Figure 19 illustrates.
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Figure 19. Method of estimating Ahd IIHinfl restriction digestion efficiency
The restriction digestion efficiency of Ahd I and Hinfl is determined by two sets of
quantitative peR, each followed by CDCE. The first set ofPCR is performed before the
digestion using the IS l/1S2 primer pair and using the 438-bp mutant internal standard.
An aliquot of the IS I/IS2-amplified sample is amplified once again using the P3/Pl
primer pair to generate an amplified sample suitable for CDCE separation, measuring the
total copy number of the chosen HPRT target (CT). These procedures are repeated for the
second set of peR after the digestion to measure the copy nllmber of the chosen target
not cleaved by Ahd I and Hin!1 (Cu). The measured copy numbers, CT and Cu, are then
used to determine the digestion efficiency ([1 - (Cu + C t)] x 100).
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3.8.5.2 Apo I: ligated clamp
To generate the chosen HPRT target with the ligated clamp, Apo I restriction digestion
was performed, followed by clamp ligation. The reaction mixture of Apo I contained 50
mM Tris-HCI (pH 7.9 at 25°C), 10 mM MgCI2 , 100 mM NaCI, and 1 mM dithiothreitol.
10 mg/ml BSA was added to a final concentration of 0.1 mg/ml, which was incubated
with 4 to 10 U of Apo I (New England BioLabs, Beverly, MA) at 36°C for 2 hr.
The digestion efficiency of Apo I was estimated by measuring the copy number of the
chosen target with the natural clamp before (CB) and after the digestion (CF). To measure
the target copy number, quantitative PCR, followed by CDCE, was performed. For this
PCR, the P3/Pl primer pair and the 198-bp mutant internal standard were used. CF
represents the target copy number left uncleaved, while CB represents the total target copy
number. The digestion efficiency was estimated as: 100 - r(eF +- CB) x 100].
3.8.6 Clamp ligation
To generate the chosen HPRT target with the ligated clamp, each Apo I restriction
digestion was followed by clamp ligation. A desired clamp copy number was added to
each ligation reaction mixture containing 66 mM Tris-HCI (pH 7.5 at 20°C), 5 mM
MgCI2 , 1 mM dithioerythritol, and 1 mM ATP. This mixture was incubated at 16°C for
16 hr with 1 U of T4 DNA ligase (Boehringer Mannheim, Indianapolis, IN).
Additional incubation at 37°C for 2 hr with 10 U of RinfI restriction endonuclease
was performed with each sample containing the chosen HPRT target that was isolated
from the pool of genomic DNA digest (BstN IJDra I). The reaction mixture of HinfI
contained 10 mM Tris-HCI, 10 mM MgCI2, 50 mM NaCI, and 1 mM dithiothreitol (pH
7.9 at 25°C).
To measure the copy number of the chosen target with the ligated clamp in each
ligation sample, quantitative PCR, followed by CDCE, was performed. For this PCR, the
GCl/PI primer pair and the 169-bp mutant internal standard were used.
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3.8.7 Pre-PCR mutant enrichment by CDCE
For pre-PCR mutant enrichment by CDCE, each desired sample of Ahd I1HinfI
restriction digestion or clamp ligation was dialyzed, condensed to about 2 to 4 JlI, and
loaded into a capillary. Either 320- or 540-Jlm id capillaries were used for those samples
containing the purified wild-type DNA of peR products; 540-Jlffi id capillaries were used
for those samples containing the wild-type DNA of human cells.
The CDCE conditions were optimized to enrich mutants in mutant/wild-type
heteroduplexes since homoduplex mutant sequences in the original sample formed
heteroduplexes with the wild-type by mass action after the sample, isolated for the chosen
target in single strands, was allowed to renature. At an optimal CDCE separation
temperature, determined using a 15 em-long temperature-regulated zone, the wild-type
homoduplex was well separated from mutant/wild-type heteroduplexes, with the different
mutant/wild-type heteroduplexes having similar separation degrees. At this temperature,
co-elution of the majority, if not all, of these mutant/wild-type heteroduplexes was
allowed. Elution was performed in 20 III of 4 x TBEB for 10 min at a constant current of
50 fJA when using a 320-f.lm id capillary and in 20 fJI of 8 x TBEB for 20 min at a
constant current of 80 JlA when using a 540-f.llTI id capillary.
The efficiency of mutant enrichment by CDCE was estimated based on the ratio of the
target wild-type copy number loaded into a capillary (CT) to the wild-type copy number
co-eluted with the mutant/wild-type heteroduplexes (CHE): CT + CHE ; each wild-type copy
number was measured by quantitative PCR, followed by CDCE. For this quantitative
peR, either the P31P1 or Gel/PI primer pair was used, depending on the clamp type
desired, natural or ligated; either the 198- or 169-bp mutant internal standard was used.
As a second means to estimate the mutant enrichment efficiency, the level of a mutant
internal standard in test samples before and after the procedure was compared. The test
samples, each containing CDCE-purified target wild-type and a mutant internal standard
at a fraction of 5 x 10-4, were prepared. Mutant enrichment by CDCE was performed
with these samples, and each eluted sample of mutant/wild-type heteroduplexes was peR
amplified, followed by CDCE. The ratio of the areas under the mutant (AM) to wild-type
(Aw) peaks was then estimated (FMF = AM + Aw), with the ratio representing the mutant
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fraction after the procedure. This ratio was divided by the initial mutant fraction (IMF), 5
x 10-4, to determine the mutant enrichment efficiency: FMF + IMF.
3.8.8 Pre-PCR mutant enrichment by CE
Each desired CDCE-eluted sample of mutant/wild-type heteroduplexes was dialyzed,
condensed to about 4 Ill, and loaded into a capillary for further mutant enrichment by CEo
This procedure, performed at room temperature, used 540-l1m id capillaries at a constant
current of 80 flA; the chosen HPRT target was eluted in 5 fll of 2 x TBEB for 2 min. The
eluted DNA represented both wild-type and mutant sequences in double strands, which
were separated from the wild-type in single strands, as well as from other wild-type
containing species in CDCE-eluted samples. The efficiency of mutant enrichment by CE
was estimated as described in Section 3.8.7.
3.8.9 Hifi-PCR and post-PCR mutant enrichment by CDCE
Each pre-PCR mutant-enriched sample was PCR amplified using either the P3/Pl or
Gel/PI primer pair, depending on the clamp type desired, natural or ligated. All the
primers were converted into products by applying enough PCR cycles during which
mutant sequences formed heteroduplexes with the wild-type by mass action.
Each peR-amplified sample was then loaded into a capillary for further mutant
enrichment by CDCE (post-PCR mutant enrichment), performed using a 75-flm id
capillary at a constant current of 9 flA. CDCE-separated mutants were eluted in 10 fll of
1 x TBEB for 4 min. The efficiency of mutant enrichment was estimated as described in
Section 3.8.7.
3.8.10 Mutational analysis by eDCE
peR was performed with 1 to 2 ~l of each post-peR mutant-enriched sample. For
this peR, either the P3/Pl or GCIIPI primer pair was used, depending on the clamp type
desired, natural or ligated. All the primers were converted into products by applying
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enough PCR cycles during which mutant sequences formed heteroduplexes with the
wild-type by mass action.
The amplified sample was then separated by CDCE using a 75-llm id capillary at a
constant current of 9 fJA and using a 15 to 20 em-long temperature-regulated zone. At an
optimal separation temperature, mutant and wild-type sequences were separated from one
another, allowing for quantitative analysis of these separated mutants. At this stage,
individual mutants were purified by CDCE for sequence identification.
3.8.11 Purification of individual mutants by CDCE
To purify individual mutant sequences, CDCE separation was performed as described
in Section 3.8.10. This procedure was followed by electro-elution of each separated
mutant in 10 1-11 of 1 x TBEB. An aliquot of this eluted sample (1 to 2 Ill) was then PCR
amplified for another round of CDCE separation and elution. PCR, followed by CDCE
separation and elution, was repeated until a final-eluted sample had close to 100%
homogeneity in sequence. An aliquot of the final-eluted sample was PCR amplified to be
used as a template for DNA sequencing (MIT, Cambridge, MA).
3.9 Second target sequence: p53 exon 7
A part of the humanp53 gene (eDNA bp 673-782) was chosen as a second target
sequence to demonstrate clamp ligation and CDCE· separation. Figure 20 illustrates the
melting profile of the chosen target with the ligated clamp.
Figure 21 illustrates the characteristics of the clamp prepared for the restriction end
generated by Avr II restriction endonuclease. Avr II has a 6-base recognition sequence
and cleaves after the first base pair, generating a 5' -CTAG-3' cohesive end, as Figure 22
illustrates.
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Figure 20. Melting profile of human p53 exon 7 with ligated clamp
Restriction digestion by Avr II and Bsg I liberates the chosen p53 target from genomic
DNA. The prepared clamp for the Avr II restriction end can be ligated to the Avr II target
restriction end, making the digested target suitable for CDCE separation.
5'FITC 3'OH
gccgcctgca gcccgcgccc cccgtgcccc cgccccgccg ccggcccggg cgcctt
cggcggacgt cgggcgcggg gggcacgggg gcggggcggc ggccgggccc gcggaagatc
3'OH
Complementary to Avr II restriction end
Figure 21. Characteristics of clamp for Avr II restriction end
5'P
The sequence of the clamp is from a previous study (Cariello et aI., 1990). This clamp
has an end that is complementary to the Avr II restriction end. This end contains 5'-
phosphoryl and 3' -hydroxyl residues, allowing clamp ligation to the Avr II-generated
restriction end.
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Figure 22. Recognition sequence of Avr II restriction endonuclease
+
5'-C CTAG G-3'
3'-G GATe C-5'
t
To prepare a substrate containing the chosen p53 target for Avr II restriction digestion,
a 266-bp DNA fragment was peR amplified from wild-type genomic DNA using the HH
and AP primer pair. The amplified sequence consisted of exon 7 of the human p53 gene
(eDNA bp 673-782), an Avr II restriction recognition site, and flanking intron sequences.
The amplified sample was ethanol precipitated and restriction digested with Avr II in a
reaction mixture containing 10 mM Tris-HCl, 10 mM MgCI2 , 50 mM NaCl, and 1 mM
dithiothreitol (pH 7.9 at 25°C). This sample mixture was incubated at 36°C for 2 hr prior
to clamp ligation.
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4 RESULTS AND DISCUSSION
4.1 Melting profile results of human gene sequences
Pre-PCR mutant enrichment is a key procedure in target isolation/CDCE/hifi-PCR,
suitable for analysis of rare point mutations at fractions as low as 10-6. Pre-PeR mutant
enrichment is based on separation of mutant from wild-type sequences by CDCE and
requires that a target sequence have a neighboring natural clamp. This requirement limits
the application of the established method to DNA sequences with a natural clamp,
represented by X.
To estimate the percentage of X in the human genome, the melting profiles of several
human gene sequences were constructed and analyzed. These sequences, totaling 500-
kb, belong to five tumor suppressor and two disease-related genes. Figure 23 shows an
example of the constructed melting profile belonging to the first 3000-bp of the human
p53 gene. As Table 11 summarizes, 9% of the sequences scanned are X, suitable for
target isolation/CDCE/hifi-PCR.
For rare point mutational analysis of a larger target-pool size, a means of attaching a
clamp to any 100-bp DNA sequence of interest was devised, as Section 3.2.1 describes.
In theory, this clamp attachment technique, when combined with target
isolation/CDCE/hifi-PCR, allows analysis of point mutations at fractions as low as 10-6 in
those sequences without a natural clamp, represented by Y. Such sequences represent
890/0 of the total gene sequences scanned (see Table 11).
Two percent of the sequences scanned, represented by Z (see Table 11), cannot be
studied since separation of point mutations in sequences with melting temperatures
greater than 80°C is not yet well established. The use of DGGE, combined·with eDGE
(Wu et aI., 1999), sodium bisulphite-treated DNA (Guldberg et aI., 1998), and bipolar
clamping (Gille et aI., 1998) have been shown to improve DNA separation in such high
melting temperature sequences. However, these approaches have not been demonstrated
with CDCE. In addition, the latter two require peR prior to DNA separation, which is
not suitable for detection of rare mutations at fractions below 2 x 10-4 (see Section
2.5.3.1).
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Figure 23. Melting profile of human p53 gene (first 3000-bp)
Each X represents a DNA domain (~100-bp) juxtaposed with a domain (~100-bp) of a
higher melting temperature, or a natural clamp. The melting temperatures of these two
domains differ by at least SoC. Each Y represents a domain of any length without a
natural clamp. The melting temperature of each X or Y is below 80°C. Domains of any
length with melting temperatures greater than 80°C are marked as Z.
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Table 11. Melting profile results: entire DNA sequences of selected human genes
Gene (accession numbera)
BRCAl (L78833)
NF2 (YI8000)
p53 (X54156)
RB (LI1910)
VHL (AF010238)
HPRT (M26434)
Mitochondrial DNA (V00662)
% Total
Total number of bases
Size
85-kb
126-kb
20-kb
180-kb
15-kb
57-kb
16-kb
500-kb
xb yc Zd
11% 88% 1%
7% 90% 3%
10% 90% <1%
7% 92% 1%
11% 84% 5%
11% 880/0 1%
8% 92% <1%
9% 890/0 2%
45-kb 445-kb 10-kb
a Each accession number is from Benson et aI., 2000.
b Percentage of each gene sequence with a natural clamp, suitable for target isolation/CDCElhifi-
PCR.
C Percentage of each gene sequence without a natural clamp, suitable for combined method of
clamp ligation and target isolation/CDCE/hifi-PCR.
d Percentage of each gene sequence not suitable for CDCE-based mutation detection methods due
to its high melting temperature greater than 80aC.
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Table 12 summarizes the melting profile results of only the coding regions of six tumor
suppressor genes in which many mutations have been found in human cancer. These
results show that clamp ligation, coupled with target isolation/CDCElhifi-PCR, is
applicable to the majority, if not all, of each gene sequence scanned. Without clamp
ligation, target isolation/CDCE/hifi-PCR alone can be applied to between 0 and 6% of the
sequences scanned.
4.2 Clamp attachmentlligation
4.2.1 Estimated number ofchosen restriction ends per human cell
The proposed method of clamp attachment ligates a clamp to the restriction ends of a
chosen target in a genomic DNA digest by mass action. Thus, the number of chosen
restriction ends per diploid human cell was theoretically estimated to determine the clamp
copy number necessary for this mass action. Table 13 summarizes the estimated number
of ends per cell generated by a chosen restriction endonuclease with a 4-, 5-, or 6-base
recognition site.
Isolation of a desired target from a pool of genomic DNA digest precedes clamp
ligation in the proposed point mutation detection method (see Section 3.3). Thus, the
number of chosen restriction ends per cell after target isolation was estimated. Using the
reported efficiency of target isolation, l04-fold (Li-Sucholeiki and Thilly, 2000), Table 14
summarizes the estimated number of ends generated by a chosen restriction endonuclease
with a 4-, 5-, or 6-base recognition site. This number is per diploid human cellar per 108
diploid human cells. 108 cells is the sample size necessary for detecting mutations at
fractions as low as 10-6 with statistical significance. If, for example, a 10-fold higher
clamp copy number is necessary for ligating every restriction end of genomic DNA by
mass action, this number can be estimated by multiplying each estimated number of ends
per 108 diploid human cells in Table 14 by 10.
Clamp ligation is not specific to target restriction ends. Out of the estimated number
of chosen restriction ends per cell, only two belong to a desired target of a single-copy
nuclear gene. Table 14 summarizes the ratio of target to non-target ends generated by a
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Table 12. Melting profile results: coding regions of selected human tumor suppressor
genes
Gene Size Xc yd ze
(accession numbera)
APe (M74088)b 6578-bp 6% 94% 0%
BRCA1 (L78833) 5572-bp 0% 1000/0 0%
NF2 (Y18000) 2069-bb 4% 82% 140/0
p53 (X54156) 1182-bp 0% 100% 0%
RB (Ll1910) 2787-bp 20/0 93% 5%
VHL (AF010238) 642-bp 0% 47% 53%
a Each accession number is from Benson et aI., 2000.
b To determine X for coding regions, flanking intron sequences are necessary. Because these
sequences had not been discovered for the APe gene at the time of the melting profile
construction, X was determined for exon 15 only. Exon 15 is comprised of about 6500-bp,
representing 77% of the coding region.
C Percentage of each gene sequence with a natural clamp, suitable for target isolation/CDCE/hifi-
PCR.
d Percentage of each gene sequence without a natural clamp, suitable for combined method of
clamp ligation and target isolation/CDCE/hifi-PCR.
e Percentage of each gene sequence not suitable for CDCE-based mutation detection methods due
to its high melting temperature greater than 80°C.
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Table 13. Estimated numbers of chosen restriction ends
Size of restriction recognition site
(number of bases)
4
5
Number of chosen restriction ends per
diploid human cell*
4.69 X 107
1.17x107
6 2.93 X 106
* Estimated using Equation 3: [(6 x 109) -:- 4x ] x 2, where 6 x 109 is the number of bases per
diploid human genome, 4x is the cleavage frequency of a chosen restriction enzyme in bases (X
represents the size of the restriction recognition site), and 2 is the number of restriction ends
generated per cleavage.
Table 14. Estimated numbers of chosen restriction ends and ratios of target to non-target
restriction ends after target isolation
Size of restriction
recognition site
(number of bases)
4
5
Number of chosen
restriction ends per
diploid human cell
(#/dhc)a
4.69 X 103
1.17 X 103
Number of chosen
restriction ends per
108 diploid human
cellsb
4.69 X lOll
1.17 X lOll
Ratio of target to
non-target restriction
endsc
1 : 2.3 x 103
1 : 5.9 x 102
6 2.93 X 102 2.93 X 1010 1 : 1.5 x 102
a Estimated by dividing Equation 3 by a target isolation efficiency of 104-fold. Equation 3: [(6 x
109) -7- 4x] x 2, where 6 x 109 is the number of bases per diploid human genome, 4x is the
cleavage frequency of a chosen restriction enzyme in bases (X represents the size of the
restriction recognition site), and 2 is the number of restriction ends generated per cleavage.
b Estimated by multiplying #/dhc by 108 .
C Estimated by dividing #/dhc by 2, which represents the number of target restriction ends per cell
after target isolation.
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chosen restriction endonuclease with a 4-, 5-, or 6-base recognition site after target
isolation. Target from non-target restriction fragments with the same ligated clamp is
expected to be distinguished by the procedures following clamp ligation, pre-peR mutant
enrichment and peR, in the proposed point mutation detection method. Thus, the
presence of a l02-103-fold higher copy number of non-target restriction ends in a ligation
mixture is not expected to interfere with mutational analysis by the proposed method.
4.2.2 Optimal ligation reaction conditions
Table 15 summarizes the optimal ligation reaction conditions empirically determined,
as well as the conditions suggested by the manufacturer of T4 DNA ligase, Boehringer
Mannheim (Indianapolis, IN). When comparing these two sets of conditions, two
variables should be noted.
The first variable is incubation temperature. The temperature suggested by the
manufacturer is 4°C. However, rather a big range, 4 to 22°C, was empirically determined
to generate the maximum ligation efficiency of the substrate, the Apo I cohesive end.
When the temperature was increased to 36°C, the efficiency was reduced by 100/0 of the
maximum efficiency observed.
A big range of optimal incubation temperatures have been reported using as a
substrate the EcoR I cohesive end (5' AATT3'). This restriction end is the same as the
Apo I. These temperatures are 4 °C (Ferretti and Sgaramella, 1981), 10 to l5°C
(Dugaiczyk et aI., 1975), 15 to 25°C (Ehrlich et aI., 1977), and 25°C (Sgaramella and
Ehrlich, 1978). The melting temperature determined for the EcoR I cohesive end is 6°C
(Mertz and Davis, 1972).
Substrate concentration is the second variable of ligation reaction conditions to be
noted. While the concentration suggested by the manufacturer is 0.015 J.lM, a higher
concentration range, 0.17 to 0.55 J.lM, was shown to be necessary to generate the
maximum ligation efficiency of the substrate. When the concentration was lowered by
lO-fold (17 nM), the ligation efficiency was reduced by 10% of the maximum efficiency
observed. When lowered by another 10-fold (1.7 nM), the efficiency was further reduced
to 50%. Therefore, using a substrate concentration of 0.17 J-lM or higher was determined
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Table 15. Optimal ligation reaction conditions
The optimal ligation reaction conditions were determined empirically by varying
incubation temperatures from 4 to 36°C, incubation duration from 1 to 16 hr, units of T4
DNA ligase from 1 to 10, and substrate concentrations from 108 to 3.3 x 1011 /fll. The
prepared clamp for the Apo I restriction end was used as a substrate. The criterion used
for determining the optimal ligation reaction conditions was the conditions that generated
the maximum efficiency of clamp self-ligation. The efficiency of clamp self-ligation for
each reaction variable tested was estimated by CE, which separated the self-ligated clamp
(eL , 100-bp) from the un-ligated clamp (Cu, 48-bp): [CL + (eL + Cu)] x 100.
Reaction condition variable
Incubation temperature
Incubation duration
Unit of T4 DNA ligase
(1 U = 3.5 X 1012 molecules)
Substrate concentration
Determined empirically
16 hr
IV
1-3.3 X lOll molecules/~l
(0.17-0.55 JlM)
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Suggested by Boehringer
Mannheim
(Indianapolis, IN)
16 hr
IV
9 x 109 molecules/fll
(0.015 J1-M)
as an important factor in achieving the maximum ligation efficiency.
4.2.3 Optimal restriction digestion reaction conditions
Certain reaction conditions of restriction digestion limited clamp ligation efficiency,
clamp ligating to the digested DNA. The different Apo I restriction digestion reaction
conditions tested resulted in a similar digestion efficiency of about 95%. However, these
test conditions resulted in various clamp ligation efficiencies ranging from 21.5 to 990/0.
Table 16 summarizes these results. The restriction digestion incubation temperature
recommended by the manufacturer of Apo I, New England Biolabs (Beverly, MA), is
50°C. However, the use of such a high temperature should be avoided when planning
high efficiency clamp ligation. Lowering the temperature to 37°C resulted in clamp
ligation efficiencies higher than those observed at 50°C. In addition, shortening
restriction digestion incubation duration from 16 to 4 hr increased the ligation efficiency
at both incubation temperatures. Thus, to achieve the maximum clamp ligation
efficiency, restriction digestion must be performed at 37°C for a short period of time,
such as 4 hr.
A reason behind the inefficiency in clamp ligation with those samples restrict digested
at 50°C is yet to be determined. One possible explanation is that such a high temperature
degrades the generated restriction ends, lowering the clamp ligation efficiency.
4.2.4 Demonstration of high efficiency clamp ligation
Figure 24 illustrates high efficiency clamp ligation to Apo I restriction ends by mass
action. In this illustration, the prepared clamp is ligated to a restriction fragment copy
number of 1010, lOll, or 1012 • This copy number was selected based on the number
estimated for a chosen restriction endonuclease with a 4-, 5-, or 6-base recognition site,
as Table 14 in Section 4.2.1 summarizes. This selection represents a sample size of 108
diploid human cells after target isolation with an efficiency of 104-fold.
By using a la-fold higher clamp copy number, a clamp ligation efficiency of above
950/0 was estimated for each selected copy number of the restriction ends. This efficiency
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Table 16. Reaction conditions of Apo I restriction digestion vs. efficiency of clamp
ligation
A chosen target was PCR amplified using the P3IIS2 primer pair, ethanol precipitated,
and restriction digested under different test reaction condition variables. Using a 1012
clamp copy number, clamp ligation was performed with each test sample of lOll copies
of the digested DNA. The clamp ligation efficiency was estimated by CE, which
differentiated the clamp-ligated (L) from un-ligated (UL) restriction fragments: [L + (L +
UL)] x 100.
Incubation
temperature
Test reaction condition variable
Enzyme/substrate ratio
(D of Apo I per Jlg of Incubation duration
substrate, D/Jlg)
Clamp ligation
efficiency (%)
(mean ± SD, n=2)
1 (1U /J-lg)
4 hr
16 hr
4 hr
99.0 ± 0
94.0 ± 1.4
68.5 ± 7.8
16 hr 21.5 ± 9.2
a This enzyme/DNA ratio is equivalent to 1 U/f.lg since ApoI results in 50% activity at 37°C
(New England BioLabs, 2000-2001).
b Optimal temperature for Apo I, recommended by the manufacturer, New England Biolabs
(Beverly, MA).
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Figure 24. High efficiency clamp ligation*
A chosen target was peR amplified using the P3IIS2 primer pair, ethanol precipitated,
and restriction digested by Apo I. Using a 10-fold higher clamp copy number, clamp
ligation was performed with the digested sample containing a known copy number of the
digested DNA. The clamp ligation efficiency was estimated by CE, which differentiated
the clamp-ligated (L) from un-ligated (UL) restriction fragments: [L + (L + UL)] x 100.
* Above 95% clamp ligation efficiency was estimated for each sample.
is thought to be the maximum since increasing the clamp copy number by 10-fold did not
increase the ligation efficiency. When the same clamp copy number as the restriction end
copy number was used, the ligation efficiency was reduced to 85%. An efficiency of
300/0 was observed when a la-fold lower clamp copy number was used.
Section 4.2.2 discusses substrate concentration as an important factor in achieving the
maximum ligation efficiency. However, when mass action was coupled with ligation, the
substrate concentrations used (3.3 x 109 to 3.3 X lOll molecules/ill for clamp and 3.3 x 108
to 3.3 X 1010 molecules/ill for Apo I restriction end) did not affect the clamp ligation
efficiency.
In brief, a clamp ligation efficiency of above 95% by mass action was demonstrated.
For this demonstration, a IO-fold higher clamp copy number was used in a ligation
reaction mixture containing different restriction end numbers, ranging from 1010 to 1012.
4.3 Test target sequence: HPRT exon3
4.3.1 Demonstration of CDCE separation: ligated vs. natural clamp
Figures 25 and 26 illustrate CDCE separation of the low Tm mutation in the chosen
HPRT target from the wild-type. Figure 25 illustrates the separation using the natural
clamp, and Figure 26, using the ligated clamp.
These clamps generated a similar separation degree of the mutant from wild-type
sequences by CDCE at different temperatures below 71.5°C. The same was true for the
high Tm mutant (A -> G transition at HPRT cDNA bp 316). However, the target with the
natural clamp completely converted to single strands (58) at temperatures at or above
71.5°C. This conversion happened because the natural clamp lost its ability to hold the
two DNA strands together. On the other hand, the ligated clamp was able to separate the
mutant from wild-type sequences at temperatures below 85°C. At or above 85°C, the
ligated clamp also lost its ability to hold the two strands together. Complete strand
dissociation of the same target with the ligated clamp started to appear at a higher
temperature than with the natural clamp, as the melting profiles predict (see Figure 15 in
Section 3.4).
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Figure 25. CDCE separation of low Till mutant from wild-type sequences:
HPRT exon 3 with natural clamp
Using the P3/Pl primer pair, peR was performed with a mixture containing the wild-
type and the mutant internal standard (low Tm mutant, G -> A transition at HPRT eDNA
bp 309) at an equal molar ratio. During this peR, mutanUwild-type heteroduplexes, in
addition to the homoduplex of each kind, were formed. The peR-amplified sample was
separated by CDCE, performed using a 6 em-long temperature-regulated zone of desired
temperatures.
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Figure 26. CDCE separation of low Tm mutant from wild-type sequences:
HPRT exon 3 with ligated clamp
Using the GCIIPI primer pair, peR was performed with a mixture containing the
wild-type and the mutant internal standard (low Tm mutant, G -> A transition at HPRT
eDNA bp 309) at an equal molar ratio. During this peR, mutant/wild-type
heteroduplexes, in addition to the homoduplex of eaeh kind, were formed. The PCR-
amplified sample was separated by CDCE, performed using a 6 em-long temperature-
regulated zone of desired temperatures.
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CDCE separation results demonstrate the ability of the ligated clamp to separate point
mutations in the chosen target from the wild-type. These results also demonstrate that a
similar degree of CDCE separation is achievable at temperatures below 71.5°C for the
chosen target with either the natural or ligated clamp.
4.3.2 Fidelity ofPlu DNA polymerase
As Section 2.5.3.1 discusses, analysis of rare mutations requires a polymerase with
high fidelity. For this reason, Plu DNA polymerase was chosen for PCR performed in
this study.
The reported fidelity of Pfu is about 10-6/bp/doubling (Lundberg et aI., 1991; Barnes,
1994; Flaman et aI., 1994; Cline et aI., 1996; Smith and Modrich, 1996; Andre et aI.,
1997; Parsons and Heflich, 1998; Li-Sucholeiki and Thilly, 2000). When the fidelity was
estimated using the chosen HPRT sequence as a target, about 2 x 10-6/bp/doubling was
observed.
4.3.3 HPRT pseudogenes
Once a human target gene sequence is chosen for mutational analysis, target gene-like
sequences, pseudogenes, must be examined. Pseudogenes are linked sequences, which
consist of considerable sequence homology with functional genes. However, these
pseudogenes are not functional since they contain mutations that inactivate their
transcription and translation (Wilde, 1986; Venter et aI., 2001). Thus, a mutation assay
must be planned carefully so that pseudogenes do not confound analysis of the chosen
gene sequence.
Pseudogenes are divided into two groups. The pseudogenes in the first group are
linked to parent genes and therefore are thought to be the result of gene duplication
(Wilde, 1986; Mighell et aI., 2000). The pseudogenes in the second group are dispersed
to different chromosomes in the genome (Wilde, 1986; Mighell et aI., 2000). The major
characteristic of the pseudogenes in the second group is that they are "intron-Iess," or
"processed," and therefore are thought to arise through retrotransposition of processed
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mRNA transcripts into the genome (Vanin, 1985; Wilde, 1986; Mighell et aI., 2000).
The second group of pseudogenes appears to outnumber the first (Vanin, 1985 ~ Wilde,
1986).
One study estimates 2909 processed pseudogenes in the human genome (Venter et al.,
2001) while another estimates about a IO-fold higher number, 23,000 to 33, 000
(Goncalves et aI., 2000). The first study is based on sequence analysis of the entire
human genome, and the second, of human chromosome 22 (Dunham et aI., 1999),
suggesting that the estimate in the first study is more accurate than that in the second.
The number of pseudogenes per gene varies from one to multiple for those genes with a
pseudogene(s) (Venter et aI., 2001).
Analysis of transcripts that give rise to processed pseudogenes has shown that these
transcripts have shorter average lengths compared to those with no pseudogene (Venter et
aI., 2001). While no significant difference was observed in the overall GC content in one
study (Venter et aI., 2001), another study observed low GC content for those genes with a
processed pseudogene(s) (Goncalves et aI., 2000). Additional characteristics of these
genes are that they are widely expressed and highly conserved (Goncalves et al., 2000).
The human HPRT gene was chosen as a test target gene in this study. This gene has
been demonstrated to have HPRT-like sequences, thought to be processed pseudogenes
(Patel et aI., 1983; Gennett and Thilly, 1988). HPRT exon-like sequences were also
found using the Basic Local Alignment Search Tool (BLAST). Figure 27 illustrates these
HPRT-like sequences in the human genome. Two additional findings were performed
using GenBank: accession numbers U10112 (Sellner and Turbett, 1996) (493-bp
comprised of human HPRT exon 2- and 3-like sequences) and U43684 (276-bp
comprised of human HPRT exon 3- and 4-like sequences).
To prevent the HPRT pseudogenes in the human genome from confounding
mutational analysis of the chosen gene sequence, this analysis was planned carefully. As
part of this planning, the primers and probes that do not share the sequence with these
pseudogenes were selected.
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Figure 27. HPRTpseudogenes in the human genome
a Adapted from Gennett, 1988. Southern blotting and HPRT exon-specific probes were
used in this study.
b Based on the BLAST search of the human genome: > 85% sequence homology for 75%
of each exon length was used as a search criterion. BLAST is a tool for searching protein
and DNA databases for sequence similarities (Altschul et aI., 1990; Altschul et aI., 1997).
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4.4 Use of internal standards
The internal standards described in Section 3.5 were used for two quantitative
analyses in this study. These standards allowed quantitative peR, measuring the copy
number of a chosen sequence in desired samples. They also permitted enumeration of
individual mutant sequences in initial samples upon mutational analysis by CDCE.
Quantitative peR is based on co-amplification of a desired sequence with an internal
standard at known concentrations using one set of primers (Reischl and Kochanowski,
1995; Zimmermann and Mannhalter, 1996; Schnell and Mendoza, 1997; Raeymaekers,
2000). When these amplified species are differentiated, by CDCE for example, one can
estimate the unknown initial copy number from the known quantities.
Use of an internal standard for quantitative analysis generates more accurate
estimation compared to other PCR-based methods that rely on an external standard.
These methods measure the quantity of a chosen sequence in the exponential phase using
the dilution series of the external standard as a reference (Reischl and Kochanowski,
1995; Zimmermann and Mannhalter, 1996; Schnell and Mendoza, 1997; Raeymaekers,
2000). The advantage of using an internal standard for quantitative analysis is that the
analysis is not affected by tube-ta-tube variations in amplification efficiency
(Raeymaekers,2000). Moreover, measurement of a chosen sequence copy number is not
restricted to the exponential phase (Raeymaekers, 2000).
However, it is a prerequisite that an internal standard has the same PCR-amplification
efficiency as the sequence to be quantified. Internal standards of different sequence
lengths and compositions have been shown to generate differential peR-amplification
efficiencies (McDowell et aI., 1998). In addition, quantitative analysis of co-amplified
peR products being affected by allelic preference in DNA amplification has been
suggested (Keohavong et aI., 1991). Allelic preference in DNA amplification refers to
preferential amplification of mutant sequences relative to the wild-type, or vice versa.
The internal standards used in this study are the same length and sequence as the
corresponding sequence to be measured but they differ by one base pair. Such standards
can be differentiated from the corresponding sequence by CDCE, allowing quantitative
analysis. When the PCR-amplification efficiency of each internal standard was compared
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to that of the corresponding sequence, no significant difference was observed. Figure 28
illustrates this comparison. Typically, experiments performed in this study applied about
20 doublings for quantitative PCR and about 40 doublings prior to mutational analysis by
CDCE.
These internal standards, when added to the initial samples, allowed enumerating
individual mutant sequences upon mutational analysis by CDCE. Analysis of rare
mutations requires numerous procedures prior to mutation detection (see Section 3.3).
Thus, use of an internal standard is crucial to accurately enumerate individual mutant
sequences in the initial samples.
4.5 Mutational analysis: ligated vs. natural clamp
4.5.1 With CDCE-purified wild-type DNA ofpeR products
4.5.1.1 Initial DNA samples
To discover the mutation detection sensitivity of the ligated clamp procedure in
comparison to the natural clamp procedure, the wild-type DNA of the chosen HPRT
target was prepared. As an initial study, the wild-type DNA of human cells was replaced
with that of PCR products (Section 4.5.2 discusses the sensitivity comparison in human
cells). This replacement allowed skipping the first three steps summarized in Section 3.3.
However, the use of peR products required purification of the wild-type. Otherwise,
polymerase-generated mutations in the amplified target would have interfered with
determining the true mutation detection sensitivity.
To be used as initial samples, the following three components were mixed: the CDCE-
purified wild-type DNA, the 198-bp mutant internal standard in heteroduplexes at a
known fraction, 5 x 10-6,5 X 10-5, or 5 x 10-4, and 60 to 600 ng of human genomic DNA
per 2 x 108 copies of the target wild-type. This mixture mimicked the stage after target
isolation. It was necessary to use a mutant internal standard in heteroduplexes since
homoduplex mutant sequences form heteroduplexes with the wild-type by mass action
after a sample isolated for a chosen target in single strands is allowed to renature. When
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A. Wild-type (Wt) vs. Internal standard 1 (Is 1: G-> Atransition at cDNA bp 309)
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B. Wild-type (Wt) vs. Internal standard 2 (Is 2: G -> T transversion at cDNA bp 312)
Figure 28. PCR-amplification efficiencies: wild-type vs. internal standards
A mixture containing the wild-type of the chosen HPRT target and each internal
standard at an equal molar ratio was PCR amplified using the P3IPI primer pair.
After a desired number of doublings, the amplified sample was separated by CDCE
to estimate the molar ratio of the amplified species. This ratio served as a reference
to compare the peR-amplification efficiencies of these species.
a 10 doublings are equivalent to a 103-fold target amplification, 20 doublings, a 106-
fold, and so forth.
planning this mixture, a target isolation efficiency of 103- to 104-fold was chosen using
600 flg of human genomic DNA (::::: 108 cells) as an initial sample size. 108 cells is the
sample size necessary for detecting mutations at fractions as low as 10-6 with statistical
significance (±20% precision). 104-fold is the isolation efficiency observed in a previous
study (Li-Sucholeiki and Thilly, 2000).
4.5.1.2 Restriction digestion and clamp ligation
Apo I restriction digestion was performed with the initial samples of CDCE-purified
wild-type DNA, and the digestion efficiency was estimated to be above 95%. In these
digested samples containing the added 60 to 600 ng of human genomic DNA (equivalent
to :::::104-105 cells), between 1.2 x 101] and 1.2 x 10]2 Apo I-generated restriction ends were
expected (see Section 4.2.1: Apo I is equivalent to a restriction endonuclease with a 5-bp
recognition site). Thus, to achieve high efficiency clamp ligation to the expected range of
Apo I restriction end numbers, either a 1013 or 10]2 clamp copy number was used for each
ligation reaction. This number represents a 10-fold higher clamp copy number compared
to each expected number of Apo I restriction ends. Under such a condition, a clamp
ligation efficiency of above 95% was achieved in Section 4.2.4.
To ensure that the added clamp copy number in each ligation reaction did generate the
maximum clamp ligation efficiency, clamp dilution experiments were performed, as
Table 17 summarizes. A similar clamp-ligated target copy number is observed in all
negative control samples of different test clamp copy numbers. On the other hand, the
samples of 60 or 600 ng of human genomic DNA show a decrease in the measured target
copy number as the clamp copy number decreases. This decrease starts from the 10]]
clamp copy number for those samples with 60 ng of genomic DNA and from the 10]2
clamp copy number for those with 600 ng.
The clamp dilution experiments demonstrate that the clamp copy number limits the
clamp ligation efficiency. This demonstration confirms an observation made in Section
4.2.4. The clamp dilution experiments also demonstrate that the 10]3 clamp copy number
is large enough to generate the maximum clamp ligation efficiency for a sample size of
up to 600 ng of human genomic DNA. In addition, the theoretically estimated number of
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Table 17. Summary of clamp dilution experiments
A 2 X 108 copy number of the chosen HPRT target with the natural clamp was added
to each test sample, and those samples without added genomic DNA were used as
negative controls. After Apo I restriction digestion, followed by clamp ligation, the copy
number of the clamp-ligated target in each test sample was measured by PCR and CDCE.
For this PCR, the GCIIPI primer pair was used. The measured copy number served as a
reference to compare the clamp ligation efficiencies among different test samples.
Copy number of
clamp
Copy number of clamp-ligated HPRT target
(HPRT cDNA bp 223-318) (mean ± SD, n=2)
7.5 ± 0.6 x 107
6.0 ± 0 x 107
7.1 ± 0.5 x 107
7.7 ± 1.1 x 107 8.6 ± 0.9 x 107
5.2 ± 0.4 x 106
1010 6.6 ± 0.2 x 107 5.2 ± 0.1 x 106 6.1 ± 1.1 x 105
a Theoretically estimated numbers, estimated by multiplying Equation 3 by 104 for 60 ng and by
105 for 600 ng. Equation 3: [(6 x 109) -7- 4x] x 2, where 6 x 109 is the number of bases per
diploid human genome, 4x is the cleavage frequency of a chosen restriction enzyme in bases (X =
5 for Apo I restriction enzyme), and 2 is the number of restriction ends generated per cleavage.
60 ng (104 cells) and 600 ng (105 cells) of human genomic DNA are the sample sizes after target
isolation with efficiencies of 104- and 103-fold, respectively, using an initial sample size of 108
cells.
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Apo I restriction ends per given cell number is shown to be in close agreement with those
determined empirically.
4.5.1.3 Pre-PCR mutant enrichment
4.5.1.3.1 Necessity
Analysis of rare mutations requires enrichment of mutant sequences relative to their
abundant wild-type. This procedure reduces the wild-type copy number while retaining
the same mutant copy numbers. As a result, mutant fractions are increased in mutant-
enriched samples compared to those in initial samples. CDCE, for example, spatially
separates mutant from wild-type sequences, and elution of these separated mutants allows
mutant enrichment. Such a procedure can be performed before or after PCR, depending
on the mutant copy numbers in desired samples (Kim et aI., 2001).
When analyzing mutations at fractions below about 2 x 10-4, pre-PCR mutant
enrichment is an absolute requirement. This necessity is based on the fidelity of Pfu
DNA polymerase with the applied peR cycles representing 20 target doublings (see
Section 2.5.3.1). Figure 29 illustrates the levels of background noise generated by Pfu
using the CDCE-purified wild-type DNA of the chosen HPRT target as a template. After
20 doublings of target amplification, the level of Pfu-generated background noise is about
5 to 2 times lower than the mutant internal standard added at an initial fraction of 10-3
(see Figure 29B). This background noise level does not increase as a function of
template denaturation time (see Figure 29B vs. C: a 3-fold increase from 14 to 42 s at
94°C per doubling). This observation rules out the possibility of DNA lesions, generated
by heat during PCR, contributing as background noise. On the other hand, the level of
background noise increases as the number of doublings is increased (see Figure 29B vs.
D). These results indicate that the fidelity of Pfu determines the level of background
nOIse.
Given the fidelity of Pfu and assuming that 20 doublings must be performed prior to
mutational analysis by CDCE, only those mutations at fractions above 2 x 10-4 can be
directly analyzed. Thus, for analysis of mutations at fractions below 2 x 10-4, pre-PCR
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Figure 29. Levels of mutations generated by Pfu DNA polymerase during peR
The chosen HPRTtarget was PCR amplified using the P3IPI primer pair, followed by
CDCE purification of the wild-type DNA (A). An additional peR was performed using
the purified wild-type DNA as a template. For this peR, Bused 20·doublings and a
template denaturation time of 14 s at 94°C per doubling (Ix heat), C used 20 doublings
and a template denaturation time of 42 s at 94°C per doubling (3x heat), and D used 60
doublings and a template denaturation time of 14 s at 94°C per doubling (Ix heat). Post-
peR mutant enrichment, followed by peR, was performed prior to mutational analysis
by CDCE.
130
A. CDCE-purified wild-type DNA
II
III ~...---------------..... III
I
B. 20d, Ix heat
c. 20d, 3x heat
III .....1-----------------1..... III
D. 60d, Ix heat
III __...I--------------~.... III
18.00 20.00 22.00 24.00 26.00 28.00
Minutes
I represents the wild-type in homoduplex; II represents the mutant internal standard (IS:
G to A transition at HPRT eDNA bp 309) added at an initial fraction of 10-3 ; III
represents a region where the majority of Pfu-generated mutations in the chosen target
migrate; the CDCE-separated mutants are in mutant/wild-type heteroduplexes.
mutant enrichment must be performed. This procedure increases these mutant fractions
prior to peR, allowing mutation detection above the level of background noise generated
by Pfu.
4.5.1.3.2 Efficiency
Pre-PCR mutant enrichment allows analysis of rare mutations at fractions below 2 x
10-4 . However, the sensitivity of a mutation detection method is expected to vary
depending on the efficiency of pre-peR mutant enrichment. This prediction is based on a
previous study (Li-Sucholeiki and Thilly, 2000). In this study, the sensitivity of the
natural clamp procedure was demonstrated to be limited by the fidelity of Pfu DNA
polymerase, or equivalently, by the efficiency of pre-peR mutant enrichment. Thus, the
sensitivity of the proposed point mutation detection method can be predicted based on the
efficiency of pre-PCR mutant enrichment.
On average, the efficiency of pre-peR mutant enrichment was estimated to be 32 ± 4-
fold for the chosen HPRT target with the ligated clamp. This efficiency represents a 32-
fold decreased copy number of the wild-type or a 32-fold increased mutant fraction in
pre-PCR mutant-enriched samples compared to that in initial samples. An average
efficiency of 125 ± 28-fold was estimated for the same target with the natural clamp.
These estimations represent the total mutant enrichment efficiencies after CDCE
followed by CEo
CE was performed as a means to reduce the copy number of the wild-type in single
strands in the CDCE-eluted samples of mutant/wild-type heteroduplexes. As much as
3% target DNA in double strands converted to single strands during sample loading into a
capillary. The single-stranded target, regardless of whether mutant or wild-type, co-
migrated with mutant/wild-type heteroduplexes under optimal CDCE-separation
conditions. To reduce the copy number of single-stranded wild-type in the CDCE-eluted
samples, the double-stranded target was separated from the single-stranded target by CEo
This procedure was followed by elution of the double-stranded target.
The average efficiency of pre-PCR mutant enrichment estimated for the·ligated clamp
procedure is about 4-fold lower than that for the natural clamp procedure. This
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estimation predicts about a 4-fold lower mutation detection sensitivity for the ligated
clamp procedure. The following section discusses the cause of this decrease.
4.5.1.3.3 Cause of decreased efficiency
The efficiency of pre-PCR mutant enrichment is about 4-fold lower for the ligated
clamp procedure compared to that for the natural clamp procedure. To determine the
cause of this decreased efficiency, the effects of variables introduced by clamp ligation
on the mutant enrichment efficiency were investigated. The three variables investigated
were: (1) non-target Apo I restriction fragments in ligation reaction mixtures, (2) the
preparation procedure of the ligated clamp, and (3) the sequence context of the ligated
clamp.
(1) Non-target Ava I restriction fragments in ligation reaction mixtures: Section 4.2.1
discusses the ratio of target to non-target restriction ends in ligation reaction mixtures. In
Section 4.2.1, a 102- to 103-fold higher copy number of non-target restriction ends was
estimated after target isolation. These non-target restriction ends with the ligated clamp
may interfere with target amplification and CDCE separation when estimating the mutant
enrichment efficiency. As a result, an inaccurate estimation may be generated.
To test this possibility, control samples, each containing 0, 60, or 600 ng of human
genomic DNA, were prepared. When the mutant enrichment efficiencies were compared
among these samples, no statistically significant difference was observed. Therefore,
non-target Apo I restriction fragments in ligation reaction mixtures were determined not
to be the cause of the decreased efficiency of pre-PeR mutant enrichment.
(2) The preparation procedure of the ligated clamp: As a first means of preparing the
clamp for ligation, two complementary oligonucleotides were synthesized, purified by
PAGE, and hybridized to each other (see Section 3.2.3.1). The PAGE-purified
oligonucleotides were supplied by Synthetic Genetics with a claimed purification
efficiency of 95%. Purification of the oligonucleotides was necessary since impure
intermediates were expected in the crude synthesis mixtures (Caruthers et aI., 1983;
Itakura et aI., 1984; Warren and Vella, 1995).
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High-performance liquid chromatography (HPLC) is effective in purifying synthetic
oligonucleotides shorter than about 30 bases in length (Itakura et aI., 1984; Warren and
Vella, 1995). For oligonucleotides up to 100 bases in length, a number of purification
methods have been reported (Johnson et aI., 1990; Frenz and Hancock, 1991; Warren and
Vella, 1993). Among them, PAGE is the most widely used (Efcavitch, 1990).
Regardless of a purification method of choice, some degree of impurity is expected in the
purified mixture (e.g., a 5% impurity with a 950/0 purification efficiency).
An impure clamp, resulting from the impurities of the clamp oligonucleotides,
possibly caused the decreased efficiency of pre-PCR mutant enrichment. This clamp,
when ligated to the chosen target, may have generated slower electrophoretic mobilities
than the pure clamp generated under optimal CDCE-separation conditions. If this is true,
the target wild-type with the impure clamp co-migrated with mutant/wild-type
heteroduplexes. As a result, the decreased mutant enrichment efficiency was generated.
To test this possibility, a second means of preparing the clamp was devised (see
Section 3.2.3.2). This procedure is thought to generate the pureist form of the clamp
using current technologies. The mutant enrichment efficiency of the control sample of
the first clamp preparation procedure was compared to that of the second; no statistically
significant difference was observed. Therefore, the impurities of the clamp
oligonucleotides were determined not to be the cause of the decreased efficiency of pre-
PCR mutant enrichment.
(3) The sequence context of the ligated clamp: This variable was detennined to be the
cause of the decreased efficiency of pre-PCR mutant enrichment. The ligated and natural
clamps have differences in their sequence contexts, such as 83 and 53% GC contents,
respectively. Thus, the effect of this variable on the mutant enrichment efficiency was
investigated.
For this investigation, a control clamp comprising the sequence of the natural clamp
was prepared using the second means of preparing the clamp. The chosen target with the
ligated control clamp is the same as that with the ligated clamp, except that the sequence
of the ligated clamp is replaced with that of the natural clamp. On average, the efficiency
of mutant enrichment for the sample of control clamp was estimated to be 4 times higher
than that for the sample of the ligated clamp. Therefore, the sequence context of the
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ligated clamp was determined to be the cause of the decreased efficiency of pre-PeR
mutant enrichment.
The ligated clamp with a high GC content is a crucial factor in the proposed point
mutation detection method. Such a clamp allows analysis of DNA sequences with
melting temperatures below 80°C. However, the sequence of the ligated clamp causes
the decreased efficiency of pre-PCR mutant enrichment. Section 4.5.1.3.2 discusses the
efficiency of pre-PCR mutant enrichment as being directly related to the sensitivity of a
mutation detection method. In brief, the sensitivity of ligated clamp procedure has to be
sacrificed to keep the procedure general to the human genome.
4.5.1.4 Hifi-PCR and post-PCR mutant enrichment
The CDCE-mutation detection limit was determined to be about 10-3 without prior
mutant enrichment. This determination is slightly different from that observed in a
previous study, 3 x 10-4 (Khrapko et aI., 1994a). This limit of 10-3 requires post-PCR
mutant enrichment for those PCR-amplified samples containing mutations at fractions at
or below 10-3•
Figure 30 illustrates CDCE-mutation detection before and after post-PCR mutant
enrichment. The mutant internal standard added at an initial fraction of 10-3 is right at the
detection limit before the procedure (Figure 30A). After the procedure, the same mutant
is detected above the detection limit (Figure 30B). Mutations in a chosen target, created
by Pfu DNA polymerase during PCR, are expected in post-PCR mutant-enriched
samples. Figure 30B illustrates these Pfu-generated mutations appearing as background
nOIse.
On average, the efficiency of post-PCR mutant enrichment by CDCE was estimated to
be IS-fold for the ligated and natural clamp procedures. This efficiency represents a 15-
fold increased mutant fraction in post-PCR mutant-enriched samples compared to that in
original PCR-amplified samples. For example, a mutant fraction of 1.5 x 10-2 is
generated in post-PCR mutant-enriched samples using a mutant fraction of 10-3 in
original PCR-amplified samples. As a result, mutations are detected 15 times above the
CDCE detection limit of 10-3•
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Figure 30. Mutation detection by CDCE: before vs. after post-PCR mutant enrichment*
A. The chosen HPRT target with the natural clamp was PCR amplified using the P31P1
primer pair prior to mutational analysis by CDCE.
B. post-peR mutant enrichment by CDCE was perfonned with the peR-amplified
sample from Figure 30 A. An additional peR was performed prior to mutational
analysis by CDCE.
* IS represents the mutant internal standard (G to A transition at HPRT eDNA bp 309) added at
an initial fraction of 10-3; I represents a region where the majority of Pfu-generated mutations in
the chosen target migrate; the CDCE-separated mutants are in mutant/wild-type heteroduplexes;
the wild-type peak is shown at 1/20 of its full height.
4.5.1.5 Sensitivity
Table 18 summarizes the efficiencies of pre- and post-PCR mutant enrichment. The
combination of these two procedures results in the total mutant enrichment efficiency of
480-fold for the ligated clamp procedure and 1875-fold for the natural clamp procedure.
This total efficiency predicts an increased mutant fraction of 2.4 x 10-2 in final mutant-
enriched samples using an initial fraction of 5 x 10-5. An increased fraction of 9.4 x 10-2
is predicted for the natural clamp procedure. Figures 31 and 32 illustrate CDCE
detection of the mutant internal standard added at an initial fraction of 5 x 10-4,5 X 10-5,
or 5 x 10-6.
Given that mutations in final mutant-enriched samples are detected above the
detection limit of CDCE, analysis of mutations in original samples is limited by the level
of background noise. Equivalently, the mutation detection sensitivity of the ligated or
natural clamp procedure is limited by this level. Background noise results from DNA
modifications generated prior to peR and mutations generated by DNA polymerase
during peR. Sections 4.5.1.6 and 4.5.2.10 discuss the source of background noise.
The average level of background mutants (ME) was compared to that of the mutant
internal standard (Mr) added at the known initial fraction (F) to estimate the sensitivity:
[(ME + Mr)] x F. The background mutants compared are six predominant mutations
generated by Pfu DNA polymerase used for amplifying pre-PCR mutant-enriched
samples (see Section 4.5.2.10). A sensitivity of 10-5 was estimated for the ligated clamp
procedure, and 3 x 10-6 for the natural clamp procedure. This decreased sensitivity was
predicted in Section 4.5.1.3.2.
4.5.1.6 Source of background noise
In Section 4.5.1.5, CDCE-purified wild-type DNA was used as initial DNA samples to
estimate the mutation detection sensitivities. With these samples Apo I restriction
digestion was performed at 37°C for 2 hr, and pre-PCR mutant enrichment was
performed at ::::: 66°C for 1 to 2 hr. These samples were not exposed to additional heat
prior to PCR. These preparation procedures suggest Pfu, a DNA polymerase used for
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Table 18. Summary of mutant enrichment efficiencies
Average efficiency
Mode of mutant enrichment
Pre-PCR
Post-PCR
Total
Ligated clamp
32-fold
I5-fold
480-fold
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Natural clamp
I25-fold
I5-fold
I875-fold
I II: 5 X 10-4
III .... .. III
I
Q)
u
c=Q)
U
r:..n
lj)
H
0
:::s
~
lj)
>.~
~
ro
,.......(
III .ell
Q)
II- III ~
I
II: 5 x 10-6
III .....I------------~... III
18.00 20.00 22.00 24.00 26.00 28.00
Minutes
Figure 31. Mutation detection by CDCE: natural clamp
(initial samples of CDCE-purified wild-type DNA)*
Pre-PeR mutant enrichment by CDCE, followed by CE, was performed with each
initial sample of CDCE-purified wild-type DNA. This procedure was followed by PCR
using the P31P1 primer pair to amplify the chosen HPRT target with the natural clamp.
Post-PCR mutant enrichment by CDCE, followed by peR, was performed prior to
mutational analysis by CDCE.
*1 represents the wild-type in homoduplex; II represents the mutant internal standard (IS: G to A
transition at HPRTcDNA bp 309) added at an initial fraction ofS x 10-4,5 X 10-5, or 5 x 10-6; III
represents a region where the majority of the background mutants migrate; the CDCE-separated
mutants are in mutant/wild-type heteroduplexes.
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Figure 32. Mutation detection by CDCE: ligated clamp
(initial samples of CDCE-purified wild-type DNA)*
Apo I restriction digestion and clamp ligation were performed with each initial sample
of CDCE-purified wild-type DNA. These procedures were followed by pre-PCR mutant
enrichment by CDCE and CEo Using the GCIIPI primer pair, the chosen HPRTtarget
with the ligated clamp was peR amplified, followed by post-PCR mutant enrichment by
CDCE. Final mutant-enriched samples were peR amplified prior to mutational analysis
by CDCE.
*1 represents the wild-type in homoduplex; IT represents peR by-products; ill represents the
mutant internal standard (IS: G to A transition at HPRT cDNA bp 309) added at an initial fraction
of 5 x 10-4,5 X 10-5, or 5 x 10-6; IV represents a region where the majority of the background
mutants migrate; the CDCE-separated mutants are in mutant/wild-type heteroduplexes.
PCR, as the source of background noise.
Using an initial sample size of 2 x 108 wild-type copy number, a sample size of 6 x 106
((2 X 108) + 32) was estimated for the ligated clamp procedure, and 2 x 106 ((2 X 108) +
125) for the natural clamp procedure in pre-PeR mutant-enriched samples. These sample
sizes were estimated by directly measuring the wild-type copy number in the mutant-
enriched samples. These estimations are equivalent to those calculated using the
efficiencies of pre-PCR mutant enrichment. About 20 doublings were applied to each
pre-PCR mutant-enriched sample to convert all the primers into products. 20 doublings
are equivalent to a 106- fold target amplification.
An increased mutant fraction of 1.6 x 10-3 in pre-PCR mutant-enriched samples is
expected using an initial mutant fraction of 5 x 10-5. This expectation is based on the
efficiency of pre-PCR mutant enrichment observed for the ligated clamp procedure.
After 20 doublings of target amplification, this increased mutant fraction is expected to
be 4 times greater than the mutant fraction that belongs to predominant mutations
generated by Pfu during PCR amplification of pre-PCR mutant-enriched samples ((2 x
10-6/bp/doubling) x 20 doublings x 10 =4 x 10-4). The expected Pfu-mutant fraction is
based on the fidelity of Pfu observed for the chosen HPRT target. In addition, this mutant
fraction is based on the predominant Pfu mutations occurring 10 times more frequently
than expected by chance after 20 doublings. The expected level of Pfu-mutant fraction is
in close agreement with the sensitivity observed for the ligated clamp procedure (1.3 x
10-5: [(4 x 10-5) + (1.6 x 10-3)] x 5 x 10-5). This agreement is true for the natural clamp
procedure.
These agreements indicate that the fidelity of Pfu determines the level of background
noise upon mutational analysis by CDCE. To verify this indication, the level of
background noise as a function of doublings was investigated. As Figure 33 illustrates,
the level of background noise increases as a function of doublings. Figure 33A
represents a pre-PCR mutant-enriched sample after 20 doublings. Figures 33B and C
represent the same sample with an additional 20 doublings.
These results demonstrate that the level of background noise is determined by the
fidelity of Pfu. Equivalently, this fidelity determines the mutation detection sensitivity of
either the ligated or natural clamp procedure. Section 4.5.2.10 discusses the positions
141
A.20d
I II II IV __
II- IV
B. 40d #1
(],)
u
0(]..)
U
rfJ
(]..)
~
0
~
~
Co)
:>-
.~
..j...l
C'O
I II II ~
....
... IV
(]..)
IV ~
C. 40d #2
I II II IV ..... ....--------------...... IV
18.00 20.00 22.00 24.00 26.00 28.00
Minutes
Figure 33. Background mutants vs. doublings*
Apo I restriction digestion and clamp ligation were performed with each initial sample
of CDCE-purified wild-type DNA. These procedures were followed by pre-peR mutant
enrichment by CDCE and CEo Using the GCIIPI primer pair, the chosen HPRTtarget
with the ligated clamp was peR amplified using either 20 (A) or 40 (B and C) doublings.
After post-PCR mutant enrichment by CDCE, final mutant-enriched samples were peR
amplified and analyzed by CDCE.
*1 represents the wild-type in homoduplex; II represents peR by-products; III represents the
mutant internal standard (IS: G to A transition at HPRT eDNA bp 309) added at an initial fraction
of 5 x 10-5; IV represents a region where the majority of the background mutants migrate; the
CDCE-separated mutants are in mutant/wild-type heteroduplexes; 20 doublings are equivalent to
a 106-fold target amplification, and 40 doublings, a l012-fold.
and kinds of Pfu mutations in the chosen HPRT target.
4.5.2 With wild-type DNA of human cells
4.5.2.1 Initial DNA samples
To discover the mutation detection sensitivity of the ligated clamp procedure in
comparison to the natural clamp procedure in human cells, TK6 was chosen as a target
cell line. TK6, an approximately diploid human B cell line, was originally established
from a male patient with hereditary spherocytosis (Levy et aI., 1968) and was isolated
after treatment with ICR-191 (Skopek et aI., 1987). TK6 is hemizygous at HPRTlocus
and is heterozygous at tk locus. Thus, selection of mutations in these loci can be
performed using selecting agents, such as 6TG.
TK6 cells were obtained from a previous study (Tomita-Mitchell, 1999). These cells
had been left untreated, maintained in exponential growth by daily dilution, and frozen
after 15.5 generations. The expected total HPRTmutant fraction in these cells is about
4.2 x 10-6 (2.7 X 10-7 X 15.5). This expectation is based on the spontaneous mutation rate
per doubling, 2.7 x 10-7, observed for the HPRT gene (Tomita-Mitchell, 1999).
Assuming a target size of about 1000-bp for this gene, HPRT hotspot mutations that had
occurred 10 to 100 times more frequently than expected by chance, would appear at
fractions of 4.2 x 10-8 ([(4.2 x 10-6) -7- 1000] x 10) to 4.2 X 10-7 ([(4.2 x 10-6) -7- 1000] x
100) in these cells. Such HPRT hotspot mutations in human cells have been shown to
represent about 50% of the point mutations that alter the physiological function of the
gene product (Kat, 1992; Tomita-Mitchell et aI., 2000). These expected mutant fractions
are lower than the mutation detection sensitivities determined for the ligated and natural
clamp procedures using the initial samples of CDCE-purified wild-type DNA. To
compare the sensitivity of the ligated clamp procedure in human cells to that of the
natural clamp procedure, genomic DNA isolated from the TK6 cells of Tomita-Mitchell
(1999) was used as initial samples.
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4.5.2.2 Genomic DNA isolation
A procedure described in a previous study allows DNA isolation with minimal
exposure to potential mutagenic agents, such as phenol (Khrapko et aI., 1997b). In this
procedure, genomic DNA is isolated from cells by digestion with proteinase K, SDS, and
RNase A, followed by ethanol precipitation of the DNA. The DNA isolated by this
procedure has been demonstrated to be suitable for analysis of point mutations at
fractions as low as 10-6 (Khrapko et aI., 1997a,b; Coller et aI., 1998; Marcelino et aI.,
1998; Li-Sucholeiki and Thilly, 2000).
The quantity and quality of genomic DNA isolated from human cells was assessed by
a UV spectrophotometer. The typical DNA yield was over 90% with the ratio of A260 to
A2so in the range of 1.6 to 2.0.
4.5.2.3 Sequential restriction digestion
Figure 34 illustrates two sequential restriction digestion procedures, with target
isolation in between. The order of these procedures is necessary to generate the chosen
HPRT target suitable for CDCE separation with a minimum cost. Monetary cost has to
be considered since liberating the chosen target from a large quantity of genomic DNA,
such as 60 Jlg (::::::107 cells), in many samples can be expensive. 60 flg is the sample size
necessary for detecting mutations at fractions as low as 10-5 with statistical significance
(±20% precision).
For the first restriction digestion, BstN I and Dra I were selected. These enzymes
liberate the 438-bp HPRTtarget-embedded fragment from human genomic DNA at a
minimum cost. After this target-embedded fragment was isolated from the BstN I and
Dra I digest, the second restriction digestion followed. This second digestion generated
the chosen target suitable for CDCE separation. The cost of restriction endonucleases for
the second digestion is no longer a limiting factor since an initial sample size is reduced
after target isolation. For example, an initial sample size of 60 Jlg is reduced to 6 ng
using an isolation efficiency of 104-fold. For the second restriction digestion, Ahd I and
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Figure 34. Restriction digestion by BstN I, Dra I, Ahd I, HinfI, and Apo I
The first restriction digestion by BstN I and Dra I liberates the 438-bp HPRT target-
embedded fragment from human genomic DNA. After this target-embedded fragment is
isolated from the BstN I and Dra I digest, the second restriction digestion followed. This
digestion generates the chosen target suitable for CDCE separation. Restriction digestion
with Ahd I and Hin!I is performed for the natural clamp procedure, and with Apo I for
the ligated clamp procedure.
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HinfI were selected for the natural clamp procedure. For the ligated clamp procedure,
Apo I was chosen.
4.5.2.4 Target isolation
Figure 18 in Section 3.8.3.1 illustrates isolation of a chosen target from a pool of
genomic DNA digest. Using the chosen HPRT sequence as a target, this procedure
generated a 72 ± 2 % target yield. This target yield closely agrees with that observed in a
previous study (74%, Li-Sucholeiki and Thilly, 2000).
As a first means of estimating the isolation efficiency of the chosen HPRT target
relative to non-target sequences in the pool of genomic DNA digest, a part of human
mitochondrial DNA (DNA bp 10011-10215) was selected as a non-target reference.
About a few hundred to a thousand mitochondrial sequence copies per human cell have
been estimated (Robin and Wong, 1988; Marcelino et aI., 1998; Khrapko et aI., 1999).
One HPRT sequence copy (X-linked) is expected per male-derived cell, TK6. The molar
ratio of the mitochondrial to target sequences in initial samples was estimated to be about
2000/1 (R1). This ratio was compared to that in target-isolated samples, 1/0.55 ± 0.23
(RF), to estimate the isolation efficiency: R1 +- RF, 3.6 x 103-fold.
As a second means of estimating the efficiency of target isolation, the absorbencies of
initial and target-isolated samples were measured by a UV spectrophotometer at a
wavelength of 260 nrn, and the sample DNA concentrations per a given target copy
number were compared. By this method, an efficiency of 700 ± 210-fold was estimated.
On average, this efficiency is about 5-fold lower than that estimated by the first method.
The second method is thought to be more accurate since the measurement refers to all
non-target sequences a sample may have, while the measurement in the first method
relies on one non-target sequence.
Using the first means of estimating the target isolation efficiency, one study has
reported a 3-fold greater efficiency (Li-Sucholeiki and Thilly, 2000) compared to that
observed in this study. Two possible causes of this difference are the use of two different
target sequences and a 2-fold difference in the initial ratio of target to non-target
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sequences. The HPRT target used in this study is expected to be present as one copy per
cell. A part of the human APe gene, used as a target in the previous study, is expected to
be present as two copies per cell.
Based on the target yield and the isolation efficiency observed for the chosen HPRT
target, a sample size of 86 ng (107 cells + 700 =1.4 X 104 cells) is expected in target-
isolated samples using an initial sample size of 60 Ilg human genomic DNA (107 target
copy number in 107 cells). In these target-isolated samples, a target copy number of 7 x
106 is expected (107 x 0.7 =7 x 106).
4.5.2.5 Target renaturation
4.5.2.5.1 Potential source of background noise
The established protocol for target isolation isolates a chosen target in single strands.
Thus, target renaturation is necessary prior to pre-PCR mutant enrichment by CDCE.
Substrate concentration, incubation temperature, and buffer composition have been
identified as important factors in DNA renaturation (Doty et aI., 1960; Marmur and Lane,
1960~ Marmur and Doty, 1961; Thrower and Peacocke, 1966~ Thrower and Peacocke,
1968). In a previous study, incubation at 55°C for 16 hr in 0.2 M NaCl was performed
with each target-isolated sample (Li-Sucholeiki and Thilly, 2000). The substrate
concentration used in the study of Li-Sucholeiki and Thilly (2000) was 108/111 (personal
communication) .
The established protocol for target renaturation was investigated since it requires
sample exposure to heat, at 55°C, for a long period of time, 16 hr. Heat induces DNA
modifications at different rates, with the rates depending on temperature, DNA
conformation, pH, and buffer composition (Greer and Zamenhof, 1962; Lindahl and
Nyberg, 1972; Lindahl and Karlstrom, 1973; Lindahl and Nyberg, 1974; Ehrlich et aI.,
1986). Table 19 summarizes the published rates of heat-induced DNA modifications at
various temperatures.
Single-stranded target DNA with modifications, when renatured with the wild-type, is
expected to change thermal stability from that without modifications. Indeed,
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Table 19. Rates of heat-induced DNA modifications vs. temperatures
Type of modification Temperature Rate*
95°C 2.0 x 10-7/sec
Deamination of
cytosine 70°C 1.2 x lO-8/sec
sooe 1.0 x 10-9/sec
Deamination of adenine liOoe 4.0 x 10-8/sec
Depyrimidination 95°C 2.0 x lO-8/sec
Depurination 95°C 1.5 x 10-7/sec
* Each is a published rate for single-stranded DNA.
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Reference(s)
Lindahl and Nyberg, 1974;
Ehrlich et aI., 1986
Ehrlich et aI., 1986;
Frederico et aI., 1990
Frederico et al., 1990
Karran and Lindahl, 1980
Lindahl and Karlstrom,
1973
Wang et aI., 1982
deamination of cytosine, resulting in G:U pairs, has been shown to reduce the thermal
stability by about 2.2°C (Ullman and McCarthy, 1973a). Reduction in the thermal
stabiltiy has also been observed with depurination (Ullman and McCarthy, 1973b).
These studies suggest heat-induced modifications in a chosen target in the eluted samples
of mutant/wild-type heteroduplexes after pre-PCR mutant enrichment by CDCE. These
modified species can appear as background noise upon mutational analysis by CDCE, as
Section 4.5.2.10 discusses.
DNA modification fractions introduced by each procedure in the proposed point
mutation detection method were estimated. Those procedures prior to pre-PCR mutant
enrichment were investigated. Those procedures that require incubation at temperatures
at or below 37°C were excluded from this investigation. For example, deamination of
cytosine has been shown to be negligible in those samples incubated at 37°C for up to 5
days (Wang et aI., 1982). The same has been observed for depurination after incubation
at 37°C for 2 months (Lindahl and Nyberg, 1972).
As Table 20 summarizes, target renaturation is the procedure that generates
deaminated cytosine at the highest fraction. This observation is expected to be true for
the other modified species due to the nature of target renaturation requiring sample
exposure to heat for 16 hr (see 4.5.2.5.2 for the renaturation efficiencies over different
incubation time periods). Thus, available renaturation methods that require incubation at
temperatures below 55°C were sought, and three were found.
The first method uses denaturants, such as formamide and urea. Addition of
denaturants to renaturation mixtures has been shown to decrease the Till of the substrate
DNA (McConaughy et aI., 1969; Bltithmann et aI., 1973; Hutton, 1977). However, no
simple linear relationship has been established between mean thermal stabilities of
substrates and denaturant concentrations (Schmeckpeper and Smith, 1972). In addition, a
reduced renaturation rate is expected in mixtures with denaturants compared to those
without. This reduction has been explained by the increased solution viscosities as a
result of adding denaturants to reaction mixtures (Thrower and Peacocke, 1968;
Schmeckpeper and Smith, 1972; Hutton, 1977). Based on this reduced rate, longer
sample exposure to heat is expected for those samples with denaturants compared to
those without. For this reason, this method was rejected.
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Table 20. Expected fractions of heat-induced DNA modifications
Procedure Temperature/ Expected fractions C & d
(ss or ds) duration
a&b
Deamination Deamination De- De-
of cytosine of adenine pyrirnidination purination
Genomic
DNA 50°C/3 hr
isolation
Cds)
IOOoe/1 min >1.2 x 10-5 <2.4 X 10-6 >1.2 X 10-6 >9 X 10-6
Target 70°C/4 min 2.9 x 10-6
isolation
(ss)
60°C/2 hr >7.2 x 10-6
50°C/30 min 1.8 x 10-6
Target 55°C/16 hr >5.8 x 10-5
renaturation
(ss)
a Listed are those procedures that require incubation at temperatures above 37°C prior to pre-PCR
mutant enrichment in the proposed point mutation detection method.
b Single- (ss) or double-stranded (ds) DNA confonnation in each procedure.
C Based on the published rates at each temperature (see Table] 9).
d Those fractions left blank are due to the lack of published rates at desired temperatures.
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The second method, phenol emulsion reassociation technique, allows renaturation at
or below room temperature in sample mixtures containing phenol (Kohne et a1., 1977).
Since phenol is thought to be a potential mutagenic agent, this method was rejected.
The third method uses DMSO and this method was chosen as an alternative to the
established method that uses the incubation temperature of 55°C. Addition of 40%
DMSO to renaturation mixtures has been shown to decrease the Tm of the substrate DNA
by 27°C (Escara and Hutton, 1980). This addition is expected to increase the solution
viscosities, lowering the renaturation rate. However, the rate has been shown to increase
as the concentration of DMSO is increased (Escara and Hutton, 1980). The effect of
DMSO on the solution dielectric constant has been suggested as a cause of this
observation contradictory to the expectation (Escara and Hutton, 1980).
DMSO has been used as a cryoprotective agent (Ashwood-Smith, 1979; Greene et aI.,
1970). A number of studies have been performed to characterize this agent. No toxic
effects have been observed on HeLa cells exposed to 5% DMSO for 24 hr at 37°C
(Greene et aI., 1970). No genetic changes have been observed over extended periods of
storage using 10% DMSO (Ashwood-Smith, 1979; Ashwood-Smith, 1985). In addition,
it has been shown that DNA cleavage is about 120-fold more frequent in 0% DMSO at
Tm+10°C than in 40% DMSO at Tm+10°C (Escara and Hutton, 1980). Depurination has
been shown to be about the same in these two variables (Escara and Hutton, 1980).
These studies suggest that the renaturation method using DMSO can potentially reduce
formation of heat-induced DNA modifications during target renaturation.
As a second means of target renaturation, incubation was performed at 28°C in
mixtures containing 40% DMSO. The efficiency of this method over different incubation
time periods is discussed in the following section.
4.5.2.5.2 Efficiency
Figure 35 summarizes efficiencies of two renaturation methods over different
incubation time periods. These results demonstrate that a renaturation efficiency of about
90% can be achieved after 16 hr-Iong incubation using either method. The other 10% is
thought to represent the target that never renatured. Some of the substrate DNA has been
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Figure 35. Renaturation efficiencies vs. incubation duration*
A chosen target was PCR was amplified using the IS 1IIS2 primer pair, and this
amplified target at a concentration of 108/Jll was denatured. Using different test
incubation time periods, renaturation was performed at 55°C (A) or at 28°C in the
presence of 40% DMSO in the renaturation reaction mixture (B). Each renatured sample
was restriction digested by Apo I, and the digestion efficiency served as a reference to
measure the renaturation efficiencies over different incubation time periods.
* The substrate without denaturation was used as a positive control CApo I digestion efficiency:
>95%). The substrate with denaturation and with 0 hr incubation duration was used as a negative
control (Apo I digestion efficiency: 0%).
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shown never to renature (Thrower and Peacocke, 1968). The inability to achieve
complete renaturation has also been explained by phosphate-ester backbone breakage of
substrate DNA during denaturation and renaturation (Marmur and Doty, 1961).
4.5.2.6 Restriction digestion and clamp ligation
The restriction digestion efficiency of Apo I was estimated to be about 80% (ligated
clamp). The same digestion efficiency was estimated for Ahd I and Hinfl (natural
clamp). These efficiencies are about 10% lower than those observed in another study
using the samples of target isolation, followed by target renaturation (Li-Sucholeiki, X.-
C., personal communication).
Target isolation is thought to be a cause of this decrease. If this procedure isolates the
Watson and Crick strands of a target with unequal efficiencies, a decrease in restriction
digestion efficiency is expected. For example, digestion efficiencies of up to 81 % (up to
90% of the 0.9 Crick strand) are expected in target-isolated samples containing the
Watson and Crick strands of a target at a molar ratio of 1 to 0.9. This expectation is
based a previous observation in which up to about 90% renaturation efficiencies were
achieved in samples containing the Watson and Crick strands of a target at an equal
molar ratio (see Section 4.5.2.5.2).
Clamp ligation was performed with each sample of Apo I restriction digestion. A
clamp copy number of lOll per 107 target copy number was determined to be necessary to
generate the maximum clamp ligation efficiency by mass action. This clamp copy
number was determined by clamp dilution experiments, as Section 4.5.1.2 discusses.
4.5.2.7 Pre-peR mutant enrichment
The efficiency of pre-PCR mutant enrichment was estimated after CDCE, followed by
CEo In addition to the wild-type in single strands (see Section 4.5.1.3.2), two more
potential wild-type-containing species are expected in the CDCE-eluted samples of
mutant/wild-type heteroduplexes using the initial samples of human cells. The first is the
wild-type that may be renatured with non-target residual cellular DNA in target-isolated
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samples. The second is the wild type-embedded BstN I/Dra I fragment left uncleaved
after the second restriction digestion. These wild-type-containing species may co-
migrate with mutant/wild-type heteroduplexes under optimal CDCE-separation
conditions. As a means to reduce the copy number of the wild-type-containing species in
the CDCE-eluted samples, CE was performed. CE differentiated the targets of different
lengths, allowing this reduction.
Initially, a capillary bore size of 320-flill id was used for pre-PCR mutant enrichment.
Based on the loading capacity determined for this bore size (2.5 flg) (Li and Thilly,
1996), a 107 target copy number was estimated to be a suitable sample size. This target
copy number was estimated to be equivalent to about 86 ng DNA, calculated using the
efficiency of target isolation. Using the bore size of 320-Jlffi id, the average efficiency of
mutant enrichment was estimated to be la-fold for the natural clamp procedure. This is
about 12-fold lower than that observed in the initial samples of CDCE-purified wild-type
DNA. These initial samples contain up to about 600 ng of human genomic DNA.
One possible cause of this decrease is that the bore size of 320-Jlffi id is not able to
handle impurities in samples accumulated prior to pre-PCR mutant enrichment. Such
impurities, when loaded into a capillary, may cause a "peak-broadening effect," resulting
in more of the wild-type co-migrating with mutant/wild-type heteroduplexes under
optimal CDCE-separation conditions. When a capillary bore size of 540-flm id (loading
capacity: 10 flg (Li and Thilly, 1996)) was used instead, the average mutant enrichment
efficiency increased to 60 ± 8.3-fold. An average efficiency of 19 ± 4-fold was estimated
for the ligated clamp procedure using the capillary bore size of 540-flm id.
These measured efficiencies using the bore size of 540-flm id are about 2-fold lower
compared to those in the initial samples of CDCE-purified wild-type DNA. A similar
observation has been reported (between >1- and >2-fold lower efficiencies) (Li-
Sucholeiki and Thilly, 2000). These lower efficiencies observed for the ligated and
natural clamp procedures predict a 2-fold lower mutation detection sensitivity, as Section
4.5.1.3.2 discusses. This decrease in efficiency is possibly caused by variables
introduced by the different initial samples: CDCE-purified wild-type vs. wild-type in
human cells.
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Using the capillary bore size of 540-)lffi id and using the initial samples of human
cells, the average efficiency of pre-PCR mutant enrichment observed for the natural
clamp procedure is 2- to 3-fold lower than that in a previous study (Li-Sucholeiki and
Thilly, 2000). This decrease is possibly caused by the use of two different target
sequences. Some sequences possibly generate higher efficiencies than other sequences.
However, more sequences need to be investigated to validate this assumption.
4.5.2.8 Hifi-PCR and post-PCR mutant enrichment
The average efficiency of post-peR mutant enrichment by CDCE was estimated to be
I5-fold for the ligated and natural clamp procedures. This efficiency agrees with that
observed in the initial samples of CDCE-purified wild-type DNA.
4.5.2.9 Sensitivity and accuracy
Figure 36 illustrates mutation detection by CDCE. A mutation detection sensitivity of
5 x 10-6 was estimated for the natural clamp procedure, and 2 x 10-5 for the ligated clamp
procedure. The sensitivity of the ligated clamp procedure represents detection of as few
as 200 copies of each mutant in the presence of 107 copies of the wild-type. These
sensitivities are slightly lower compared to those in the initial samples of CDCE-purified
wild-type DNA. Section 4.5.2.7 predicts this decrease.
Using the initial samples of human cells, the sensitivity estimated for the natural
clamp procedure is 5-fold lower that that in a previous study (5 x 10-6 vs. IO-6/bp) (Li-
Sucholeiki and Thilly, 2000). However, a direct comparison cannot be made since
different target sequences were used. Sensitivity is related to the efficiency of pre-PeR
mutant enrichment and to the fidelity of Pfu DNA polymerase, as Sections 4.5.1.3.2 and
4.5.1.6 discuss. These relationships can generate various sensitivities using different
target sequences. However, more sequences need to be investigated to understand the
relationship between the sensitivity and the use of different target sequences.
Figure 37 illustrates CDCE-mutation detection of mutant internal standards added at
different initial fractions ranging from 3 to 27 X 10-5 using the ligated clamp procedure.
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Figure 36. Mutation detection by CDCE: ligated vs. natural clamp
(initial samples of human cells)
Genomic DNA isolation, restriction digestion with BstN I and Dra I, and target
isolation were performed with each initial sample of human cells. For the natural clamp
procedure (A and B), pre-PCR mutant enrichment by CDCE, followed by CE, was
performed. For the ligated clamp procedure (C), Apo I restriction digestion and clamp
ligation were performed prior to pre-PCR mutant enrichment. PCR was performed with
each mutant-enriched sample using either the P3IPI or GCIIPI primer pair, depending on
the clamp type desired. This procedure was followed by post-PCR mutant enrichment by
CDCE. Final-mutant enriched samples were peR amplified prior to mutational analysis
by CDCE.
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A. Natural clamp #1
III
IV ..'ClIIII------------....... IV
B. Natural clamp #2
IV --IIIII------------......IIJ- IV
IV ..'ClIIII----------------1IJ- IVI
II
III C. Ligated clamp
18.00 20.00 22.00 24.00 26.00 28.00
Minutes
I represents the wild-type in hornoduplex; II represents PCR by-products; III represents
the mutant internal standard (IS: G to A transition at HPRT cDNA bp 309) added at an
initial fraction of 5 x 10-5; IV represents a region where the majority of the background
mutants migrate; the CDCE-separated mutants are in mutant/wild-type heteroduplexes; A
and B are independently performed experimental results.
Figure 37. CDCE-mutation detection vs. mutant fractions: ligated clamp
(initial samples of human cells)
Genomic DNA isolation, restriction digestion with BstN I and Dra I, and target
isolation were performed with each initial sample of human cells. Apo I restriction
digestion and clamp ligation were then performed prior to pre-PCR mutant enrichment by
CDCE and CEo PCR was performed with each mutant-enriched sample using the
GCI/PI primer pair, followed by post-PCR mutant enrichment by CDCE. Final-mutant
enriched samples were peR amplified and analyzed by CDCE.
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Minutes
I represents the wild-type in homoduplex; II represents PCR by-products; III represents a
region where the majority of the background mutants migrate; IV represents the mutant
internal standard of genomic DNA (lSI: G -> T transversion at HPRTcDNA bp 312)
added at an initial fraction of 3 x 10-5, 9 x 10-5, or 2.7 x 10-4; V represents the mutant
internal standard of PCR products (IS2: G to A transition at HPRT eDNA bp 309) added
at an initial fraction of 5 x 10-5; the CDCE-separated mutants are in mutant/wild-type
heteroduplexes.
Figure 38 illustrates the quantitative analysis of Figure 37. These results demonstrate the
accuracy of the ligated clamp procedure.
4.5.2.10 Source of background noise
Section 4.5.1.6 discusses Pfu DNA polymerase as the source of background noise
using the initial samples of CDCE-purified wild-type DNA. Using the initial samples of
human cells, additional sources of background noise are expected. Section 4.5.2.5.1
discusses heat-induced DNA modifications. In addition, ethanol and UV light have been
identified as causes of DNA modifications (Hanekamp, 1993). These modifications in
pre-PCR mutant-enriched samples can be peR-amplified and, as a result, appear as
background noise upon mutational analysis by CDCE.
For example, deamination of cytosine, forming uracil, can result in C to T transition.
When adenine is converted to hypoxanthine as a result of deamination, this lesion forms a
more stable base pair with cytosine than with thymine, resulting in A to G transition
(Lindahl, 1979; Lindahl, 1993). Although apurinic/apyrimidinic (AP, abasic) sites can
block DNA synthesis (Sagher and Strauss, 1985; Lindahl, 1993), bypassing of these sites
during DNA synthesis can be mutagenic (Shearman and Loeb, 1979; Schaaper et aI.,
1983; Kunkel, 1984; Loeb, 1985; Loeb and Preston, 1986).
Section 4.5.2.5.1 identifies target renaturation as the procedure that generates heat-
induced DNA modifications at the highest fractions in the proposed point mutation
detection method. For this reason, the level of background noise using the established
target renaturation method was compared to that of the alternative method. The
established method uses an incubation temperature of 55°C, and the alternative method
uses a temperature of 28°C with 40% DMSO in reaction mixtures (see Section 4.5.2.5).
These two methods generated no difference in the level of background noise. This
observation suggests that the established target renaturation method, requiring incubation
at 55°C for 16 hr, is not the source of background noise.
Using the initial samples of human cells, Pfu DNA polynlerase has been identified as
the source of background noise (Li-Sucholeiki and Thilly, 2000). In this present study,
three observations were made to confirm the previous study.
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Figure 38. Accuracy of mutation detection by CDCE: ligated clamp
Genomic DNA isolation, restriction digestion with BstN I and Dra I, and target
isolation were performed with each initial sample of human cells. Apo I restriction
digestion and clamp ligation were then performed prior to pre-PCR mutant enrichment by
CDCE and CEo PCR was performed with each mutant-enriched sample using the
GCI/Pl primer pair, followed by post-peR mutant enrichment by CDCE. Final-mutant
enriched samples were PCR amplified and analyzed by CDCE. Each output was
estimated by comparing the area oflSl (0 -> T transversion at HPRTcDNA bp 312)
added at an initial fraction of 3 x 10-5, 9 x 10-5, or 2.7 x 10-4 to that of IS2 added at an
initial fraction of 5 x 10-5 (I): (IS 1 + IS2) x I; the average area of the background mutants
(B) was compared to the area of IS2 to estimate the average background mutant fraction
in each sample: (B + 152) x I.
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First, the efficiencies of pre-PeR mutant enrichment and the sensitivities were
observed to correlate. Section 4.5.1.6 discusses this correlation as being an indication
that the fidelity of Pfu determines the level of background noise.
Second, the level of background noise in the initial samples of human cells was
observed to increase as the number of doublings increased. This observation was
previously demonstrated using the initial samples of CDCE-purified wild-type DNA in
Section 4.5.1.6.
Third, the background mutants in a PCR-noise control sample were observed to co-
migrate with those in the initial samples of human cells under optimal CDCE-separation
conditions. Figure 39A represents CDCE-purified wild-type DNA used as a template to
prepare the PCR-noise control. Figure 39B represents the PeR-noise control, prepared
by amplifying the chosen target using Pfu. Figure 39C represents the initial samples of
human cells using the ligated clamp procedure. A set of co-migrating mutants was
purified and sequenced. Sequencing analysis showed that each of the co-migrating
mutants is the same with regard to position and kind. Figure 40 and Table 21 summarize
the sequencing results.
The predominant Pfu-mutations in the chosen HPRT target were identified to be 4 G
to T tranversions, 1 G to A transition, and 1 A to G transition. As Section 2.5.3.1
discusses, G to T transversion has been determined as the predominant mutation type of
Plu. The mutations identified in the chosen HPRT target represent about 60% of the total
Pfu-mutations. These mutations appeared at an average fraction equivalent to about 2 x
10-5 in original samples. This average mutant fraction limited the sensitivity of the
ligated clamp procedure.
As this section has discussed, heat-induced DNA modifications can appear as
background noise. For example, deaminated cytosine is expected to appear in the chosen
target at a fraction greater than 5.8 x 10-5 in pre-PeR mutant-enriched samples (see Table
20 in Section 4.5.2.5.1). This expectation is greater than the average mutant fraction
observed for the predominant Pfu mutations.
To date, a limited number of studies are available to explain why Plu, not target
renaturation, is the source of background noise. Plu has been shown to specifically
recognize the presence of uracil in single-stranded DNA and stall DNA synthesis (Lasken
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Figure 39. Source of background noise: Pfu DNA polymerase*
A. peR was performed using the GCIIPI primer pair to amplify the chosen HPRTtarget
with the ligated clamp, followed by CDCE purification of the wild-type DNA.
B. A mixture containing the CDCE-purified wild-type DNA (Figure 39A) and the
mutant internal standard (G to A transition at HPRT eDNA bp 309) at a fraction of
10-3 was peR amplified using the GCIIPI primer pair. post-peR mutant enrichment,
followed by peR, was performed prior to mutational analysis by CDCE.
C. Genomic DNA isolation, restriction digestion with BstN I andDra I, and target
isolation were performed with the initial sample of human cells. Apo I restriction
digestion and clamp ligation were performed with the target-isolated sample
containing the mutant internal standard (G to A transition at HPRT cDNA bp 309)
added at an initial fraction of 5 x 10-5. These procedures were followed by pre-PeR
mutant enrichment by CDCE and CEo peR was performed with the mutant-enriched
sample using the Gel/PI primer pair, followed by post-PCR mutant enrichment by
CDCE. The final-mutant enriched sample was peR amplified and analyzed by
CDCE.
* I represents the wild-type in homoduplex; II represents PCRby-products; the CDCE-
separated mutants in mutant/wild-type heteroduplexes; Figure 40 and Table 21
summarize the positions and kinds of mutants.
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The line represents least squares regression, generated as a result of using 6 independent
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the fitted mutant fractions by liner regression; each set of two triangles represents the
corresponding output mutant fractions of each input mutant fraction; each set represents
duplicate experiments; the squares represent the average background mutant fractions in
individual samples.
Figure 40. Positions and kinds of mutations in chosen HPRT target
5'- cAATTC TTTGC TGACC TGCTG GATTA CATCA AAGCA CTGAA
A (c)
T (b) T (d)
A (e)
iA(t)t
TAGAA ATAGT GATAG ATCCA TTCCT ATGAC TGTAG ATTTT
A (g)
G (a)
i
A (h)
t
ATCAG ACTGA AGAGC TATTG T -3'
* cDNA bp 218-318; the group of bases in bold represents Apo I restriction end to which
the clamp was ligated; see·Table 21 for the source of each mutation.
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Table 21. Summary of mutations in chosen HPRT target
Mutant Position Kind Source
c 275 G->T Pfu
f 276 G->T Pfu
b 280 G->A Pfu
e 287 G->T Pfu
d 289 G->T Pfu
a 301 A->G Pfu
g 309 G->A Internal standard of peR products
h 312 G->T Internal standard of genomic DNA
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et aI., 1996; Greagg et aI., 1999). As a result, the major primer-extension product was
observed to be significantly shorter than an expected full-length product (Greagg et aI.,
1999). This observation was made for both the 3' to 5' proofreading exonuclease
proficient and deficient versions of Pfu (Greagg et aI., 1999). On the other hand, the
prinler extension to a full-length product was observed when tested with Taq DNA
polymerase (Greagg et aI., 1999). These results suggest that the shorter primer extension
is specific to Pfu. More studies investigating the effects of Pfu on other heat-induced
DNA modifications are necessary. These studies may answer why Pfu is the source of
background noise for the ligated and natural clamp procedures.
4.6 Demonstration of CDCE separation: p53 exon 7
Many mutations in the p53 gene have been found in various types of human cancer
(Hainaut et aI., 1998; Hernandez-Boussard et al., 1999b). For this reason, a part of the
human p53 gene (cDNA bp 673-782), representing the entire exon 7, was chosen as a
second target. Since this target does not have a neighboring natural clamp, clamp ligation
is necessary for mutational analysis by CDCE.
Figure 41 illustrates CDCE separation results using the ligated clamp at different
temperatures. These results demonstrate the ability of the ligated clamp to separate point
mutations in the chosen p53 target from the wild-type.
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Figure 41. CDCE separation of high Tm mutant from wild-type sequences:
p53 exon 7 with ligated clamp
A mutant with a higher melting temperature (high Tm mutant, A -> G transition atp53
cDNA bp 763) than that of the wild-type was peR amplified using the GC2lBS-stable
primer pair. An additional peR was performed with a mixture containing the wild-type
and the PeR-amplified mutant at an equal molar ratio. The GC2IBS primer pair (pS3
eDNA bp 673-782) was used for this peR in whieh mutant/wild-type heteroduplexes, in
addition to the homoduplex of each kind, were formed. This PCR sample was separated
by CDCE, performed using a 15 em-long temperature-regulated zone of desired
temperatures.
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5 CONCLUSIONS
For mutational analysis of a larger pool of target genes and tissues, genotype-based
methods are preferred over phenotype-based methods. This preference, combined with
the ability to measure mutations at low fractions, allows analysis of a variety of human
samples, including normal tissues.
For such analysis, a mutation assay was developed. The key development was high
efficiency DNA ligation in which a clamp is ligated to any 100-bp sequence of interest by
mass action. Clamp ligation was combined with the established CDCE-based mutation
detection method developed for DNA sequences with a natural clamp. The established
method alone allows analysis of rare point mutations in only about 9% of the human
genome. An additional 89% of the human genome can be analyzed by the combined
method.
The sensitivity of the combined method was demonstrated to be 2 x 10-5 in human
cells. This demonstration represents detection of at least 200 copies of each mutant in the
presence of 107 copies of the wild-type. This sensitivity was observed to be 4-fold lower
than that of the established method, when sensitivities were compared using the same
target, a part of the human HPRT gene (cDNA-bp 223-318). The GC-rich sequence of
the ligated clamp was determined to be the cause of this decrease.
The sensitivity of the combined method was limited by the fidelity of Pfu DNA
polymerase used for peR. The polymerase generated 4 G -> T transversions, 1 A -> G
transition, and 1 G -> A transition in the chosen HPRT target. These mutations appeared
at an average fraction equivalent to about 2 x 10-5 in the original samples. This average
mutant fraction limited the sensitivity of the combined method.
Future applications of the combined method to analysis of a variety of human samples
may allow understanding of human point mutagenesis.
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6 SUGGESTED FUTURE STUDIES
6.1. Increase in mutation detection sensitivity
The fidelity of Pfu DNA polymerase limits the sensitivity of mutation detection
methods. With increased fidelity, the sensitivity can be increased. Studies on
mechanisms by which Pfu generates mutations in an amplified target may suggest a
means to increase the fidelity.
Conventional Pfu is the 3' to 5' proofreading exonuclease-proficient version of Pfu
(exo+ version) (Lundberg et aI., 1991). Potentially, a small amount of the exonuclease
deficient version of Pfu (exo- version) is present in batches of conventional Pfu (Thilly,
W. G., personal communication). This mixed version may be caused by mutations
occurring during transcription and translation of the exo+ version of the enzyme.
A previous observation supports the mixed-version possibility (Kim, unpublished
results). In this observation, mutations in a chosen target created by conventional Pfu
were shown to co-migrate with those created by the exo- version under optimal CDCE-
separation conditions. These co-migrating mutations are thought to be the same
mutations; however, sequencing analysis needs to be performed for verification.
This observation supports the hypothesis that a small amount of the exo- version
present in the mixed version causes all the mutations, determining the fidelity of the
mixed version. If this is true, purification of the exo+ version in the mixed version may
increase fidelity (Thilly, W. G., personal communication).
6.2. Applications
6.2.1 Inherited mutations
As Section 2.6 describes, the ability to measure mutations at fractions down to 5 x 10-5
allows analysis of inherited mutations with statistical significance in a sample size of 107
cells, derived from 105 persons. Such analysis can be performed with the mutation assay
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developed in this thesis. As a result, the relationships of genes to diseases can be tested
and causative alleles over the entire genes can be discovered.
6.2.2 Somatic mutations
As Section 2.4 summarizes, a limited number of somatic mutational studies have been
performed on the tissues of healthy individuals. Based on these studies, the mutation
assay developed in this thesis is suggested for analysis of p53 somatic point mutations in
the lungs of healthy individuals. Two p53 point mutations in the gene-coding region at
an average fraction of about 5 x 10-5 have been observed in healthy human lungs (Li-
Sucholeiki et aI., Unpublished results).
The hypothesis that cigarette smoke induces mutations or/and mutant fractions can be
directly tested by comparing mutational spectra in lOO-bp p53 sequences in smokers' and
non-smokers' lungs. Since none of the human p53 exons has a natural clamp, clamp
ligation is necessary to test such a hypothesis.
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